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l. Mucositis kan niet warden voorkomen door een enkelvoudige 
interventie. 
2.  De betrouwbaarheid van het scoren van mucositis wordt verbeterd 
door het trainen van de onderzoeker. 
3. Het bepalen van het percentage vitale epitheelcellen van het 
mondslijmvlies is een objectieve parameter voor het ontstaan van 
bestralingsmucosi tis. 
4. De rol van Gram-negatieve bacterien bij het ontstaan van mucositis 
is modulerend en niet causaal. 
5. Het gezegde "voorkomen is beter dan genezen" is voor mucositis 
vooralsnog een utopie. 
6. Een multidisciplinaire werkgroep hoofdhals tumoren client een 
mondhygienist als teamlid te hebben. 
7. Een inzichtelijke complicatie registratie van een ziekenhuis­
afdeling is een kenmerk van kwaliteit. 
8. Gezien de positionering binnen de mondzorg, zal de mond­
hygienist in staat moeten zijn om alle visueel waarneembare 
afwijkingen in het aandachtsgebied als zodanig te herkennen. 
9. De rol van de mondhygienist in de gezondheidszorg dient gericht 
te zijn op alle facetten van preventieve mondzorg. 
10. Door de mondzorg uitgevoerd door de mondhygienist niet op te 
nemen in de nieuwe Zorgverzekeringswet wordt voorbij gegaan 
aan het proces van taakherschikking in de gezondheidszorg. 
11. Het getuigt van visie om het schrijven van wetenschappelijke 
publicaties op te nemen in de criteria van het Kwaliteitsregister 
Paramedici. 
12. Je moet datgene accepteren in het leven wat niet te veranderen is 
en datgene veranderen wat niet te accepteren is. 
Mieke Bijenhof ( 1966-1991) 
13. Failure is the opportunity to begin again more intelligently. 
Henry Ford 
14. Door het verbod voor alle pleziervaartuigen om zogenaamd zwart 
afvalwater te lozen op het oppervlaktewater, kan het onderwater 
toilet overboard worden gezet. 
15. "Het zal me een zorg zijn" krijgt een heel andere betekenis na de 
invoering van het nieuwe zorgstelsel. 
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Oral mucositis induced by radiotherapy or chemotherapy is a frequently 
occurring side-effect in patients with cancer. It is painful and restricts oral 
function, such as speech, swallowing and chewing. Oral mucositis is 
associated with an increase in the number of systemic infections, days in 
hospital and overall costs.1.i These aspects can limit the cancer therapy and 
have a negative impact on patients health-related quality of life (HRQOL) .3 
Mucositis was reported to be the most troubling side-effect of cancer therapy 
by 38% of patients treated with head and neck radiation and 42% of the 
patients treated with high-dose chemotherapy.4•5 (Figure I and 2) 
The incidence of mucositis is dependent on the cancer treatment 
regimen. The current head and neck radiotherapy protocols have a mucositis 
incidence of 85-100%.6 The incidence of mucositis can approach 90-100% in 
patients receiving aggressive myeoloablative chemotherapy7, and is present 
in 40% of patients with a solid tumor, who have chemotherapy induced 
myelosuppression. 1 
Secondary infection of mucosa! ulcers, are seen in severe mucositis, and 
can provide a port of entry for microorganisms into the circulation, which 
can lead to life-threatening septicemia, especially in myelosuppressed 
patients.8 
These data illustrate the impact of oral mucositis on cancer treatment. 
Understanding and knowledge of the development of oral mucositis and 
the preventive possibilities are becoming increasingly important since the 
actual regimens for mucositis prevention are, until now, mainly symptomatic 
or palliative. 
The aim of this thesis is to investigate new approaches for evaluation 
and new options for management of cancer therapy induced oral mucositis. 
Many studies have been published concerning prevention of oral mucositis, 
but most studies had small samples sizes or used different scoring methods 
which make comparison of the results difficult. Insufficient power and the 
lack of sensitivity of the outcomes measures make it hard to draw definitive 
conclusions regarding the use of these interventions for the prevention of 
oral mucositis. Chapter 2 reviews this literature on the effectiveness of 
interventions for the prevention for oral mucositis in cancer patients treated 
with head and neck radiotherapy, chemotherapy, or chemoradiation. It 
focuses, whenever possible, on meta-analyses of randomized clinical trials 
of interventions for the prevention of oral mucositis. 
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Figure 1. Radiation induced pseudomembranous mucositis on the right cheek and soft palate region 
of the mouth, after 32 Gy cumulative radiation dose (conventional fractionation schedule, 2 Gy per 
day, 5 times a week) 
Figure 2. Chemoradiation induced pseudomembranous mucosit is on the dorsum of the tongue and 
pharyngeal region of the mouth, after 52 Gy cumulative radiation dose and two chemotherapy cycles 
with carboplatin and 5 f/uorouracil. A demarcation is noticed between the radiated and non radiated 
area of the tongue 
1 1  
Accurate evaluation of the effect of new preventive modalities on 
mucositis is a prerequisite, at which in multicenter trials, establishment of 
adequate inter-evaluator reliability is an important concern, with mucositis 
as outcome variable. Training of evaluators in scoring oral mucositis is 
thought to be important to increase inter-evaluator reliability.9 In chapter 3 
the effect of training of evaluators on scoring of oral mucositis is studied. 
Mostly clinical observational oral mucositis scores are based on a 
combination of mucosal parameters (signs) together with general complaints 
(symptoms). Differences in definition and operationalization of these 
general complaints hamper proper comparison of the outcomes using these 
scoring systems.10 With respect to the mechanisms of mucositis, it seems to 
be important to investigate it more objectively on a cellular level. Chapter 4 
describes an assay based on cells retrieved from an oral mouthwash to 
quantify oral mucositis in head and neck cancer patients who received 
radiotherapy and to compare the results with the WHO scoring system. 
In neutropenic cancer patients, oral mucositis is a potential portal of 
entry for the indigenous oral flora leading to bacteremia or sepsis. Fever is 
one of the first clinical signs of bacterial infection in these patients. The 
standard therapy for patients with fever and chemotherapy induced 
neutropenia is hospitalization and intravenous administration of broad­
spectrum antibiotics. A risk assessment model has been developed, using 
objective clinical parameters and the plasma IL-8, to select patients with 
febrile neutropenia at low risk for bacterial infection.11 Plasma IL-8 is 
considered to be a systemic inflammatory response parameter to foci of 
infection. Chapter 5 describes the relationship between oral mucositis and 
systemic IL-8 levels in neutropenic cancer patients with fever, without a 
local bacterial infection or a clinical sepsis. 
Changed oral flora, colonizing the oral mucosa, may aggravate the 
mucosa reaction following radiation. The carriage and colonization of 
aerobic Gram-negative bacilli are thought to play a role in the pathogenesis 
of irradiation mucositis.12 In chapter 6 the results are presented of a 
randomized, double blind, placebo-controlled study evaluating the effects 
of selective oral flora elimination with an antibiotic lozenge on the 
development of irradiation induced oral mucositis, feeding, weight loss 
and colonization of aerobic Gram-negative bacilli and yeast. 
Radiation injury to the epithelium, causing mucositis, is associated with 
production of active oxygen and cytokines. During this process cyclooxy-
12 
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genase 2 (COX-2) is induced and has been found to be responsible for the 
synthesis of prostaglandins which cause the separation of tight cellular 
junctions and increase in vascular permeability.13 Flurbipofen is an efficient 
inhibitor of COX-2, and might therefore delay or prevent mucositis.14 In 
addition flurbiprofen has anti-inflammatory and anti-proliferative 
properties which probably can also delay oral mucositis and/ or alleviate 
the severity of this side-effect. Chapter 7 describes the outcomes of a pilot 
study evaluating the effects of flurbiprofen in a tooth patch on the 
development, severity and duration of pseudomembranous oral mucositis 
in patients treated with curative head and neck radiotherapy. 
Cytoprotective agents, such as amifostine (Ethyol®, WR-2721), may 
reduce the toxicity induced by radiotherapy or chemotherapy. Amifostine 
is a prodrug, which is active as a protective agent when dephosphorylated 
by alkaline phosphatase to its active metabolite WR-1065. Once inside the 
cell, WR-1065 protects against chemotherapy and radiotherapy induced 
damage by scavenging free radicals, donating hydrogen ions to free radicals, 
depleting oxygen, and direct binding and inactivating cytotoxic drugs. 15 
Chapter 8 presents the results of a phase II trial evaluating the effect of 
local application of WR-1065, the active compound of amifostine, on oral 
mucositis in non-small cell lung cancer patients treated with epirubicin and 
gemcitabine. The effect of WR-1065 on mucositis was the primary end point 
of this study. The secondary end point was to determine the WR-1065 
concentration in oral epithelial mucosa cells in this patient population. 
Chapter 9 describes the summary of the thesis, considerations on the 
outcomes and potential future perspectives in mucositis research. 
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Aim This meta-analyses aims to evaluate the effectiveness of interventions 
for the prevention of oral mucositis in cancer patients, treated with head 
and neck radiotherapy and/ or chemotherapy; with a focus on randomized 
clinical trials. 
Methods A literature search was performed for randomized controlled 
clinical studies between 1966-2004 aiming at prevention of mucositis, in 
cancer patients, undergoing head and neck radiation, chemotherapy or 
chemoradiation. The control group consisted of a placebo, no intervention 
or another intervention group. Mucositis was scored either by the WHO, or 
the NCl-CTC score, or the absence or presence of ulcerations, or the presence 
or absence of grade 3 and 4 mucositis. 
Results The meta-analyses included 45 studies fulfilling the inclusion criteria, 
in which 8 different interventions were evaluated; i.e. local application of 
chlorhexidine; iseganan; PTA (polymyxin E, tobramycine and amphotericin 
B); GM-CSF /G-CSF; oral cooling; sucralfate and glutamine; and systemic 
administration of amifostine and GM-CSF / G-CSF. Four interventions 
showed a significant preventive effect on the development or severity of 
oral mucositis; PTA with an odds ratio (OR) = 0.61 (95% confidence interval 
(Cl) 0.39-0.96); GM-CSF OR= 0.53 (CI: 0.33-0.87); oral cooling OR=0.3 (Cl: 
0.16-0.56); amifostine OR=0.37 (Cl: 0.15-0.89). 
Conclusion To date, no single intervention completely prevents oral 
mucositis, so combined preventive therapy strategies seems to be required 
to ensure more successful outcomes. 
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I NTRODUCTIO N  
Oral mucositis is defined as an injury o f  the oral mucosa in cancer patients, 
either induced by radiation of patients who have head and neck cancer, or 
due to chemotherapy. This has debilitating and painful side-effects and 
adversely affects the nutritional status of the patient. Mucositis is associated 
with an increase in the number of systemic infections, days in hospital and 
overall costs, and these aspects have a negative impact on health-related 
quality of life (HRQOL).1-5 Mucositis was reported to be the most troubling 
side-effect of cancer therapy by 38% of patients treated with head and neck 
radiation and 42% of the patients treated with high-dose chemotherapy.6•7 
Many studies have been published about interventions for the prevention 
of mucositis, but most studies had small samples sizes, or used different 
scoring methods, which make comparison of the results difficult. Insufficient 
sample power, the lack of sensitivity of the outcomes measures, and study 
design flaws, make it hard to draw definitive conclusions regarding the 
use of these interventions or to provide evidence-based guidelines for the 
prevention of oral mucositis.8 
This review aims to evaluate the effectiveness of interventions for the 
prevention of oral mucositis in cancer patients treated with head and neck 
radiotherapy, chemotherapy, or chemoradiation. It focuses, whenever 
possible, on meta-analyses of randomized clinical trials of interventions 
for the prevention of oral mucositis. 
CAU SES OF MUCOSITI S 
In a conventional radiotherapy scheme of fractionation, a first mucosal 
reaction in the form of a white mucosal hyperkeratinization can be observed 
after a cumulative radiation dose of 10-20 Gy. Clinically, erythema is 
considered to be the first sign which is usually visible after 20 Gy cumulative 
dosage. Thereafter, ulcerations can occur which are often covered with a 
pseudomembranous layer. This more severe stage of mucositis will develop 
after about 30 Gy, mostly after 3 weeks of radiotherapy.9 After completion 
of the radiotherapy the mucositis will decline between 2 to 6 weeks later. 
The oral mucositis induced by chemotherapy is more acute than that 
due to radiotherapy.10 Around 5-8 days following chemotherapy erythema 
occurs which usually is followed, within 2 days by edema and ulceration. 
Mucositis due to chemotherapy lasts for approximately 7 to 10 days. 
17 
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Mucositis lesions, both in radiotherapy and chemotherapy, are localized in 
the non-keratinized mucosa such as the buccal and labial mucosa, ventral 
and lateral surface of the tongue, floor of the mouth and soft palate. 
The incidence of mucositis is dependent on the cancer treatment 
regimen. The current head and neck radiotherapy protocols have a mucositis 
incidence of 85-100%. For altered fractionated radiation the incidence is 
100%, for chemoradiation 89% and for conventional radiation 97%.11 The 
incidence of mucositis can approach 90-100% in patient receiving aggressive 
myeloablative chemotherapy.12 In solid tumor patients, who have chemotherapy 
induced myelosuppression, mucositis occurred during 37% of 1,236 cycles 
of chemotherapy.1 
The severity of mucositis depends on different factors; e.g. anti-cancer 
treatment protocol, age and diagnosis of the patient, level of oral hygiene 
during therapy and genetic factors. 13·15 
Historically, mucositis was thought to arise as a consequence of direct 
and indirect toxic effects on epithelial cells. The colonization of the damaged 
mucosa by bacteria, fungi and viruses can superimpose secondary 
infections.16-18 Furthermore, it was thought that the development of mucositis 
was facilitated by trauma, i.e. due to the effects of dentures on the oral 
mucosa or oral hygiene habits.13·19 
Nowadays mucositis is recognized as an epithelial and sub-epithelial 
injury and is thought to develop in a five-stage model, namely: 1) initiation; 
2) upregulation with generation of messengers; 3) signaling and amplifica­
tion; 4) ulceration with inflammation; and 5) healing.20 In figure 1 possible 
pathways of interventions for mucositis prevention are depicted in relation 
to this model. The development of mucositis according this five-stage model 
is an immediate and simultaneously process in all the different tissue 
compartments and cellular levels. 
1) Initiation 
Radiotherapy and chemotherapy induce cell damage. Mucosa! cell death 
is induced by DNA strand breaks and found in both the epithelial and sub­
epithelial cells. In this stage most cell destruction is found in the submucosa, 
whereas the effects on the basal membrane and stratum spinosum are more 
selective.21 Simultaneously, non-DNA related cell damage starts by the 
production of reactive oxygen species by both radiotherapy and chemo­
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Figure 1. The development of mucositis in a 5 stage model (adapted from Son is (2004)) and pathways 
of interventions for mucositis prevention 
2) Message generation 
Radiotherapy and chemotherapy, together with the induced reactive oxygen 
species, effectively activate biological control mechanisms, including a 
select group of transcription factors, of which NF-KB is probably one of the 
most significant.23•24 Activated NF-KB can upregulate up to 200 genes, 
including those that code for pro-inflammatory cytokines (TNF-a, IL-1� 
and IL-6) and adhesion molecules which produce effector proteins that 
initiate tissue injury. At the same time, radiotherapy, chemotherapy and 
reactive oxygen species activate both neutral and acidic sphinogmyelinases 
and ceramide synthase, which mediate death of submucosal endothelial 
cells and fibroblasts.25 Moreover, fibroblast destruction is associated with 
fibronectin and metalloproteinases production, which results in increased 
apoptosis. This rapid cascade of changes occurs in a clinically normal 
mucosal lining. 
1 9  
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3) Signaling and amplification 
The radiotherapy and chemotherapy related production in the mucosa and 
submucosal of proteins has two distinguishable effects. Apart from target­
cell injury these proteins affect signaling and amplification functions. For 
example TNF-a is not only an efficient mediator of cellular and tissue injury, 
but also activates NF-KB and sphinogmyelinase. This potentiates the activity 
of these control mechanisms following the initial damage by radiotherapy 
and chemotherapyY During this phase, the apoptotic changes in the 
epithelium result in clinically observable altered mucosal appearance. 
4) Ulceration 
The ulcerative phase of mucositis is the most clinically significant event 
and is responsible for pain and loss of barrier function. The ulcers are 
colonized with both aerobic and anaerobic Gram-positive and Gram­
negative microorganisms. Cell wall products from colonizing bacteria are 
likely to penetrate into the submucosa, where they can activate infiltrating 
macrophages, which are thought to increase TNF-a, IL-1� and IL-6 
production.26 These cytokines probably promote the expression of pro­
apoptotic genes and potentiate tissue injury. Inflammatory cells then migrate 
by chemotaxis to the base of the lesion, where they produce damaging 
enzymes. 
5) Healing 
Mucosal ulcers induced by radiotherapy and chemotherapy heal sponta­
neously after cessation of therapy by the dynamic mechanisms of epithelial 
wound healing. It is thought that submucosal extracellular matrix and 
mesenchyme regulate epithelial-cell migration and proliferation. An intact 
mucosal surface is created by epithelial cell migration, over the denuded 
connective tissue. 
LITERATURE SEARCH STRATEG Y  AND STATI STICAL ANALYSES 
The Medline, Embase and CINAHL databases were searched for articles 
published from January 1966 to December 2004, using the following search 
strategy: [neoplasms] AND [(mucositis OR stomatitis)] AND [limit to 
(clinical trial OR randomized-controlled trial)]. Citation lists were examined 
and all interventions identified were listed and were classified according 
to their possible mechanism of action. The search was repeated for each 
20 
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intervention using the strategy described above. All articles found with 
this search were retrieved and selected on the basis of the inclusion criteria. 
Included in this review were randomized controlled clinical studies aiming 
prevention of mucositis, of patients undergoing head and neck radiation, 
chemotherapy or chemoradiation, and written in English. The control group 
consisted of a placebo, no intervention, or another intervention group. The 
outcome of mucositis was scored by the WHO score or the NCI-CTC score, 
the absence or presence of ulcerations or the presence or absence of grade 3 
and 4 mucositis. Only studies in which the data on these outcome variables 
were available were included in the meta-analysis. Studies were excluded 
if inadequate data were available on the outcome variable of mucositis. 
The literature search revealed 109 publications, but in five of these, 
prevention of oral mucositis was not the study objective. Of the remaining 
104 studies, 13 were non-randomized and 29 studies did not contain data 
in a comprehensive form. Seventeen articles each stood alone as far as their 
intervention was concerned. Therefore, a total of 45 articles were included 
in the meta-analyses (Table 1) .  
A meta-analysis was performed to estimate the effect of the different 
interventions on the outcome variable of mucositis defined by presence of 
mucositis, ulceration and grade 3 and 4 mucositis for the several combined 
studies. When the included studies showed heterogeneity regarding the 
effect estimates, the results of the meta-analyses are based on the random 
effects models, otherwise the results are based on the fixed effects models. 
Random effects (DerSimonian-Laird) meta-analysis computes the odds 
ratios (OR) of the individual studies, the summary, the random effects 
variance, and Woolf's test for heterogeneity. The fixed effect (Mantel­
Haenszel) meta-analysis computes the Mantel-Haenszel summary. Studies 
with zero or infinite ORs were omitted, as their variance cannot be calculated 
with accuracy. ORs were considered to be significant if the 95% confidence 
interval (95% CI) did not include the value 1 .  
The 'plot' method presented in the figures shows standard meta-analysis 
plots. The 95% confidence interval for each study is depicted by a horizontal 
line, and the point estimate is depicted by a square whose height is inversely 
proportional to the standard error of the estimate. The summary OR is drawn 
as a diamond with horizontal limits at the confidence limits and width 
inversely proportional to its standard error. Meta-analyses were performed 




N Table 1 . Studies included in the meta-a nalyses 
Reference No. of study patients 
(intervention/control) 
�ptic and antimicrobial agents 
Chloorhexidine 
Cheng, 2003 31 34 ( 1 7/1 7) 
Dodd, 1996 32 222 ( 1 1 0/1 1 2) 
Ferretti, 1 988 35 49 (24/25) 
Ferretti , 1 990 36 36 ( 1 8/1 8) 
Ferretti, 1 990 36 28 (1 5/1 3) 
Foote, 1 994 37 52 (25/27) 
Pitten, 2003 39 47 (24/23) 
SpiJkervet, 1 989 "'' 30 ( 1 5/1 5) 
/seganan 
Giles, 2004 44 502 (25 1 /2 5 1 ) 
Trotti, 2004 45 424 (253/17 1 )  
PTA 
El Sayed, 2002 47 136 (69/67) 
Okuno, 1 997 48 1 03 (49/54) 
Stokman, 2003 49 58 (28/30) 
Symonds, 19g5 � 2 2 1  ( 1 1 2/1 09) 
W1jers, 2001 �1 77 (3g/38) 
c.,.iokines and/or growth.facto.rs 
GM CSFIG CSF 
Cartee, 1 995 62 
Chi, 1 9g5 63 
Crawford, 1 999 64 
Dazzi, 2003 65 
Katano, 1 995 68 
Makkonen, 2000 69 
Nemunaitis, 1 9g5 70 
Schneider, 1 999 72 
Valcarcel, 2002 73 
van der Lel ie, 200 1 74 
45 (36/g) 
20 (9/1 1 )  
1 95 (93/1 02) 
90 (46/44) 
1 4  (7/7) 
40 (20/20) 
1 09 (53/56) 
1 4  (8/6) 
35  ( 1 6/1 9) 





Controlled/ Study characteristics Result-impact on Cause � Double-blind oral mucositis 
N 
ax• Yes/No Chlorhex1d1ne versus benzydamine Reduction 
CTX Yes/Yes Chlorhex1dine versus placebo No difference 
ax1 BMP Yes/Yes Chlorhexidme versus placebo S1gn1f1cant reduction 
ax Yes/Yes Chlorhex1d ine versus placebo Significant reduction 
RTX' Yes/Yes Chlorhexidine versus placebo No difference 
RTX Yes/Yes Chlorhexid ine versus placebo No difference 
CTX Yes/Yes Chlorhex1d1ne versus fluoride solution No d ifference 
RTX Yes/Yes Chlorhex1dme versus placebo No difference 
ax Yes/Yes lseganan versus p lacebo No difference 
RTX/ax t RTX Yes/Yes lseganan versus placebo No difference 
RTX Yes/Yes Ant1microb1al lozenge versus placebo No difference 
RTX Yes/Yes PTA lozenges versus placebo No difference 
RTX Yes/Yes PTA lozenges versus placebo No difference 
RTX Yes/Yes PTA lozenges versus placebo No d ifferences 
RTX Yes/Yes PTA oral paste versus placebo No d ifference 
ax Yes/Yes GM-CSF versus placebo No difference 
ax Yes/No GM-CSF versus no mtervent1on S1gnif1cant reduction 
ax Yes/Yes r-metHuG-CSF versus placebo Significant reduction 
ax+BMT Yes/Yes GM-CSF versus placebo No differences 
ax Yes/No G-CSF versus no mtervention S1gn1f1cant reduction 
RTX Yes/No GM-CSF versus no intervention No d ifference 
ax ... BMT Yes/Yes rhGM-CSF versus placebo Significant reduction 
RTX Yes/Yes r-metHuG-CSF versus placebo Reduction 
ax+BMT Yes/Yes rhGM-CSF versus placebo No differences 
ax+BMT Yes/Yes GM-CSF versus p lacebo No d ifference 
IV 
w 
Loc:all� applied aoa-pba([nac;Q/Qg1cal methods 
Oral coo/mg 
Cascrnu, 1 994 n 
Mahood, 1 991  78 
Mouth c:oat1ag agents 
Sucralfate 
Carter, 1 999 82 
Castagna, 2001 83 
Ceng1z, 1 999 84 
Chiara, 2001 85 
Dodd, 2003 86 
Makkonen, 1 994 91 
N ottage, 2003 92 
Pfeiffer, 1 990 93 
Shenep, 1 988 94 
Radical scaveagers 
Amifostine 
Antonadou, 2002 97 
Bourhis, 2000 9! 
Brizel, 2000 99 
Buntzel, 1 998 100 
Hartmann, 2001 101 
Koukourakis, 2000 102 




Okuno, 1 999 '11 
84 (44/40) 
93 (50/43) 
1 02 (52/50) 
1 02 (51/5 1 )  
2 8  ( 1 8/1 0) 
40 (20/20) 






24 ( 1 2/1 2) 
303 ( 1 53/1 50) 
39 (25/1 4) 
40 (20/20) 
39 ( 1 9/20) 
1 87 (93/94) 
1 7  (8/9) 
1 34 (66/68) 
5-fUd Yes/No Oral cooling versus no intervention S1gnif1cant reduction 
5-FU Yes/No Oral cooling versus no 1ntervent1on S1gn 1f1cant reduction 
R1X Yes/Yes Sucralfate versus placebo No d ifference 
ox Yes/Yes Sucralfate versus placebo Reduction of mucos1t1s 
R1X Yes/Yes Sucralfate versus placebo S1gn1frcant reduction 
ox Yes/Yes Sucralfate versus placebo No d ifference 
R1X Yes/Yes Sucralfate versus salt & soda mouthwash No d ifference 
R1X Yes/Yes Sucralfate versus placebo No d ifference 
ox Yes/Yes Sucralfate versus placebo No d ifference 
ox Yes/Yes Sucralfate versus placebo S1gnrf1cant reduction 
ox Yes/Yes Sucralfate versus placebo No d ifference 
R1X+OX Yes/No Am1fostrne versus no 1ntervent1on S1gnrf1cant reduction 
R1X Yes/No Am1fost1ne versus no intervention Reduction 
R1X Yes/No Am1fostine versus no 1ntervent1on No difference 
R1X+OX Yes/No Am1fost1ne versus no 1ntervent1on S1gn1f1cant reduction 
CTX+BMT Yes/No Am1fost1ne versus no 1ntervent1on S1gnrf1cant reduction 
R1X Yes/No Am1fost1ne versus no 1ntervent1on Sign ificant reduction 
ox Yes/No Am1fost1ne versus no 1ntervent1on S1gn1f1cant reduction 
R1X Yes/No Oral glutam1ne versus p lacebo Reduction 
5-FU Yes/Yes Oral glutam1ne versus placebo No d ifference 
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I NTERVENTION STRATEG I E S  
For the various intervention strategies, results of the meta-analyses are 
presented when more than one study of an intervention is available that 
fulfilled the inclusion criteria . 
Basic Oral Care 
The NIH consensus (1989) states that patients who receive head and neck 
radiation or chemotherapy must be evaluated, before the start of cancer 
treatment for potential risk factors for oral complications, by a thorough 
oral and dental evaluation, including a radiographic examination.28 
In two randomized clinical trials various different oral care protocols 
were tested.29•30 In both studies an intensive oral care protocol was compared 
with a standard oral care protocol. The intensive oral care protocol varied 
in the different studies. In one study, intensive oral care included treatment 
of dental lesions before the chemotherapy, and tooth and gum brushing 
during aplasia (granulocytes < 0.5xl09 /1 and/ or platelet count < 20xl09 /1).29 
In another study radiotherapy patients, were divided in three groups. In 
two groups the protocol consisted of oral care instructions, tooth brushing 
and rinsing with sterile water. One group started on day 1 of radiotherapy 
and one group started 1 week before radiotherapy. The control group 
received no instructions.30 Both studies showed that additional oral care is 
important and has a positive attenuation effect in the development of oral 
mucositis. No meta-analysis was performed because in one study the data 
were not presented according to the inclusion criteria on the outcome 
variable and therefore only one study was available for analysis. 
Topical antiseptic and antimicrobial agents 
Studies with topical antiseptic and antimicrobial agents attempted to 
determine whether oral mucositis, due to colonization of the mouth with 
aerobic and anaerobic Gram-positive and Gram-negative microorganisms 
or yeast, could be prevented. 
Chlorhexidine, as an oral rinse, with concentrations of at least 0.12% is 
an anti-plaque agent with potential antimicrobial activity. It has been 
evaluated in ten randomized clinical trials for preventing oral mucositis 
but the outcomes were different.31-40 Of these studies only seven fulfilled 
the inclusion criteria on the outcome variable for the meta-analysis (Table 1) .  
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The study by Ferretti and colleagues was included in the database as two 
different studies, one for radiotherapy, and one for chemotherapy.36 Three 
studies used "presence of ulceration" as the outcome, one study used 
"presence of mucositis" and four studies used both. The meta-analysis 
however showed no effect of chlorhexidine in the prevention of mucositis 
in chemotherapy and radiotherapy patients, OR=0.7 (CI: 0.43-1 . 12). 
Povidone-iodine is an antiseptic agent that is effective against oral 
bacteria. In the single randomized clinical trial in which povidone-iodine 
was used as a mouth rinse (Betaisosona®Mund-Antiseptikum, diluted 1 :8), 
radiochemotherapy induced mucositis was significantly decreased.41 
Iseganan is a structural analogue of naturally occurring protegin-1 .  
Protegins, initially isolated from porcine neutrophils, are antimicrobial 
peptides involved in local and systemic host defense. Iseganan has rapid 
microbicidal activity in saliva. It is a microbicidal against a broad spectrum 
of endogenous oral flora including Gram-positive and Gram-negative 
bacteria and yeast, and it can be applied topically to the oral mucosa with 
no detectable systemic absorption.42 In the three published studies, there 
was no significant effect of iseganan on the prevention of oral mucositis 
induced by radiotherapy, chemotherapy or chemoradiation.43-45 The first 
study of Giles (2003) is not included in this meta-analysis because of a major 
randomization flaw.43 The two included studies used the "presence of 
ulceration" as the outcome and evaluated both chemotherapy and 
radiotherapy patients. The meta-analysis showed no effect on prevention 
of ulcerations, OR=0.75 (Cl: 0 .55-1.02). 
Other studies investigated the effects of topical application of  
antimicrobials by a combination of polymyxin E,  tobramycine and 
amphotericin B (PTA) in a lozenge or paste for selective elimination of the 
oral flora in radiotherapy patients. The goal of this combination was to 
eliminate aerobic Gram-negative bacteria and yeast.46 Several randomized 
placebo controlled trials, employing PTA, have been conducted and the 
results were not in total agreement.47-51 All five studies, all in radiotherapy 
patients, were included in the meta-analysis. All these studies used 
"presence of mucositis" and "presence of ulcerations" as the outcome. The 
meta-analysis found a preventive effect of PTA on the development of 
ulcerations with an OR of 0.61 (CI: 0.39-0.96) (Figure 2). However, no effect 





















0 10 0 16 0.25 0 40 1 00 
favours treatment 
2 51 3 98 
favours control 
OR 
(95% Cl Fixed) 
0 69(0 28-1 72) 
0 39 (0 19-0 82) 
0 75 (0 23-2 41) 
1 20 (0 41-3 52) 
0 60 (0 09-3 86) 
0 61 (0 39-0 96) 
Figure 2. Standard meta-analysis plot result of PTA for the outcome "presence of ulceration" 
GM-CSF/G-CSF (systemic adm1mstrabon) 
Study Treatment Control OR 
n/N n/N (95% Cl Fixed) 
Katano, 1995 217 717 O 00 (cannot be estimated) 
Crawford. 1999 26/93 48/102 --- 0 44 (0 24-0 79) 
' 
Nemuna1hs, 1995 10/53 8/56 :m 1 40 (0 50-3 86) 
' 
Schnettler, 1999 BIB 6/6 cannot be estimated 
Makkonen, 2000 19/20 19/20 1 00(0 06-17 18) 
Total 65/181 88/191 +! 0 53 (0 33·0 87) 
0.10 0.32 1.00 3.16 10.00 
favours treatment favours control 
Figure 3. Standard meta-analysis plot result of GM CSFIG CSF (systemic administration) for the outcome 
"presence of mucositis" 
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Anti-inflammatory agents 
Benzydamine is a non-steroidal drug with analgesic, anesthetic, anti­
inflammatory, and antimicrobial properties. Benzydamine inhibits the 
production and effects of inflammatory cytokines, particularly TNF-a. It 
has especially been evaluated for the prevention and reduction of radiation 
induced oral mucositis with different outcomes.52-56 In a large, multicenter, 
double-blinded randomized trial, benzydamine improved the ulcer-free rate 
and diminished the incidence of ulceration and erythema.57 However, no 
study contained data that fulfilled the inclusion criteria on the outcome 
variable for the meta-analysis. 
Topical prostaglandins are agents believed to possess anti-inflammatory 
and cytoprotective properties. Both prostaglandin E1 (misoprostol) and 
prostaglandin E2 have been evaluated in a small series of radiotherapy or 
chemotherapy patients and there were conflicting outcomes.58-60 The manner 
in which the data was presented did not permit a meta-analysis. 
In one study, corticosteroids showed no reduction in the intensity or 
duration of radiotherapy induced mucositis.61 
Cytokines and/or growth factors 
The hematopoietic growth factors, granulocyte-macrophage colony­
stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G­
CSF) can promote the accumulation of activated neutrophils in the mucosa, 
and can directly induce proliferation of endothelial cells and keratinocytes. 
The mucosa! protective effects of GM-CSF and G-CSF were tested in 13 
randomized placebo controlled trials, with systemic administration or local 
application by mouthwashes, in various chemotherapy, radiotherapy, or 
chemoradiation regimens.62-74 Ten out of 13 studies could be included in the 
meta-analysis (Table 1) .  Six studies used GM-CSF /G-CSF as a systemic 
administration 63·64•68-70·72 and 4 studies used GM-CSF /G-CSF as a mouth­
wash.62·65·73·74 The "presence of mucositis" was used in 5 out of 6 studies 
(systemic intervention) and in 3 out of 4 studies (mouthwash) as the 
outcome. The meta-analysis found a significant effect of GM-CSF and 
G-CSF in preventing mucositis in the systemic intervention group with an 
OR of 0.53 (CI: 0.33-0.87) (Figure 3). No preventive effect was found for the 
topical administration of GM-CSF and G-CSF, OR=0.32 (Cl: 0.06-1.67). 
Transforming growth factor-133 (TGF- j33) is a cytokine that stimulates 
or inhibits cell proliferation depending on cell type. The interim analysis of 
a randomized clinical trial showed no preventive effect on chemotherapy 
induced oral mucositis.75 
27 
(H A P T E R  2 
Probably, the most promising growth factor is the recombinant human 
keratinocyte growth factor (rHuKGF; palifermin). In a phase ID, randomized, 
double-blind, placebo-controlled study palifermin, intravenously, signi­
ficantly reduced the incidence (35%) and duration (3 days) of severe 
mucositis in patients with hematologic malignancies undergoing autologous 
peripheral blood progenitor cell transplantation after fractionated total-body 
irradiation.76 Palifermin seems promising for the chemotherapy patient but 
data on radiotherapy patients are not yet available. 
Locally applied non-phannacological methods 
Oral cooling of the mouth by sucking on ice cubes causes local vasodilatation 
and reduces blood flow to the epithelium. Thus, it was thought that this 
approach would reduce the chemotherapeutic drug delivery to oral mucosa 
cells. In two randomized trials in patients receiving a 5-fluorouracil bolus a 
50% reduction in mucositis was observed by sucking on ice.77•78 These two 
studies were included in the meta-analysis. Both studies used "presence of 
mucositis" as the outcome for the prevention of 5-fluorouracil induced 
mucositis. The meta-analysis for this outcome revealed a significant 
preventive effect with an OR of 0.3 (0.16-0.56) (Figure 4). 
Low-energy helium-neon laser has been reported to promote wound 
healing and to reduce pain and inflammation. In three double-blind 
controlled studies, the severity and duration of oral mucositis in radiation 
and chemotherapy patients, treated with low-energy helium-neon laser was 
reduced 79-81 • Unfortunately, the manner in which the data was presented 
did not permit a meta-analysis. 
Mouth coating agents 
Sucralfate is a basic aluminium salt of sucrose octasulfate which in the past 
has been used in the treatment of gastric and duodenal ulcers. Nowadays, 
it is sometimes used in the treatment of radiation-esophagitis. Sucralfate 
acts as a protective coating by forming an ionic bond to proteins in the 
ulcer site. Furthermore, sucralfate stimulates prostaglandin production and 
mucosa! cell renewal. To date, there have been 13 randomized trials with 
sucralfate, as an oral suspension, performed in various treatment protocols. 82_q4 
Nine out of 13 studies could be included in the meta-analysis (Table 1). 
Only two 84 88 reported a significant reduction of radiation induced mucositis 
Five studies used "presence of mucositis" as outcome, one study used 




Cascmu. 1994 14144 
Mahood, 1991 22150 
Totol 36194 
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Oral coohng 
Control OR 
n/N (95% Cl Fixed) 
20/40 ---.---+ 0.47 (0 19-1 13) 
35143 ----- 0 18 (0 07-0 46) 
55/83 � 0 30 (0 1&-0 56) 
0 10 0 16 0 25 0 40 1 00 
favours treatment favours control 
Figure 4. Standard meta analys is plot result of oral cooling for the outcome "presence of mucositis" 
found no effect of sucralfate on prevention of mucositis or ulcerations in 
chemotherapy and radiotherapy patients, OR=0.82 (CI: 0.05-1 .33) . 
Radical scavenger 
Amifostine (WR 2721, Ethyol) is an organic thiophosphate compound which 
selectively protects normal cells from treatment-related toxicity. It is a pro­
drug, which is active as a protective agent when dephosphorylated by 
alkaline phosphatase to its active metabolite WR-1065. WR-1065 is 
preferentially taken up by normal rather than neoplastic cells because of 
the higher alkaline phosphatase activity, better vascularization and higher 
pH of normal tissue. Once inside the cell, WR-1065 protects against 
chemotherapy and radiation induced damage by scavenging free radicals, 
donating hydrogen ions to free radicals, depleting oxygen, and by direct 
binding to and inactivating cytotoxic drugs.95•96 Nine randomized clinical 
trials have used amifostine intravenously or subcutaneously administration 
for the prevention of mucositis in various treatment regimens with different 
outcomes.97-105 Seven studies could be included in the meta-analysis (Table 1). 
All studies used "presence of grade 3 and 4 mucositis" as the outcome and 
were performed in chemotherapy, radiotherapy or chemoradiation patients. 
The meta-analysis found a significant effect of amifostine in the prevention 
of grade 3 and 4 mucositis in chemotherapy and radiotherapy patients with 
an OR of 0.37 (0.15-0.89) (Figure 5). 
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0 01 0 02 0 04 0 10 0 25 1 0 
favours treatment 
OR 
(95% Cl Random) 
0 08 (0 01-0 71)  
0 77 (0 48-1 23) 
0 00 (cannot be estimated) 
0.00 (cannot be estimated) 
0 00 (cannot be estimated) 
0 33 (0.09·1.27) 
0.26 (0.08-0.81) 
0 37 (0 15-0 89) 
favours control 
Figure 5. Standard meta analysis plot result of amifostine for the outcome "presence of grade 3 and 
grade 4 mucositis" 
Amino acids 
Glutamine is an amino acid, required for the support and maintenance of 
intestinal growth and function. During episodes of catabolic stress there is 
a marked intracellular depletion of glutamine.106 Oral glutamine was tested 
in five studies with different outcomes.107-111 Two studies could be used for 
the meta-analysis using the "presence of mucositis" as outcome variable.109•111 
The meta-analysis found no effect of glutamine on prevention of mucositis 
in chemotherapy and radiotherapy patients, OR=l .25 (Cl: 0.61-2.59). 
Anti-oxidants 
The use of anti-oxidants such as azelastine hydrochloride 112, vitamin E 113 
and zinc sulfate 114 for the prevention of oral mucositis in radiotherapy or 
chemoradiation seems to be interesting but needs further research. 
Antineoplastic agents antagonists 
Allopurinol is a structural isomer of hypoxanthine, which is used for the 
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treatment of gout. Some pilot studies have shown that allopurinol mouth­
wash decreased 5-fluorouracil induced mucositis. However, in the single 
randomized, placebo-controlled, double blind study no effect of allopurinol 
mouthwash on 5-fluorouracil induced mucositis was observed.115 
Immunomodulaton1 drugs 
Pentoxifylline is a xanthine derivate, capable of downregulating TNF-a 
production and stimulating vascular endothelial production of prosta­
glandins I2 and E2. The two randomized clinical trials studying the effect of 
oral administration of pentoxifylline for the prevention of chemotherapy 
induced mucositis failed to show any benefit.116•117 The manner in which 
the data was presented did not permit a meta-analysis. 
Anti-cholinergic agents 
Oral administration of pilocarpine hydrochloride is approved for treatment 
of radiation induced xerostomia in several countries. It is a naturally occurring, 
cholinergic, parasympathomimetic alkaloid that has a broad range of phar­
macologic effects, including increasing secretion from the exocrine glands 
(sweat, salivary, lachrymal, gastric, pancreatic and intestinal glands). Only 
one randomized, double-blind, placebo-controlled cross-over study has been 
published, showing a significant decrease in the development of chemo­
therapy induced oral mucositis.118 
Miscellaneous 
Traumeel S®is a homeopathic medication containing 12 botanical substances 
and 2 mineral substances. It has been sold over the counter in pharmacies 
for over 50 years and it is available worldwide for use as an anti-inflamma­
tory, analgesic, anti-edematous and anti-exudative drug. In a randomized, 
placebo-controlled study, Traumeel S®, as a moutwash, significantly reduced 
the severity and duration of chemotherapy induced mucositis.119 
The topical application of honey was investigated in a randomized, non­
blinded study in radiotherapy patients.12° In this study, a significant 
reduction of mucositis grade 3 and 4 was detected. 
In a double-blind, randomized study the efficacy of a calcium phosphate 
mouth rinse (Caphosol®) with fluoride treatments was tested for the 
prevention of mucositis in patients undergoing hematopoietic stem cell 
transplantation.121 The use of the mouthwash Caphosol® had a significant 
effect in decreasing the duration and severity of mucositis. 
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Aloe vera contains numerous vitamins and minerals, enzymes, amino 
acids, natural sugars and agents which may be anti-inflammatory and anti­
microbial. The aloe vera gel has been used for topical treatment of wounds, 
minor burns, and skin irritations. In a double-blind, randomized clinical 
trial for prevention of radiation induced mucositis topical aloe vera did not 
show any benefit.122 
Chamomile mouthwash is a solution prepared from the flower of the 
chamomile plant. This plant contains many different substances which are 
suggested to have anti-inflammatory, antibacterial and antifungal properties. 
The use of chamomile mouthwash in a double-blind, randomized clinical 
trial for the prevention of 5-fluorouracil induced mucositis did not show 
any benefit either.123 
CONCLUSION AN D PERSPECTIVES 
A search of the literature revealed a total of 27 different interventions for 
the prevention of oral mucositis. Based on our criteria, a meta-analysis could 
be performed on eight of these interventions. Four interventions, namely 
PTA lozenges or paste, systemic administration of GM-CSF or G-CSF, oral 
cooling and amifostine showed a preventive effect on the development or 
severity of oral mucositis. 
Our meta-analyses show that GM-CSF and G-CSF is the only inter­
vention with some beneficial effect on the development of mucositis. PTA 
and amifostine decreased the severity of mucositis. Oral cooling prevented 
mucositis in 5-fluorouracil induced mucositis. Perhaps a multiple agent 
therapy that targets different biological events is necessary for the prevention 
of oral mucositis. 
From the 14 single-published studies nine interventions showed some 
positive results in prevention of mucositis. Most studies consisted of small 
samples sizes, were not double-blinded or did not use a placebo-controlled 
design. Further research with well designed studies is necessary for 
providing evidence if any of the interventions is effective in prevention of 
mucositis. Palifermin, the recombinant human keratinocyte growth factor, 
intravenously, seems to be the most promising intervention for the prevention 
of mucositis in patients with hematologic malignancies undergoing 
autologous peripheral blood progenitor cell transplantation after fractionated 
total-body irradiation. 
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To date, i t  can be concluded that no single intervention i s  capable of 
completely preventing oral mucositis. Future studies should evaluate 
combination of interventions for the prevention of oral mucositis. 
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SUM MARY 
Background In the assessment of mucositis the inter-evaluator variability 
needs to be minimized and would likely to be best accomplished by training. 
The aim of this study was to evaluate the effect of training on concordance 
of evaluators in scoring oral mucositis. 
Methods The evaluators were informed about the pathobiology and clinical 
appearance of mucositis and were trained in scoring mucositis according 
the Oral Mucositis Assessment Scale (OMAS). The effect of the training 
was evaluated by a pre- and post-training test. Each test consisted of 15 
slides depicting oral mucositis. The pre- and post-training scores were 
compared to the reference standard. 
Results During 8 months at 6 meetings 65 evaluators were trained. The 
mean percentage correctly scored slides according the OMAS increased 
significantly between the pre- and post-training test (P<0.001). 
Co11clusio11 Training evaluators in scoring oral mucositis has a significant 
improvement on the outcome of mucositis assessment. 
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I NTRODUCTIO N  
Mucositis of the oral mucosa is a frequent cause of morbidity in cancer therapy 
with a serious burden on patients. Severe mucositis causes considerable 
pain and discomfort, leading to a higher need of pain medication, parenteral 
nutrition and length of hospitalization.1-2 
Many studies in which agents are tested with potential useful outcomes 
on mucositis have their shortcomings. Studies were underpowered, lacked 
an adequate control arm, were not investigator or patient blinded or had 
other major design flaws.3 To determine the value of new agents aimed at 
prevention of mucositis, well designed, sufficiently powered and appropriately 
executed studies are needed. Due to the lack of sufficient patient numbers 
at single study sites, often a multicenter design is necessary to obtain data 
within an acceptable time frame. Moreover, time frames for preventive studies 
on sequelae of cancer therapy are very tight because of new developments 
or changes in ablative therapies like changes in fractionation schedules in 
radiotherapy or new combinations of cancer cytotoxic therapies.4 
One of the major concerns in controlled multicenter trials with mucositis 
is the establishment of adequate inter-evaluator reliability to reduce outcome 
variability. In the implementation of the evaluation method in a multicenter 
trial, standardization between the different study sites and evaluators is 
essential for decreasing error variance and reducing type II error, i.e. failing 
to detect true differences between active drug and placebo. Furthermore a 
poor inter-evaluator reliability decreases statistical power, resulting in 
necessity for larger sample sizes to be able to detect significant differences 
between drug and placebo.5 
To increase the inter-evaluator reliability in multicenter trials start up 
training meetings are necessary to standardize evaluators to the same 
method of scoring and baseline knowledge. 
According to the regulations of the United States Food and Drug 
Administration (FDA) selected investigators and evaluators should be 
qualified by training and experienced to investigate the device (21Code of 
Federal Regulations (CFR) 812). Industry-sponsored trials, with the intention 
for FDA approval, will need to have start up training meetings to conform 
these regulations. 
In testing efficacy of training of evaluators there should be pre- and 
post-testing conducted to examine on empirical basis whether the training 
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was effective. This testing should evaluate the improvement in: 1) conceptual 
understanding of the scoring method; 2) accuracy, i.e. how scores by the 
evaluator agree with the reference standard; 3) inter-evaluator reliability. 
Between pre- and post-testing phase, a didactic training should be provided.6 
One of the most important issues in research is a well defined endpoint. 
Regarding mucositis studies, in most instances mucositis will be used as 
primary endpoint defined as ulcerative or pseudomembranous mucositis. 
Several mucositis rating scales are clinical observational scores, based on a 
combination of local mucositis parameters (signs) together with general 
complaints such as pain and effects on eating.7 Differences in definition 
and operationalization of these general complaints hamper proper 
comparison of the outcomes using these scoring systems. 
For assessment of the mucosal changes related to anti-cancer therapies 
the Oral Mucositis Assessment Scale (OMAS) has been developed.8 The 
OMAS is a simple, quantitative and accurate mucositis score especially 
validated for research application in multicenter clinical trials. In this score, 
a clear definition of mucositis symptoms, erythema and ulceration, are 
established. The OMAS has been shown to be highly reproducible between 
observers (r >0.8), responsive over time (r >0.9) and accurately records the 
anatomic elements considered being associated with mucositis.8 
The aim of this study was to evaluate the effect of training on concordance 
of evaluators in scoring oral mucositis according the OMAS score. 
MATERIALS AND M ETH ODS 
Training meetings were organized as  start up of a phase III multicenter 
clinical trial. During these meetings evaluators were trained in scoring 
mucositis according the OMAS and informed about the intention of the 
study, the pathobiology and clinical appearance of mucositis. All meetings 
were conducted by the same trainer (F.S.). 
The training meeting consisted of a pre-testing phase, didactic training 
and post-testing phase, all of which was performed on the same day. The 
pre-testing phase consisted of a slideshow of 15 slides with clinical pictures 
of different regions of the mouth with or without different stages of 
mucositis. For each slide the evaluator had to fill in on a form the mucositis 
score, according the OMAS of the depicted region, based on visible ulceration 
and/or erythema, and the size of the lesion (ulceration) or intention 
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(erythema) (Table 1) .  The score forms were collected after the slideshow. 
The didactic training consisted of a thorough review of the pathobiology of 
mucositis, the scoring method of mucositis according to OMAS, and an 
explanation of the different clinical aspects of mucositis. The post-testing 
phase consisted of a retest of the same 15 mucositis slides of which the 
evaluator again needed to fill in the score forms. 
Table 1 .  Scoring mucositis according the Oral M ucositis Assessment Scale (OMAS) 
Location Erythema* U lceration�Pseudomem bra nes** 
U pper lip 0 2 0 2 3 
Lower l ip 0 2 0 2 3 
Right cheek 0 2 0 2 3 
Left cheek 0 2 0 2 3 
Right ventral and lateral tongue 0 2 0 2 3 
Left ventral and lateral tongue 0 2 0 2 3 
Floor of the mouth 0 2 0 2 3 
Soft palate 0 2 0 2 3 
Hard palate 0 2 0 2 3 
* Erythema: 0 - none; 1 not severe; 2 severe 
* *  Ulcerations!Pseudomembranes: 0 - no lesion; 1 < 1 cm; 2 1 cm2 3 cm2; 3 = > 3 cm2 
The scores of the evaluators were compared to a reference standard score. 
The reference standard was developed as follows. All 15 slides were scored 
for ulceration and erythema according the OMAS and rated for visible 
ulceration and/ or erythema, independently by three experienced evaluators 
(S.S., F.S., M.S.) in the field of mucositis scoring prior to the start up meet­
ings. A consensus meeting was held to discuss discrepancies in their scores. 
Consensus was reached by means of discussion. The outcomes of these 
scores were used as the reference standard score for each slide. 
Statistical analysis 
The scores of the evaluators according the OMAS and presence or absence 
of ulcerations and/ or erythema, were dichotomized in either correct or 
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incorrect comparing to the reference standard. The Student's t-test for depend­
ent samples was used to analyze the mean performance (expressed as the 
percentages of correct scores) of the evaluators in two ways, one ignoring 
the missing and secondly considering the missing as incorrect scores. 
McNemar's test was used to analyze the percentages correct scores of the 
different slides separately. 
A P  value of <0.05 was considered significant. 
RESULTS 
In the course of 8 months, 6 start-up training meetings were organized and 
a total of 65 evaluators were trained. The average group size was 11 
evaluators (range 8-15). The professional background of the evaluators 
varied from dentists, physicians, nurses and research assistants. The results 
of the dichotomized scores on the 15 slides of the pre- and post-test training 
are summarized in table 2. 
Table 2 . Summary of the correc , incorrect and missing scores of the 65 evaluators for the 1 5 slides 
accord ing OMAS: T1 is p re-test training scores; T2 1s post-test tra in ing scores 
Tl T2 
% n % n 
Ulceration Correct 45 435 62 608 
Incorrect 50 49 1 28  269 
M issing 5 49 1 0  98 
Erythema Correct 59 567 69 669 
Incorrect 35 344 2 1  207 
M 1ss1ng 6 55 1 0  99 
Comparing the mean performance of the evaluators, ignoring the 
missing, the mean evaluator 's percentage correctly scored slides according 
to the OMAS increased significantly between pre- and post-test training 
for both ulceration from 47% to 69% (95% CI: 17 to 26) and erythema from 
63% to 77% (95% CI: 11 to 17).  Considering the missing as incorrect scores, 
the mean percentages increased less pronounced but still significant at the 
0.001 level. The mean percentage correctly scored ulceration increased between 
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Table 3 .  Proportion of scoring improvement of each sl ide after training of the evaluators 
Sl ide Mucositis Proportion 95% a 
of improvement 
Ulceration 0 .00 (-0.05 to 0.05) 
Erythema 0. 1 2  (-0.01 to 0.25) 
2 U lceration 0 .37* ( 0 .24 to 0.50) 
Erythema 0.25* ( 0. 1 4  to 0.37) 
3 U lceration 0 .03 (-0.08 to 0 . 1 5) 
Erythema -0.03 (-0.2 1 to 0. 1 4) 
4 U lceration -0. 04 (-0. 1 3  to 0.05) 
Erythema 0 .06 (-0.02 to 0. 1 4) 
5 U lceration 0 .40* ( 0.28 to 0.52) 
Erythema 0 . 02 (-0.06 to 0.09) 
6 Ulceration 0 .63* ( 0.50 to 0.75) 
Erythema 0. 20* ( 0.07 to 0.33) 
7 U lceration 0 .22* ( 0.09 to 0.34) 
E rythema 0 . 3 1 *  ( 0. 1 7  to 0.45) 
8 U lceration 0 .33* ( 0 . 1 9 to 0.47) 
Erythema 0.42* ( 0.27 to 0.57) 
9 U lceration 0. 1 1  * ( 0.03 to 0. 1 9) 
Erythema 0. 29* ( 1 . 1 3  to 0.45) 
1 0  U lceration 0. 30* ( 0. 1 2  to 0.48) 
Erythema 0 .02 (-0.02 to 0.06) 
1 1  U lceration 0. 1 8* ( 0.06 to 0.30) 
Erythema 0.27* ( 0. 1 0  to 0.44) 
1 2  Ulceration 0 .25* ( 0.09 to 0.4 1 )  
Erythema 0 .07 (-0.08 to 0.22) 
1 3  U lceration 0 . 00 (-0. 1 2  to 0. 1 2) 
Erythema 0 .08* ( 0.00 to 0 . 1 5) 
1 4  U lceration 0 . 52* ( 0.38 to 0.66) 
Erythema 0. 1 4  (-0.02 to 0.30) 
1 5  U lceration 0. 1 9* ( 0.04 to 0.35) 
Erythema 0.07 (-0.01 to 0 . 1 5) 
* represents a significant improvement (P < 0.05) 
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pre- and post-test training from 45% to 62% (95% CI: 12 to 23) and for 
erythema from 59% to 69% (95% CI: 5 to 14) 
Comparing the results of the evaluators of scoring the absence or 
presence of ulceration and/ or erythema, the correctly scored slides increased 
significantly between pre- and post-test training for both ulceration from 
83% to 92% (95% CI: 2 to 16) and erythema from 79% to 85% (95% CI: 1 to 12). 
The proportion improvements for the different slides are shown in table 3.  
Analyzing the scores for each of the 15 slides separately, 14 improvements 
were found for assessment of ulceration and of these improvements, 11 
were significant. Also on erythema, on 14 slides improvements were found 
and 11 were significant. 
D I SCUSS ION 
This study has shown that training of  evaluators has a positive significant 
influence on scoring oral mucositis. 
Analyzing the slides separately, three slides were poorly scored. More 
than 87% of the evaluators scored these three slides wrong in the pre-test 
and post-test after training according to OMAS score. These slides were 
not easy to evaluate with respect to the size of the lesion. A possible 
explanation might be a poor slide exposure or poor depiction of the anatomic 
site. In the future, it would probably be better to keep these three slides out 
of the training meeting. In a post hoc analysis, leaving these three slides 
out of the training meeting, the mean evaluator's percentage correctly scored 
slides according the OMAS increased for ulceration from 52% to 81 % and 
for erythema from 62% to 78%. However, scoring oral mucositis in the 
clinical situation should be easier because it allows inspection of the whole 
mouth and all anatomic sites are visible and the evaluator can change the 
position of the patient in obtaining a better view. 
Scoring only the absence or presence of mucositis signs erythema and/ 
or ulceration gave a higher mean percentage of correctly scored slides than 
when the size or the intention of the lesion had to be taken into account 
both at pre- and post-testing. Scoring of dimensions on a slide is very difficult 
and can only be done if a reference, like a tooth, is visible on the slide. Some 
of the slides did not have such a reference. This could be the explanation of 
the difference in mean percentages correctly scored slides between both 
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scoring methods. These outcomes can be an argument for the use of a scoring 
method, which only evaluates the absence or presence of the mucositis signs 
erythema and/or ulceration. Clinically, the ulcerative stage of mucositis is 
the most considerable stage and responsible for the pain and loss of function. 
In several studies aimed at prevention of mucositis, the primary endpoint 
is prevention of ulcerations. The World Health Organization Oral Toxicity 
Scale (WHO) score measures anatomic, symptomatic, and functional 
components of oral mucositis.9 The WHO score is easy to use, to learn and 
measures no lesion dimensions. In contrast, the OMAS is focused on the 
anatomic compound of mucositis alone, and is more precisely related to 
the mucosal changes and dimensions of the lesions due to cancer therapies. 
In clinical research with mucositis as primary endpoint, it would probable 
be best to use both, a method measuring mucositis in a subjective way and 
a method measuring only in an objective way. 
In this present study, the professional background of the evaluators 
varied and unfortunately the distribution was unknown. This drawback 
could be interpreted as flaw of this study, however it is known from others 
studies that the type of medical professional background does not influence 
the scoring outcome.8 
Post-training monitoring of the evaluators and calibration during a 
(multicenter) study is necessary to determine reliability and to prevent evaluator 
drift. 6 An evaluator can have high levels of competence and reliability before 
the study starts but this can fade away in time. It is necessary to involve a 
positive feedback loop post-training, which could measure the degree of 
the evaluators' comprehension. The phase III study, for which these trainings 
where accomplished, was stopped prematurely due to the instability of the 
intervention agent. Therefore, no information is available from this study 
about the evaluators reliability and drift with time. 
Training is essential to gain standardization of the evaluators and to 
increase intra- and inter-evaluator reliability. Not only for standardizing of 
scoring procedures but also to provide every study site and evaluator similar 
information. Moreover in multicenter trials, concordance between the 
evaluators at different study sites is a prerequisite. 
Based on this study and previous research future multicenter trails on 
mucositis prevention the following training prerequisites are recommen­
ded.6.10 Training needs to consist of: 1 )  training of the scoring method used 
as endpoint of the study; 2) didactic training comprising a review of 
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pathobiology of mucositis and of the scoring method; 3) training in scoring 
and processing of data; 4) testing efficacy of training intervention by pre­
and post-testing and 5) post-training monitoring of the quality of scoring. 
In conclusion, training evaluators in scoring oral mucositis has a signifi­
cant improvement on the outcome of mucositis evaluation. 
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SUM MARY 
Background An in vitro assay has been developed for quantitative 
assessment of chemotherapy induced oral mucositis. In the present study 
this method was evaluated for assessment of irradiation mucositis at a 
cellular level. 
Patients and methods Ten patients with head and neck cancer participated 
in this study. All patients were treated with conventional fractionated 
curative postoperative radiotherapy. Prior to, and weekly during, the irradiation 
course, oral washings were obtained to determine viability of epithelial cells 
by trypan blue dye exclusion. Maturation of epithelial cells was assessed 
from smears in buccal mucosa of these patients (Papanicolaou staining). 
The viability data were compared with the WHO score for mucositis. 
Results Epithelial cell viability increased during the first three weeks of 
radiation (P=0.04), and was seen earlier than the subjective mucosal changes 
with the WHO score. Cell maturity shifted from immature and intermediate 
to mature (P=0.03). 
Conclusions The cell viability assay can be considered as an objective 
method for following the development of irradiation mucositis, and seems 
to be more sensitive during the first three weeks of irradiation than the 
clinical WHO scoring method. 
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I NTRODUCTI O N  
Oral mucositis i s  the inflammatory reaction o f  the oral mucosa due to 
radiotherapy and/ or chemotherapy. Oral complications are inevitable 
sequelae of head and neck irradiation, involving pseudomembranous and 
ulcerative mucositis in about 80% of the patients.1 It is often painful, afflicts 
oral functioning such as swallowing and eating, diminishes the quality of 
life and can be dose-limiting.2 Ionizing radiation causes damage of rapidly 
proliferating cells of the basal cell layer of the epithelium. The severity of 
mucositis due to radiotherapy depends on the type of radiation, fractionation 
schedule, total cumulative dose and the volume of irradiated tissue.3-5 
During a conventional curative radiation schedule the first signs of 
mucositis - a white discoloration or erythema - will appear after 10 Gy radio­
therapy. These signs are caused by a higher degree of hyperkeratinization 
and vascular dilatation, respectively. The more severe stages of mucositis, 
i.e. pseudomembranes and ulceration, occur after 30 Gy. These signs are 
due to further breakdown of the mucous membrane together with vascular 
changes.1-3•6 
The biological basis of mucositis is the sterilization of proliferating cells 
in the germinative layer of the epithelium. Their gradual proliferative failure 
causes a deficit in the cellular supply of the functional layers. Due to the 
natural loss of the superficial layer by mechanical wear and tear, hypoplasia 
of the epithelium and eventually ulcerative mucositis develops.7-9 
At a cellular level, the development of mucositis due to radiation is 
only partially understood. Recently a hypothesis was proposed, describing 
the development of mucositis in four consecutive phases, namely the 
inflammatory /vascular phase, the epithelial phase, the ulcerative/bacterial 
phase and the healing phase.10 
To compare outcomes of preventive strategies or treatment modalities 
an objective, reliable and reproducible scoring system would be helpful. 
Most available scoring systems are clinical observational scores based on a 
combination of local mucositis parameters (signs) together with general 
complaints such as pain and effect on eating.11 Differences in definition and 
operationalization of these general complaints hamper proper comparison 
of the outcomes using these scoring systems. Some other scoring systems 
appeared to be unreliable and not reproducible, while some are difficult to 
use in a clinical setting.11 Of the available scoring systems, the WHO score 
and the NCI score are most frequently applied. However, these scoring 
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systems are based on a combination of local mucositis signs and general 
complaints. Thus, the same difficulties apply to these two methods.11 •13 
With Sonis's hypothesis10 for mucositis development and new perspec­
tives of preventive strategies in mind, a method for quantifying mucositis 
at a cellular level is demanded. 
To investigate mucositis objectively and on a cellular level, Wymenga 
and colleagues developed an in vitro assay for chemotherapy induced 
mucositis.14 The aim of the present study was to investigate whether this 
method can be used to quantify mucositis in head and neck cancer patients 
who received radiotherapy and to compare the results with the WHO 
scoring system. 
PATI E NTS AND M ETHO D S  
From February 1997 till December 1997, consecutive patients with oral, oral­
pharyngeal or salivary gland squamous cell malignancies were considered 
for entering the study. Eligible were patients if they received postoperative 
radiotherapy as follows: (1) with a conventional fractionation of 2 Gy per 
day with a 6 MV accelerator and (2) with a minimum accumulative dose of 
50 Gy according the ICRU 50 recommendations. Patients were not eligible 
with: (1) an oral mucosa defect other than related to tumour surgery, (2) a 
need for an obturator or resection prosthesis, (3) treated with antibiotics for 
an infection in the 2 week period before the start of irradiation, (4) oral 
candidiasis or acute periodontitis, or (5) nasogastric tube feeding at the 
start of irradiation. 
The evaluation period enclosed the whole period of 6 week period of 
irradiation. 
From the 11 patients included in this study one patient quitted the 
radiotherapy treatment after 2 weeks and was excluded from the study. 
The 10 remaining patients evaluated in this study comprised seven men 
and three women, with a mean age of 59.2 (range, 42-77 years). Nine patients 
had a squamous cell carcinoma, (seven oral, and two in the tonsil area), 
and one patient had an adenocarcinoma of the parotid gland. 
According to our supportive oral care protocol all patients were 
evaluated for potential risk factors for oral complications, such as 
exacerbation of peri-apical and periodontal infections, by means of a 
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thorough oral and dental evaluation, including a radiographic examination.15 
All potential risk factors were appropriately eliminated before start of 
radiotherapy. The supportive oral care regimen consisted of a daily standard 
protocol of cleansing the oral cavity by spraying with saline by the dental 
hygienist, and rinsing of the mouth by the patients themselves with a salt­
baking soda solution at least eight times a day. Edentulous patients were 
not allowed to wear their dentures during the course of radiotherapy. In 
this study, five patients were edentulous, three were dentate and two were 
partially dentate. 
The Medical Ethical Board Committee approved the study and all 
patients gave written informed consent. 
A control group, which consist of 10 healthy volunteers, seven men and 
three women, with a mean age of 54.3 (range, 48-63 years), was evaluated 
for comparison of the baseline outcome of epithelial cell maturation and 
viability. 
Scoring mucositis 
Prior to, and at the end of each week of radiation, an oral washing, as well 
as a buccal smear with a cytobrush, were obtained for epithelial cell 
determination of viability and maturation. At the same time, mucositis was 
clinically evaluated using the WHO toxicity grading.12 Mucosa! epithelial 
cells were obtained twice from the control group, at a weekly interval, for 
measurement of viability and maturation. 
To acquire an oral washing, patients gargled and rinsed their mouth 
with 10 ml sterile saline for 30 sec, and spat out into a tube. This expectorate 
was centrifuged within 10 min after collection (190 g, 10 min, room 
temperature) and the supernatant was discarded. The fluid was washed 
with 10 ml saline and centrifuged again to eliminate salivary fibers. Pellets 
were resuspended in 1 ml RPMI 1640 medium (Gibco, Paisley, UK) 
containing 5% fetal calf serum. Subsequently, 50 µl suspension and 50 µl 
trypan blue dye (0.4% in 0.15 m NaCl) were combined and immediately 
transferred to a hemocytometer. Cell counts were performed, after which 
the percentage viable cells and total cells number were calculated. 
Determination of the viability was performed independently from the 
clinical mucositis scoring. 
Buccal mucosa smears were put on glass-slides and stained according 
to Papanicolaou. Epithelial cell morphology was assessed after collection 
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of all slides at the end of study period.16 The assessment was a blinded and 
randomized, and was performed by one observer ( M.A.S.). Orange stained 
cells were classified as mature, while blue / green stained cells were 
categorized as immature cells. Cells with a partly orange and partly green 
appearance were graded as intermediate cells. Percentage of mature, 
intermediate and immature cells was determined from each smear. 
Mucositis was evaluated clinically on a weekly basis, according to the 
WHO toxicity grading, in which grade 0 = normal, no mucositis; grade 1 = 
soreness and erythema; grade 2 = erythema, ulcers, can eat solids; grade 3 = 
ulcers, requires liquid diet only; grade 4 = alimentation not possible. 12 
Statistical analysis 
Statistical analysis included: Spearman rank correlations and Wilcoxon 
signed rank test. A P  value < 0.05 was considered significant. 
R E SULTS 
The percentage viable cells at baseline in the patient group (46.2% ± 18%) 
did not differ from controls (47.8% ± 12%). 
During the first 3 weeks of radiotherapy the viability increased signifi­
cantly (P=0.04) from 46.2 (± 18%) to 62.9 (± 19%) (Figure 1) .  
The mean percentage of mature cells increased during radiotherapy and 
this increase was significant (P=0.03) after 2 weeks of treatment compared 
to the baseline outcome. The mean percentage of intermediate and immature 
cells decreased, although this was not significant (Figure 2). 
The WHO mucositis score is shown in figure 3. At the end of the first 
week, three patients experienced mucositis grade 1. After three weeks, nine 
patients had mucositis grade 2 or worse. 
Figure 4 shows the course of mucositis using the WHO score (grade 3, 4) 
compared with the outcome of the cell viability scores (� 5% compared 
with baseline). The change in the cell viability score preceded the change in 
the WHO score during the first 3 weeks. However, the correlation between 
these two scores was not significant in week 1 and 3 (P=0.09, P=0 .6 
respectively). In week 2 there was a significant correlation (P=0.04). 
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Figure 1. Mean percentage (+ 
sem) viable epithelial cells in an 
oral washing before and during 
radiotherapy 
Figure 2. Morphology of buccal 
epithelial cells stained according 
to Papanicolaou, mean percen­
tage (-z sem) of mature cells 
(white), intermediate (grey) and 
immature cells (black) at baseline 
and during treatment 
Figure 3. Mucosit is score accord 
ing to the WHO grading system 
before and during treatment 
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with an increased cell viability 
(.<? 5% compared with baseline • ) 
and a WHO mucosit is score grade 
3 and 4 (A.) at baseline and during 
the radiotherapy 
This study shows that the assay used, in which the changes of the oral 
epithelium at the cellular level can be quantified, can be used for scoring 
mucositis in head and neck cancer patients during radiotherapy. The clinical 
course of mucositis in these patients, who received standard oral care, 
followed an expected pattern, with over 80% of the patients developing 
severe mucositis after 3 weeks. 1  
The observed increase in percentage of viable epithelial cells during the 
first three weeks occurred due to desquamation of the non-vital upper oral 
epithelial layer, which is thought to be the basic process during irradiation 
at a mucosal level.3 Thus, whereas at baseline, many superficial non-vital 
epithelial cells are obtained with oral washing and cytobrush, during 
radiotherapy, which causes desquamation, these sampling methods yield 
mostly suprabasal (viable) epithelial cells. The increase in percentage of 
viable cells reflects the epithelial phase of mucositis described by Sonis.10 
Earlier reports showed that after three weeks of irradiation the normal 
architecture of the mucosa is disturbed and leakage and disruption in the 
basal membrane develops.3 This phenomenon almost certainly explains the 
decrease in viability after three weeks. 
In addition to the increase in percentage of viable epithelial cells during 
the first three weeks, changes in the morphology of the epithelial cells were 
also detected. A shift from immature and intermediate to more mature 
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epithelial cells was observed during the first three radiotherapy weeks. 
These changes possibly reflect the changes at the basal cell layer, i .e. 
disturbed cell proliferation of the epithelial layer due to radiotherapy.10 
In contrast, a decrease in the percentage of mature cells and an increase 
in the percentage of immature epithelial cells was reported after high-dose 
chemotherapy. 14 This difference may indicate different mechanisms of 
radiotherapy and chemotherapy at the oral mucosal level, one such 
difference being the treatment regime. In general, chemotherapy has a 
discontinuous effect due to a different schedule of administration. By con­
trast, the radiotherapy regime used in this study was a continuous process, 
on a daily basis for a period of 6-7 weeks.17 Wymenga and colleagues 
evaluated patients during one chemotherapy cycle.14 The radiation patients 
were evaluated during the whole six-week treatment period. Silverman and 
colleagues describes lesions due to chronic irritation that shed predominantly 
mature squamous cells.18 This probably explains the difference between 
the results from chemotherapy patients and radiotherapy patients. Another 
explanation relates to the effect of radiotherapy has on the cell. The cell is 
damaged by radiation and loses its reproductive integrity. A possible 
consequence for the cell may be the inability to divide, while remaining 
physiologically functional for a long period.19 This could result in the cell 
migrating to the surface, and remaining there to maturate. Furthermore, 
residual mitotic activity of irreversible damaged cells, designated as abortive 
divisions, is supposed to significantly contribute to overall cell production.20 
The increase in percentage of viable epithelial cells is seen earlier in the 
treatment regime than the clinical mucositis observed using the WHO score. 
This suggests that, during the early treatment phase, the former method is 
more sensitive in detecting mucosa! changes. After three weeks, the per­
centage of viable epithelial cells decreases, while the WHO score does not 
diminish. The viable cell method can therefore only be used for scoring the 
course and development of mucositis during the first three weeks of 
radiation. The development of severe pseudomembranes/ ulcerative 
mucositis during head and neck irradiation is at its maximum three weeks 
from the onset of radiotherapy. During this period, the viable cell method 
can closely follow the course of mucositis. The results of this study support 
the idea that this method could facilitate the evaluation of new preventive 
strategies at a cellular level. This could be of value for future studies 
evaluating preventive strategies. 
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SUMMAR Y  
Background Cancer patients treated with cytostatic drugs often develop 
oral mucositis, considered to be a mucosal injury in which various cytokines, 
e.g. interleukin 8 (IL-8), may play a role. Plasma IL-8 is a systemic inflamma­
tory response parameter. This study investigated whether oral mucositis 
affects plasma IL-8 levels in febrile neutropenic cancer patients . 
Patients and methods Patients (n=57) who were hospitalized with chemo­
therapy induced neutropenic fever were scored for oral mucositis on the 
second day of hospitalization according to a validated oral mucositis assess­
ment scale (OMAS) and WHO toxicity grading. 
Patients (n=20) with a clinical sepsis or local bacterial infection were 
excluded from this evaluation. The remaining 37 patients were divided in 
a group with and without oral mucositis. 
Results The difference in plasma IL-8 level between patients with and 
without mucositis was not significant (P=0.7). Similar no difference was 
observed in the degree and duration of granulocytopenia. 
Conclusion These results indicate that low-grade oral mucositis is not related 
to the systemic plasma IL-8 level in febrile neutropenic cancer patients 
without a clinical sepsis or local bacterial infection. 
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I NTRODUCTIO N  
Fever is among the first signs o f  bacterial infection in neutropenic patients. 
Classical inflammatory signs such as erythema, pain and swelling are often 
less overt in neutropenic cancer patients due to impaired immune defence 
mechanisms.1 
Blood plasma levels of TNF-a and ILl-� are often low whereas the levels 
of IL-6 and IL-8 increase in the peripheral blood during systemic infection 
in cancer patients with chemotherapy induced neutropenia.24 The standard 
therapy for patients with fever and chemotherapy induced neutropenia is 
hospitalization and intravenous administration of broad-spectrum antibiotics 
on empirical grounds although a considerable number of these patients 
probably have no bacterial infection. It would be a great advantage if a 
simple method, such as the measurement of IL-8 level in combination with 
a physical examination, could distinguish patients with febrile neutropenia 
and low risk of infection who would need no hospitalization with no or 
restricted use of antibiotics.5 
Oral mucositis is a sequelae in patients treated with chemotherapy, 
which can occur in 40% to 100% of the patients. 6-8 Development of mucositis, 
with the bacterial colonization of the damaged epithelium, provides an oppor­
tunity for bacteria or their products to leak through the injured mucosa, 
which may further stimulate the release of inflammatory cytokines such as 
IL-8.9•10 However, the relationship between a systemic inflammation param­
eter, such as plasma IL-8 level, and mucositis has not been studied before. In 
the development of a risk assessment model with the plasma IL-8 level as 
parameter it is important to investigate the relationship between oral mucositis 
and the plasma IL-8 level in patients without documented infections. 
A possible relationship has been described between the development 
of mucositis and herpes simplex infection (HSV) as well as the contribution 
of HSV reactivation to unexplained fever in neutropenic cancer patients.11•13 
The main purpose of this study was to investigate the relationship 
between oral mucositis and systemic IL-8 levels in neutropenic cancer 
patients with fever without a local bacterial infection or a clinical sepsis. In 
addition, the relationship was analyzed between mucositis and neutropenia, 
duration of hospitalization and fever, and herpes simplex virus re-activation 
in this population. 
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PATI E NTS AND M ETHO D S  
Included in the present study were all consecutive cancer patients (children 
and adults) who developed febrile neutropenia after outpatient chemotherapy 
and were eligible for a risk assessment study provided they were hospitalized 
on Sunday to Friday.5 Chemotherapy related neutropenia was defined as 
granulocytes < 0.5xl09 /L or leukocytes < lxl09 /L and fever as axillary body 
temperature >38.5 °C once or 38.0 - 38.5 °C 3 times over a 6-hours observation 
period.2 Patients already receiving antibiotics were excluded, as were 
patients after autologous or allogeneic bone marrow transplantation. The 
use of selective gut decontamination or Pneumocystic carinii pneumonia 
prophylaxis (oral trimethoprim-sulfamethoxazole 3/15 mg per kg/ day three 
days a week) were no exclusion criteria. 
At presentation a physical examination was performed in the enrolled 
patients. Neutropenia was determined by absolute neutrophil or leukocyte 
counts and paranasal sinus and chest radiographs were obtained. Cultures 
of blood and sites that were suspect for infection were collected. In addition 
EDTA blood specimens were collected to measure IL-8 plasma concentrations. 
Patients were scored for mucositis and a sample from the oropharynx was 
taken for detection of a possible herpes simplex virus infection (HSV). Total 
days of hospitalization, days of fever, and days of neutropenia were recorded. 
The Medical Ethical Committee approved the study and all patients and/ 
or their parents dependent of age of the patients, gave written informed 
consent. 
Clinical sepsis 
Clinical sepsis was defined as follows: systolic blood pressure s 90 mmHg 
in adults or < -2 standard deviations (SD) for age in children, or both heart 
rate > 100/min and respiratory rate > 20/min in adults or both heart and 
respiratory > +2 SD for age in children, according to systemic inflammatory 
response syndrome (SIRS) criteria.14 
Mucositis 
The mucositis was scored according the Oral Mucositis Assessment Score 
(OMAS) and WHO score without knowledge of patients characteristics and 
blood results on the second day of hospitalization. Two scoring systems 
were used to be able to compare outcomes with findings from the literature. 
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The OMAS mucositis score measures 9 sites in the mouth for erythema, 
pseudomembranes or ulcerations, scoring range 0-5.15 The WHO mucositis 
score is as follows: grade 0 = normal, no mucositis; grade 1 = soreness and 
erythema; grade 2 = erythema, ulcers, can eat solids; grade 3 = ulcers, 
requires liquid diet only; grade 4 = alimentation not possible.16 
Measurement of plasma IL-8 
Plasma IL-8 concentrations were determined using a chemiluminescent 
immunoassay system according to the manufacturer 's  instructions 
(Immulite, Diagnostic Products Corporation, Los Angeles, USA).2 
Herpes Simplex virus detection 
The viral cultures were taken with the swab technique, and transported in 
Cly-medium for laboratory culturing. Standard viral culture techniques 
were used. In patients with mucositis the swab was obtained from the 
pseudomembranes and in patients without mucositis the swab was obtained 
from the oropharynx. 
Statistical analysis 
Only the first febrile episode of each patient was used in the statistical 
analysis because repeated observations within the same subject cannot be 
considered as independent. The Mann-Whitney U test was used to analyze 
the differences in mucositis, the IL-8 plasma level, leukocyte and neutrophil 
counts, duration of hospitalization, fever and neutropenia between the 
patients with and without mucositis. Chi-square test was used to analyze 
the differences in gender, type of cancer and viral cultures between the 
patients with and without mucositis. Spearman's correlation coefficient was 
calculated for correlation between the different outcome variables. Statistical 
tests were carried out two sided at a significance level of 5%. 
RESULTS 
From May 1999 until January 2002, 57 patients were included, in whom 73 
episodes of chemotherapy related neutropenia and fever were observed. 
Only the first febrile episode of every patient was used for this analysis. 
From the 57 patients, 20 patients were diagnosed with signs of a clinical 
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sepsis (n=7) or a local bacterial infection (n=13). Local bacterial infections 
comprised sinusitis (n=2), skin and soft tissue infections (n=S), urinary tract 
infections (n=2), otitis (n=2), parotitis (n=l) and dental infection (n=l). None 
of these patients had a positive blood culture. To avoid influence of clinical 
sepsis or local bacterial infection on the plasma IL-8 level, the results of the 
20 patients diagnosed with a local bacterial infection or clinical sepsis were 
not used in the analysis. Patients characteristics of the remaining 37 are 
shown in table 1 .  Patients with mucositis were significantly older than 
Table 1 .  Patient characteristics of the patients without a cl in ical sepsis or local bacteria l  infection (n =37) 
in  relation to the presence of oral mucositis 
mucositis no mucositis P-value 
(n = 1 9) (n = 1 8) 
Age in yrs median (IQR) 37 (1 2-49) 8 (4-27) 0.02 
*Gender: male/female 1 1/8 8/1 0 0.52 
*Type of cancer: 
hematologic (n - 1 3) 62% 38% 0.50 
solid (n - 24) 46% 54% 
Leukocytes at admission x 1 09/L, 
median (IQR) (n) 0.4 (0.2-0.65) (1 O) 0.25 (0. 1 3 -0.58) ( 1 2) 0.44 
Absolute neutrophi l  count at adm1ss1on 
x 1 09/L, median (IQR) (n) 0.05 (0.01 -0.09) (9) 0 . 1 1 (0.08-0.28) (6) 0.06 
Days with neutropenia, median (!QR) 5 (4.0-6.3) 4 ( 1 .5-6.5) 0.30 
Days of fever, median (IQR) 1 ( 1 .0-2.3) 1 ( 1 .0-2.0) 0.96 
Days of hospitalization, median (IQR) 6 (3.8-8.3) 5.5 (3 .0-7 .3) 0.68 
M ucos1tis score 
OMAS mean ± SD 0.7 ± 0.9 0 
WHO 0 (n) 0 1 8  
WHO 1 (n) 6 0 
WHO 2 (n) 9 0 
WHO 3 (n) 0 0 
WH0 4 (n) 4 0 
*Viral cultures (n) 1 2  1 0  0 .21  
pos1tive/negat1ve 3/9 0/1 0  
I L-8 level pg/ml median (IQR) 70 (29-1 75) 58.5 (30.8-1 54.3) 0.70 
/QR= inter-quartile range 
All differences between the groups were analyzed using Mann Whitney U test for independent samples 
except * in which chi-square test was used 
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patients without mucositis (P=0.02). No correlation was found between age 
and the plasma IL-8 level (r=0.08, P=0.6) . The variables gender and type of 
tumour did not differ significantly between patients with and without 
mucositis. 
Mucositis 
The mean OMAS mucositis score in the total group (n=37) was 0.3 (SD 0.7); 
18 patients had no mucositis whereas 19 patients developed mucositis (mean 
OMAS score was 0.7 (SD 0.9)). From the 19 patients with mucositis, 13 
patients developed pseudomembranes or ulcerations and had WHO score 
grade 2". 2 (Table 1). Comparison of the scoring methods for mucositis showed 
a high correlation between the OMAS en WHO score (p=0.95, P=0.003). 
From 22 patients (12 patients with mucositis and 10 patients without 
mucositis) a viral microbiological sample was taken to detect a herpes 
simplex virus infection. A positive test for HSY was found in three patients, 
all three had mucositis (25%). Two of the patients had an ulcerative mucositis 
(Table 1) .  
IL-8 
The median plasma IL-8 level for patients with mucositis was 70 pg/ml 
(inter-quartile range 29-175) and for patients without mucositis 58.5 pg/ ml 
(inter-quartile range 30.8-154.3). No significant difference in plasma IL-8 
level between patients with and without mucositis was found (P:;0.7) 
(Figure 1, Table 1) .  
Mucositis in relation to duration of fever, hospitalization and neutropenia 
No significant differences were found between patients with and without 
mucositis for the duration of fever, hospitalization and neutropenia (Table 1) .  
D I SCUSS ION 
This study shows that the plasma IL-8 level as  a parameter of  systemic 
inflammation in cancer patients with febrile neutropenia is not influenced 
by low-grade oral mucositis. 
The plasma IL-8 level was used as parameter for systemic inflammation 
since in earlier studies it was found that the plasma IL-8 level was a more 
sensitive parameter in cancer patients with chemotherapy induced neutro-
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Figure 1 .  Box-and-whisker plot of the plasma IL 8 levels for the group of patients with and without 
mucositis 
penia than e.g. IL-6.2•17 Additional ly, measurement of plasma IL-8 levels at 
the onset of fever in neutropenic patients is a valuable and sensitive tool to 
define a group of low-risk patients.2•4•5•17 The current study was part of a risk 
assessment study in which the plasma IL-8 level was used as a parameter 
for systemic inflammation in febrile neutropenic patients.5 In the 
development of such a risk model it is important to investigate the impact 
of oral mucositis on the plasma IL-8 level and whether oral mucositis must 
be considered as a local infection. Mucositis in neutropenic cancer patients 
can be a potential portal of entry for the endogenous oral flora leading to 
bacteremia or sepsis. 1 1 ·18•20 In this study no significant difference was found 
in the plasma IL-8 level between patients with and without mucositis and 
therefore mucositis should not be considered as a local infection in this 
patient population. 
No influence of mucositis on the IL-8 parameter was found. However, 
the overall severity of mucositis in this patient population was low with a 
mean mucositis score (OMAS) of 0.3 (n=37). In an earlier observational study 
for development of mucositis, 75% of the patients developed mean levels 
of mucositis > 1 (OMAS) during bone marrow transplantation.21 The relative 
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low mucositis scores in this study might explain that mucositis did not 
affect the plasma IL-8 levels. This finding supports the hypothesis of Sonis 
(2004) who assumed that the release of cytokines starts in the primary 
damage response but the massive release of cytokines occurs in the ulcerative 
phase.10 
In this study in cancer patients treated at the outpatient department, 
oral mucositis was not related to duration of fever, hospitalization or neutro­
penia. This contrasts with patients undergoing hematopoietic stem-cell 
transplantation. In that patient population oral mucositis is positively 
correlated with the risk of infection, duration of hos pi taliza ti on and death. 21 
This difference in the role of oral mucositis may be explained by differences 
in intensity of chemotherapy. In the study of Sonis and colleagues (2001) 
more than 80% of the patients developed ulcerations while in the present 
study only 35% of the patients presented with ulcerations.21 
A possible relationship between HSV and oral mucositis has been 
previously proposed. 12 It was concluded that oral ulcers are associated with 
HSV infection and in some cases probably caused by the virus. In the current 
study, only three patients (25%) in the group with mucositis and no patients 
in the group without mucositis had a positive HSV culture. The number of 
positive HSV infections was too small to detect such an association with 
mucositis. Therefore, further studies in larger populations are needed to 
understand the role of HSV in mucositis and fever of unknown origin (FUO) 
in neutropenic patients. 
In conclusion, this study shows no relationship between low-grade oral 
mucositis and the plasma IL-8 level in febrile neutropenic cancer patients 
without clinical sepsis or local bacterial infection. Oral mucositis should 
therefore not be considered as a focus of infection in a risk group assessment 
based on IL-8 in out clinic patients with fever during chemotherapy induced 
neutropenia. 
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SUM MAR Y  
Background Mucositis is an acute inflammation of the oral mucosa because 
of radiotherapy and/ or chemotherapy. All patients receiving radiotherapy 
in the head and neck region develop oral mucositis. 
The aim of this study was to analyze the effects of selective oral flora 
elimination on radiotherapy induced oral mucositis, in a double blind, 
randomized, placebo-controlled trial. 
Patients and methods Sixty-five patients with a malignant tumor in the 
head and neck regions to be treated with primary curative or postoperative 
radiotherapy participated in this study. The patients received either the 
active lozenges of 1 g containing polymyxin E 2 mg, tobramycin 1 .8 mg and 
amphotericin B 10 mg (PTA) (33 patients) or the placebo lozenges (32 patients), 
four times daily during the full course of radiotherapy. Mucositis, changes 
in the oral flora, quality of feeding and changes of total body weight were 
assessed. 
Results Mucositis score did not differ between the groups during the first 5 
weeks of radiotherapy. Nasogastric tube feeding was needed in six patients 
(19%) of the placebo group and two patients (6%) of the PTA group (P=0.08). 
Mean weight loss after 5 weeks of radiation was less in the PTA group (1.3 
kg, SD 3.0) than in the placebo group (2.8 kg, SD 2.9) (P=0.05). Colonization 
index of Candida species and Gram-negative bacilli was reduced in the PTA 
group and not in the placebo group (P<0.05). No effect on other micro­
organisms was detected. 
Conclusion Selective oral flora elimination in head and neck irradiation 
patients does not prevent the development of severe mucositis. 
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I NTRODUCTIO N  
Radiotherapy in head and neck cancer patients can induce oral mucositis, 
which is an acute inflammation of the oral mucosa. Until now no effective 
intervention has been developed to prevent oral mucositis in radiotherapy.1 
This prevention is even more relevant now because altered fractionation 
schedules for the treatment of head and neck malignancies induce more 
severe mucositis.2 All patients receiving radiotherapy in the head and neck 
region develop oral mucositis to some extent, depending on radiation 
schedule, radiation field, radiation volume and cumulative dose.3 Clinically, 
mucositis appears in a conventional radiation scheme after a cumulative 
radiation dose of 10-20 Gy as a white discoloration of the mucosa because 
of hyperkeratinization. The next stage is a deepening erythema followed 
by the development of pseudomembranes and ulcerations. Severe mucositis, 
appearing as pseudomembranes, will develop at the end of the third week 
of radiation, after about 30 Gy.4,s Prevention of severe mucositis is important 
because mucositis affects the patient's feeding status, physical and mental 
well being and it can influence the course of radiotherapy.1 Further oral 
pain because of mucositis has a serious impact on the quality of life of 
patients.3 
Several mechanisms are supposed to play a role in the development of 
mucositis: changes at the cellular level of the basal cell layer, inflammatory 
process in the epithelium and influence of bacteria on mucosal surface. 
Changed oral flora, colonizing the oral mucosa, may aggravate the mucosa 
reaction because of radiation.6 The carriage and colonization of aerobic Gram­
negative bacilli are thought to play a role in the pathogenesis of irradiation 
mucositis.7 Ahypothesis has been proposed on the development of mucositis 
in four consecutive phases, in which the ulcerative/bacterial phase is thought 
to play a role in the development of fibrous pseudomembranes of the oral 
mucosa.8 A pilot study in 15 patients reported the protective effect of an 
antibiotic lozenge for selective elimination of the oral flora.9 Less severe 
mucositis and a less mean mucositis score compared to a historical control 
group was observed. None of the PTA (polymyxin E 2 mg, tobramycin 1 .8 mg 
and amphotericin B 10 mg) treated patients needed nasogastric tube feeding. 
In a cohort study including 36 patients, it was found that PTA lozenges 
may reduce irradiation mucositis.10 In contrast, randomized studies reported 
conflicting effects on mucositis by selective oral flora elimination.11-13 
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The aim of this study was to evaluate in a randomized, double blind, 
placebo-controlled trial the effects of selective oral flora elimination on the 
development of irradiation induced oral mucositis, feeding, weight loss 
and colonization of aerobic Gram-negative bacilli and yeast. 
PATI E NTS AN D M ETHODS 
Protocol 
Patients with a malignant tumor in the head and neck regions to be treated 
with primary curative or postoperative radiotherapy were eligible for this 
study. Inclusion criteria for the study were: external bilateral irradiation 
via parallel-opposed portals by a linear accelerator (4-6 Mev), fractionation 
of 2 Gy daily, five times a week, with a prescribed dose of at least 50 Gy and 
at least 50% of the oral mucosa in the field of radiation. The dose specification 
was in line with ICRU 50 recommendations.14 
Criteria for exclusion were: (1) an oral mucosa defect other than related 
to tumor surgery; (2) need for an obturator or resection prosthesis and; (3) 
treatment with antibiotics for an oral infection the last 2 weeks before the 
start of irradiation. 
As a standard procedure all patients were evaluated before radiation 
treatment for potential risk factors for oral complications by means of a 
thorough oral and dental evaluation, including a radiographic examination. 
All potential risk factors were eliminated appropriately before the start of 
radiotherapy. The supportive oral care regimen consisted of a daily protocol 
of cleansing the oral cavity by means of spraying with saline by the dental 
hygienist, and mouth rinsing by the patients with a salt-baking soda solution 
at least eight times a day to remove sticky saliva and debris. Dentate patients 
applied a neutral fluoride gel every second day with custom made trays 
and edentulous patients were not allowed to wear their dentures during 
the course of radiotherapy.15 
The Medical Ethical Committee approved the study and all eligible 
patients gave written informed consent. 
Assignment 
The eligible patients were randomized to receive active lozenges of 1 g 
containing polymyxin E 2 mg, tobramycin 1 .8 mg and amphotericin B 10 mg 
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(PTA) or placebo lozenges. The ingredients of the placebo lozenge were 
identical with the PTA lozenge except the active drugs. The colour, taste and 
form of the PTA and placebo lozenges were identical as well. Randomization 
was performed by the hospital pharmacist according to a computer-generated, 
randomized allocation schedule. Patients, clinicians, dental hygienists and 
microbiologists were blind for who was taking antibiotics. The patients used 
a PTA or placebo lozenge four times daily starting the first day of irradiation 
during the total radiation period. 
Assessments 
The study period included only the first 5 weeks of radiation because of 
the wide range of field changes above 50 Gy of radiation. During the study 
period mucositis, feeding and body weight scores were performed at the 
start of radiotherapy and twice weekly (Monday-Thursday). The assess­
ments were performed by an assigned dental hygienist. For each patient a 
mean weekly score was calculated on basis of these two scores. These mean 
scores were used for further statistical analyses. 
Twice weekly (Monday-Thursday) and two times before the start of radia­
tion oral washings were obtained to examine the oral flora for Gram-negative 
bacilli, Candida species, viridans streptococci, Enterococci, Staphylococcus 
aureus and coagulase-negative Staphylococci. 
Mucositis 
The mean mucositis was scored by using qualitative and quantitative 
parameters.4 Four different local signs of mucositis (k) might be distinguished: 
1 = white discoloration; 2 = erythema; 3 = formation of pseudomembranes; 
4 = ulceration. Mucositis of the oral cavity was determined for maximally 
eight distinguishable irradiated areas of the mouth: buccal mucosa (left and 
right), soft and hard palates, dorsum and border of the tongue (left and 
right) and the floor of the mouth. The degree of mucositis of each area was 
scored according to the local signs of mucositis. The length (E) of the local 
sign of mucositis was measured: 1 = � 1 cm; 2 = 1-2 cm; 3 = 2-4 cm; 4 = 2:: 4 cm. 
The degree of mucositis was defined as the product of the values k and E. 
The mucositis score was defined as the mean of the scores assigned to the 
irradiated areas. 
The mucositis was also scored according to the WHO score (grade 0 = 
normal, no mucositis; grade 1 = soreness and erythema; grade 2 = erythema, 
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ulcers, can eat solids; grade 3 = ulcers, requires liquid diet only; grade 4 = 
alimentation not possible) .16 
Feeding 
The quality of feeding was scored (0 = normal, no changes; 1 = symptoms 
without medication; 2 = symptoms with medication; 3 = liquid diet only; 
4 = nasogastric tube feeding) and body weight was determined. Afterwards 
the changes in weight were scored. 
Microbiological methods 
To acquire an oral washing, patients gargled and rinsed their mouth with 
10 ml sterile saline for 30 sec, and spit it into a sterile vial. 
One ml of the sample was diluted in 9 ml of Brain Heart infusion (BHI) 
(Oxoid, Basingstoke, England) and this suspension was serially diluted in 
BHI. The suspensions were than plated out onto 5% sheep blood agar, 
McConkey-3 agar (Oxoid) and Yeast morphology agar (Merck, Darmstadt, 
Germany) . The agar plates and BHI broth cultures tubes were incubated 
overnight aerobically at 37 °C. If an agar plate did not show growth and the 
corresponding BHI broth culture of the dilution series did show turbidity, 
then this suspension was plated again onto the agars mentioned above. 
With this enrichment step even low numbers of Candida species and Gram­
negative bacilli could be detected.17 By reading and counting the plates after 
incubation the viable numbers of microorganisms per ml was estimated. 
The identification was performed by standard microbiological techniques. 
Definitions 
Carriage of a particular microorganism was defined as the condition in which 
a patient showed a minimum of two consecutive oral washings positive 
for that organism. 
Colonization index of the oral cavity was defined as the sum of 
logarithms of the concentrations of a particular microorganism isolated from 
1 ml of oral-washing specimens divided by the number of oral washings. 
Statistical analysis 
Sample size calculation of this study was based on the study by Spijker­
vet.9 A two-sided a of 5% and a power of 80% were used. Additionally, a 
50% reduction of mucositis in the PTA group was determined as clinical 
relevant with a normal incidence of mucositis of 80%. Based on these 
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assumptions, 27 patients in each group would be sufficient. Intention-to­
treat analysis was performed. The difference of drop-outs between both 
groups was analyzed using Fisher's exact test. The results were analyzed, 
with respect to mean mucositis, the loss of weight, and colonization numbers 
for five different microorganisms (t-test for independent samples) and the 
WHO mucositis score and feeding (Mann-Whitney U test) . Two-sided tests, 
performed at the 5% level of significance, were used. 
Table 1 .  Patient characteristics 
Patients characteristics Placebo PTA P-value 
(n  32) (n 33) 
*Age mean ± SD (yrs) 54 ( 1 0.8) 55 ( 1 2 .5) 0.35 
Gender: male I female (n) 22/1 0 24/9 0.79 
Tumor site 
Oral cavity (n) 1 7  23 0.41 
Oropharynx (n) 1 0  8 
Hypopharynx (n) 1 1 
Unknown primary (n) 4 1 
Histology 
Squamous (n) 3 1  32 1 .00 
Other (n) 1 1 
T-stage 
T1 (n) 4 5 0.25 
T2 (n) 5 5 
T3 (n) 8 8 
T4 (n) 9 1 4  
Unknown (n) 5 1 
N stage 
NO (n) 1 0  1 4  0. 1 2  
N 1  (n) 5 1 0  
N2a (n) 2 1 
N2b (n) 9 3 
N2c (n) 1 3 
N3 (n) 4 2 
Surgery 
Yes (n) 2 1  27 0. 1 7  
No (n) 1 1  6 
Dentures 
Yes (n) 20 25 0.29 
No (n) 1 2  8 
All differences between the groups were analyzed using chi square test except * in which t test was 
used 
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RESULTS 
Patients characteristics are shown in table 1. From January 1994 to February 
1997, 65 patients were included, 33 patients received PTA lozenges and 32 
the placebo lozenges. Out of the 65 included patients, 58 patients were 
evaluable for the total evaluation period of 5 weeks. Seven patients (11 %) 
dropped out earlier from the study, five of the PTA group (15 %) and two of 
the placebo group (6%). The difference of dropouts between both groups 
was not significant. One patient (PTA) developed a skin reaction, unlikely 
caused by the PTA lozenges, and one patient (placebo) could not suck the 
lozenges because of the tumor surgery of his tongue. The other 5 dropped 
out for reasons not related to one of the lozenges. Of the seven dropouts, 
one patient stopped after 1 week, two patients after 2 weeks, one patient 
after 3 weeks and three patients after 4 weeks radiation. 
Mucositis 
The mean mucositis was the same in the PTA group and the placebo group 
during the study period (P>0.2) (Figure 1) .  During the 5-week observation 
period 89% of the patients in the PTA group developed pseudomembranes 
and in the placebo group 94%. The mucositis according the WHO score did 
not differ throughout the study period between both groups (P>0.5) . In the 
PTA group 80% of the patients developed grade 3 and 4 mucositis according 
the WHO score, and in the placebo group 90%. The appearance of pseudo­
membranes was for both groups at a similar radiation status; after 30 Gy of 
radiation. 
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Figure 1. The mean mucositis score (· SO) for the PTA group (0) and the placebo group ( 6) 
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Feeding 
Six patients (19%) in the placebo group (n=32) and two patients (6%) in the 
PTA group (n=33) needed nasogastric tube feeding during the evaluation 
period (P=0.08). 
Body weight 
The mean weight loss after 5 weeks of radiation was less in the PTA group 
by 1 .3 kg (SD 3.0) than in the placebo group 2.8 kg (SD 2.9) (P=0.05). 
Microorganism 
For viridans streptococci, Enterococci, Staphylococcus aureus and coagulase­
negative Staphylococci, a similar pattern of carriage and colonization index 
was found in both groups. 
The colonization index and carriage of Candida species at baseline was 
equal in both groups (P>0.8). During the first two radiation weeks the 
colonization index for Candida species showed an increase in the placebo 
group and a decrease in the PTA group. After 2 weeks, an increase in both 
groups was found but the difference between the two groups remained 
significant during the total study period (P<0.05). 
During the first 4 weeks a significant difference was found for the 
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Figure 2. Carriage of the oropharynx for Candida species for the PTA group (white) and the placebo 
group (black) * represents a significant difference between the PTA and placebo group 
85 
( H ll E R  6 
The colonization index and carriage of aerobic Gram-negative bacilli at 
baseline was equal in both groups (P=0.9) . During the radiation period the 
colonization index in the PTA group was less than in the placebo group, but 
the difference was only significant in the second week of radiation (P=0.05) . 
During the first 2 weeks the carriage of aerobic Gram-negative bacilli 
was reduced in the PTA group (P<0.04). In weeks 3-5 the difference was no 
longer significant (Figure 3). 
All results are summarized in table 2. 
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Figure 3. Carriage of the oropharynx for aerobic Gram negative bacilli for the PTA group (white) and 
the placebo group (black) * represents a significant difference between the PTA and placebo group 
D I SCUSSION 
In this study, no effect of  selective oral flora elimination on mucositis was 
observed. The development of mucositis follows the same pattern as 
reported in an earlier cohort study.18 According to the WHO score 80% of 
the patients in the PTA group and 90% in the placebo group developed 
mucositis grade 3 and 4. This severity of mucositis is in accordance with 
the outcomes of Okuno and colleagues. 11 In other studies, different outcomes 
are reported. A significant reduction of mucositis in the PTA group was 
found by two groups.9•10 Both studies are nonrandomized clinical trials and 
the PTA group is compared with a historical control group. 
A reduction in mucositis distribution and affected area, dysphagia and 
weight loss in the PTA group is reported by Symonds and colleagues.12 
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Table 2 .  Results o f  the PTA-placebo group for mean mucositis, weight loss, carriage and colonization 
index of Candida species and aerobic G ram-negative baci l l i  
Week 0 2 3 4 5 
x SD x SD x SD x SD x SD x SD 
Mean mucositis 
PTA 0 0 0 . 5  0 . 7  2 . 2  1 . 7 4 . 6  2 . 7  4 . 5  2 .7  5 .0  2 .3  
placebo 0 0 0 . 3  0 . 4  2 . 6  2 . 0  4 . 8  2 . 3  4 _ g 2 . 5  5 . 2  2 . 8  
We ight loss 
PTA 0 0 -0 . 3  1 .0 0.4 1 . 3 0 . 6  2 . 1  1 . 0 2 . 7  1 . 3 3 . 0  
placebo 0 0 0 . 3  0 . 9* 0.6 1 . 2 1 . 3 1 . 7 2 . 2  2 . 3  2 . 8  2 . 9* 
Candida col. index 
PTA 1 .0 1 .3 0 . 4  0 . 8  0 . 5  0 . 9  0 . 6  0 . 9  0 . 8  1 . 5 1 . 0 1 . 5 
placebo 1 . 1  1 .3 1 . 2  1 .6* 1 .6 1 . 7* 1 .7 1 . 7* 2 . 0  1 .7* 1 . 9 1 .8* 
Candida carr iage 
PTA (%) 48 2 3 . 5  1 7 . 6  3 1 .8  30 .8  36  
Placebo (%) 52 76 .5'  82.4' 68. 2 1  69.2' 64 
aerobic Gram neg 
bac. col mdex 
PTA 0.7 1 .2 0 .4 0 .8  0.4 0.9 0.6 1 . 2 0 . 5  1 .0 0 . 4  0 .9  
Placebo 0.7 1 .4 0 . 8  1 . 1 0 .9 1 . 1  * 0 . 8  1 . 0 0 . 8  1 .4 0 . 8  1 . 5 
aerobic Gram neg 
bac. carriage 
PTA (%) 5 2 .4 2 3 . 1  2 5  42.9 54. 5  40 
Placebo (%) 47 .6 76.91 75•  57 . 1  45 .5  60 
* represent a significant difference between the PTA and placebo group using an independent sample 
t test. • represent a significant difference between the PTA and placebo group using chi-square test 
From a total of 221 patients in that study, 98 (44 %) patients had a larynx 
carcinoma (PTA = 57, placebo = 41). Of these patients the radiation field 
included only a minor part of the oral mucosa, in which mucositis could 
develop. In the study of Okuno and colleagues only a subjective patient­
reported amelioration of mucositis was reported but no reduction was found 
in clinically observed mucositis.11 The PTA group (n = 54) in that study 
consisted of an unblinded (n = 29) and a blinded (n = 26) group. Only in 
the unblinded PTA group the mean mucositis, reported by the patients was 
lower than the placebo group. Recently, it was shown in a randomized study 
including 77 patients that selective oral flora elimination does not reduce 
radiation mucositis.13 A problem in that study is the short evaluation time 
of only the first 3 weeks of radiotherapy. Whereas normally development 
of severe mucositis starts after 3 weeks of radiation.2 
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A complicating factor in comparing outcomes from different studies is 
the assessment method of mucositis. All studies used different scoring 
methods. Therefore, two scoring methods were used in the current study. 
The WHO score is a widely accepted method, but this score is a combination 
of local mucositis signs and general complaints.16 The other scoring method 
in the current study is based only on mucosal signs of mucositis.4 It therefore 
provides a more precise estimation of the mucositis development at the 
mucosal level. It further makes a comparison possible with outcomes of earlier 
publications.4•19 For future studies, we recommend the use of the OMAS 
score from the mucositis study group because this scoring method is a 
reliable, well validated and widely accepted method.20 This scoring method 
was published later than the start of the current study and was therefore 
not used as scoring method in this study. 
In the current study, patients who received PTA lozenges had less weight 
loss than patients receiving placebo lozenges, assuming a better feeding 
status of the PTA-group patients (mean difference 1 .5 kg). Owing to the 
minimal effect of PTA on the mucositis level, we found the feeding outcome 
of minor clinical relevance. 
In our study, carriage and colonization of aerobic Gram-negative bacilli 
and Candida species decreased in the PTA group but was not totally 
eradicated. These findings are in line with the findings of other studies.9•10•12•13 
Based on these findings and the development and severity of mucositis it 
can be concluded that the presence of Candida species and aerobic Gram­
negative bacilli has no influence on the development of radiation induced 
mucositis. The increase of the carriage and colonization of Candida species 
and aerobic Gram-negative bacilli after 3 weeks of radiation may be explained 
by the development of xerostomia, which makes dissolving of the lozenges 
more difficult. Wijers and colleagues tried to overcome this problem by 
using a paste instead of a lozenge. However, the paste appeared to be an 
unsuccessful form of application because already after randomization 32% 
of the patients refused further participation and 77% of the patients dropped 
out after four study weeks because of bad taste and unpleasant sensation 
of the paste texture in the mouth.13 
In conclusion, PTA lozenges have a positive effect on the quality of feeding 
and amount of weight loss but cannot prevent severe mucositis. The presence 
of Candida species and aerobic Gram-negative bacilli has no effect on the 
development and severity of radiation induced mucositis. 
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Based on our findings of this randomized clinical trial, we do not 
recommend this type of supportive care for the reduction or prevention of 
radiation mucositis. 
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SUMMAR Y 
Background Mucositis is an oral sequelae of radiotherapy. In the 
development of mucositis several mechanisms play a role, such as 
inflammation and the effect of radiation on the high proliferation rate of 
oral basal epithelial cells. Therefore, administration of a drug with anti­
inflammatory and antiproliferative properties might delay the disorder and/ 
or alleviate the severity of oral mucositis. The aim of this pilot study was to 
evaluate the effect of flurbiprofen in a tooth patch on the development, 
severity and duration of pseudomembranous mucositis in patients treated 
with curative head and neck radiotherapy. 
Patients and methods The study group comprised 12 patients with a 
malignant tumor in the head and neck region to be treated with primary 
curative or postoperative radiotherapy. Patients applied once a day before 
sleep a flurbiprofen tooth patch to a natural tooth or upper denture during 
the full course of radiotherapy, starting 1 week before the onset of radio­
therapy. Oral mucositis, pain, feeding, body weight and viability and 
maturation of epithelial cells were assessed. The results were compared 
with the findings in a historical control group. 
Results No differences were found for severity and duration of pseudo­
membranous mucositis between the two groups. The onset of pseudo­
membranous/ ulcerative mucositis occurred later in the flurbiprofen group 
(14.6 ± 3.8 days, mean ± SD) than in the historical control group (11 ± 3.5 
days; P<0.05). 
Conclusion This study shows that the flurbiprofen 15 mg tooth patch cannot 
prevent the development of pseudomembranous mucositis and has no 
influence on the duration of oral mucositis. 
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I NTRODUCTION 
Oral mucositis i s  an inflammation of  the oral mucosa due to radiotherapy 
in patients with head and neck cancer.1 Until now no effective intervention 
has been developed to prevent oral mucositis following radiotherapy.2•3 
However, in a previous study benzydamine in an oral rinse has been shown 
to improve the ulcer-free rate and to diminish the incidence of ulceration 
and erythema in patients undergoing conventional curative radiotherapy.4 
Changing radiotherapy schedules or combining with chemotherapy induces 
more severe oral mucositis and makes its prevention more important.5 
Ionizing radiation damages rapidly proliferating cells, such as epithelial 
tumor cells and layer cells of the oral epithelium. The development and 
severity of irradiation mucositis depends on type of radiation, fractionation 
schedule, total cumulative dose, and irradiated tissue volume.6 During 
curative radiation without preventive strategies the first sign of mucositis 
can be objectively identified after delivery 10 Gy of radiation as a white 
discoloration or erythema of the mucosa. The more severe stages are 
clinically seen after delivery 30 Gy of radiation as the formation of 
pseudomembranes and ulceration. About 80% of patients receiving 
radiotherapy (cumulative dose of 50-70 Gy) are likely to develop ulceration/ 
pseudomembranes. 1.7 
The biological basis of mucositis is the sterilization of proliferating cells 
in the germinative layer of the epithelium. Their gradual proliferative failure 
causes a deficit in the cellular supply of the functional layers. Due to the 
natural loss of the superficial layer by mechanical wear and tear, hypoplasia 
of the epithelium and eventually ulcerative mucositis develops.8 
The development of mucositis due to radiation is only partially 
understood at cellular level. Five consecutive phases have been suggested 
recently in the development of mucositis: (1) initiation, (2) primary damage 
response, (3) signal amplification, (4) ulceration, and (5) healing.9 
Prevention of mucositis is the best treatment option. Nowadays, therapy 
is based on symptomatic treatment with the use of analgesics, oral rinses, 
topical application of disinfecting agents, topical/ systemic application of 
antibiotics. The current state of knowledge of the biological basis of mucositis 
has led to the introduction of the following experimental drugs for 
prevention of mucositis: 
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Anti-inflammatory agents, such as benzydamine �; 
Modulators of bone marrow and/ or epithelial cell differentiation such 
as granulocyte-macrophage colony-stimulating factor (GM-CSF) 10; 
Drugs protecting damaged oral mucosa from the effects of antineoplastic 
therapy such as sucralfate11, amifostine12, prostaglandin E213; 
Antimicrobial agents such as a decontamination antibiotic lozenge14, 
povidone iodine.15 
Most drugs are administered as tablets or by topical oral application (mouth 
rinse, ointment or lozenge). A few drugs, such as amifostine are administered 
parenterally. Studies of these drugs are either still in early clinical phases, 
have yielded inconclusive results, and/ or have demonstrated severe adverse 
events, such as vomiting and hypotension.16 
Radiation injury to the epithelium, causing mucositis, is associated with 
production of active oxygen and cytokines (such as IL-1 and IL-6). During 
this process cyclooxygenase 2 (COX-2) is induced and has been found to be 
responsible for the synthesis of prostaglandins which cause the separation 
of tight cellular junctions and increase in vascular permeability.17 Flurbipofen 
is an efficient inhibitor of COX-2, and might delay or prevent mucositis.18 
Secondly, flurbiprofen has an antiproliferative activity by inhibition of normal 
cell proliferation. A drug with anti-inflammatory and antiproliferative 
properties is a promising option to delay the development and/ or alleviate 
the severity of radiation mucositis. 19 
A drug delivery system (Perio Products, Jerusalem, Israel) has been 
developed consisting of a tooth patch that can be affixed to a tooth (buccal 
side) without an adhesive, and delivers the active agent to the oral mucosa.20 
Initial in vitro studies with a flurbiprofen tooth patch showed that this drug 
is released from the patch over a period of several hours. The potential 
efficacy of a flurbiprofen tooth patch on mucositis has been studied in a 
hamster model of radiation induced mucositis. Tooth patches containing 
15 mg flurbiprofen, or placebo, were inserted into hamster cheek pouches, 
one on day -5 or -3 and/ or one on day 0 immediately following acute 
irradiation of the cheek pouches with a dose of 35 Gy. Starting from 2 weeks 
after irradiation, the clinical severity and duration of oral mucositis were 
significantly reduced in hamsters which had received one flurbiprofen patch 
5 days before radiation, as compared to placebo or no drug treatment (data 
not shown; personal communication, J. Loewenstein). 
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The aim of this study was to evaluate the effects of the flurbiprofen 
tooth patch on the development, severity and duration of oral mucositis in 
patients treated with curative head and neck radiation. 
PATI E NTS AND M ETHO D S  
Patient selection 
Patients with a malignant tumor in the head and neck region to be treated 
with primary curative or postoperative radiotherapy were eligible for this 
study. Inclusion criteria for the study were: conventional, fractionated, 
postoperative radiotherapy to the oropharyngeal region using a 6 MeV 
linear accelerator. The dose was calculated using computerized planning, 
fractionation of 2 Gy daily, five times a week, for a total cumulative 
irradiation dose of 60-70 Gy, with at least half of the oral cavity within in 
the radiation field. The dose specification was in line with ICRU 50 
recommendations. 21 
Criteria for exclusion were: history of allergy to flurbiprofen, aspirin or 
another NSAIDS; an oral mucosa} defect other than related to tumor surgery; 
treated with chemotherapy concurrently or within 4 weeks before the start 
of radiotherapy; treatment concomitantly with NSAID's or diuretics; alco­
hol (> 3 units daily) or drug abuse; general health condition with active 
bleeding gastric ulcer, or significant hepatic, neurological, psychiatric, 
endocrine disease. 
As a standard procedure, all patients were evaluated before radiation 
treatment for potential risk factors for oral complications by means of a 
thorough oral and dental evaluation, including a radiographic examination. 
All potential risk factors were eliminated appropriately before the start of 
radiotherapy. The supportive oral care regimen consisted of a daily cleansing 
of the oral cavity with a saline spray administered by a dental hygienist 
and mouth rinsing by the patients themselves with a salt/baking soda 
solution at least eight times a day to remove sticky saliva and debris. Dentate 
patients applied a neutral fluoride gel every second day using custom-made 
trays.22 Patients had a natural tooth or an upper denture to which a tooth 
patch could be affixed to the buccal side. 
The Medical Ethics Committee approved the study and all eligible 
patients gave written informed consent. 
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Treatment 
Each eligible patient applied a flurbiprofen (15mg) tooth patch once a day 
before sleep at night to the same natural tooth or the upper denture to the 
buccal side. Patients administered the patches themselves starting 1 week 
before the start of radiotherapy, and on each following night. The medication 
was applied until completion of the course of radiotherapy. Drug treatment 
was discontinued at the first onset of ulceration/pseudomembrane formation 
because of possible negative effects of a NSAID on ulcers of the mucosa. 
During every study visit the patient was questioned regarding adverse 
effects of the flurbiprofen tooth patch. All patients started the radiotherapy 
at the same weekday (Monday). The total study duration for each enrolled 
patient was 14 weeks. 
Treatment evaluation 
During the study period evaluation was performed 1 week prior to the 
start of radiotherapy and thrice weekly (Monday, Wednesday, Friday) 
during 6 weeks of radiotherapy. Afterwards two follow up visits at a 1-week 
interval were scheduled. Mucositis, oral pain, and pain on swallowing and 
feeding were scored. Body weight scores were obtained once a week. Prior 
to, and at the end of each week of radiation, an oral washing, as well as a 
buccal smear with a cytobrush, were carried out for determination of 
epithelial cell viability and maturation.23 
Mucositis 
The mucositis was scored according the Oral Mucositis Assessment Scale 
(OMAS) and WHO score. OMAS evaluates nine regions of the oral cavity 
for erythema and the presence and size of pseudomembranes or ulcerations. 
The value of OMAS at any given assessment is obtained by summing the 
erythema and ulceration/pseudomembrane subscores at each site and then 
averaging these scores across all nine sites. The mean score has a range 
from 0-5. 2� The WHO mucositis score is as follows: grade 0 = normal, no 
mucositis; grade 1 = soreness and erythema; grade 2 = erythema, ulcers, 
can eat solids; grade 3 = ulcers, requires liquid diet only; grade 4 = 
alimentation not possible.25 
Pain 
Oral pain and pain on swallowing were scored subjectively on 100-mm 
visual analogue scales (VAS) ranging from no pain (0 mm) to intolerable 
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pain (100 mm), and no impact on swallowing (0 mm) to impossible to 
swallowing (100 mm) respectively. 
Feeding 
The global assessment of eating function was scored on a four-level scale: 
1 = normal food, 2 = soft food only, 3 = liquids only and 4 = no oral food 
intake possible. The total body weight was assessed once a week, beginning 
at start of radiotherapy until the study end visit. 
Viability of mucosal epithelial cells and maturation 
To acquire an oral washing, patients gargled and rinsed their mouth with 
10 ml sterile saline for 30 sec, and spat out into a tube. This expectorate was 
centrifuged within 10 min after collection (190 g, 10 min, room temperature) 
and the supernatant was discarded. The fluid was washed with 10 ml saline 
and centrifuged again to eliminate salivary fibers. Pellets were resuspended 
in 1 ml RPMI 1640 medium (Gibco, Paisley, UK) containing 5% fetal calf 
serum. Subsequently, 50 µl suspension and 50 µl trypan blue dye (0.4% in 
0.9% NaCl) were combined and immediately transferred to a hemocytometer. 
Cells were counted, after which the percentage of viable cells and total 
number of cells were calculated. 
Buccal mucosa smears were put on glass-slides and stained according 
to the procedure described by Papanicolaou and Traut.26 Epithelial cell 
morphology was assessed after collection of all slides at the end of study 
period. The assessment was blinded and randomized, and was performed 
by one observer (M.A.S.). Orange-stained cells were classified as mature, 
while blue/ green-stained cells were categorized as immature cells. Cells with 
a partly orange and partly green appearance were graded as intermediate. 
The percentages of mature, intermediate and immature cells were determined 
from each smear. 
Historical control 
The historical control group consisted of ten patients, seven men and three 
women, aged 59.2 ± 11.7 (mean±SD) (Table 1 ) .23 Nine patients had a 
squamous cell carcinoma, (seven oral, and two in the tonsil area), and one 
patient had an adenocarcinoma of the parotid gland. The patients were 
radiated according the same inclusion criteria, and the supportive oral care 
regimen was the same as used in the current study. 
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Table 1. Patient characteristics 
Patients characteristics F lurbiprofen Historical control P-value 
(n = 1 2) (n = l O) 
•Age _!_ SD (yrs) 57.7 ( 1 3.5) 59.2 ( 1 1 .7) 0.73 
Gender: male I female (n) 8 / 4  7 1 3  0.68 
Tumor site 
Oral cavity (n) 7 7 0.45 
Oropharynx (n) 4 2 
Unknown primary (n) 1 0 
Sal ivary Gland Tumor 0 1 
Histology 
Squamous (n) 1 0  g 1 .00 
Other (n) 2 1 
T-stage 
Tl (n) 0 3 0.34 
T2 (n) 6 3 
T3 (n) 1 1 
T4 (n) 4 2 
Unknown (n) 1 1 
N-stage 
NO (n) 7 4 0.60 
Nl (n) 2 2 
N2a (n) 0 0 
N2b (n) 1 1 
N2c (n) 1 0 
N3 (n) 0 2 
Unknown (n) 1 1 
Dentures 
Yes (n) 8 5 1 .00 
No (n) 4 5 
Operation 
Yes (n) 9 g 0.37 
No (n) 3 1 
All differences between the groups were analyzed using chi-square test except * in which t test was 
used 
Statistical analysis 
Student's t-test for independent samples was used to analyze the differences 
between flurbiprofen-treated patients and the historical controls with respect 
to OMAS score, loss of weight, oral pain and pain on swallowing. The Mann­
Whitney U test was used to analyze the differences in WHO mucositis score, 
feeding, viability and maturation of epithelial cells between the flurbiprofen­
treated patients and the historical controls. Spearman's correlation was used 
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to evaluate the relationship between mucositis, oral pain and pain on 
swallowing. To compare the viability of epithelial cells and maturation 
before and during radiation treatment, the Wilcoxon's signed ranks test for 
paired samples was used. Two-sided P values <0.05 were considered 
statistically significant. 
RE SULTS 
During 15 months, 24 patients were screened from among whom 12 patients 
fulfilled the inclusion criteria. The patients characteristics are shown in table 1.  
None of the patients applied the flurbiprofen 15 mg tooth patch during 
the whole radiation period due to development of pseudomembranous/ 
ulcerative mucositis at an early stage during radiotherapy. The application 
period after start of radiotherapy was 14.6 ± 3.8 days (mean±SD) and was 
in accordance with the mean onset of pseudomembranous/ulcerative 
mucositis. In comparison, the mean onset of pseudomembranes in the 
historical control group was 11 ± 3.5 days. The difference between the 
historical control and flurbiprofen groups was significant (P<0.05). 
No adverse events were reported during the evaluation period for the 
flurbiprofen tooth patch. 
Mucositis 
The mean OMAS mucositis scores are shown in figure 1. During the first 2 
weeks, the mucositis developed gradually, but after this period a steep 
increase in mucositis was observed . During the first 2 weeks, the 
development and degree of mucositis was lower in the flurbiprofen group 
than in the historical control group (Figure 1). After 2 weeks of radiation 
the difference in the mean OMAS score between the flurbiprofen and 
historical control groups was significant (P=0.007). After 3 weeks of radiation 
the OMAS mucositis score was not significantly different between the two 
groups. 
The WHO mucositis score for the flurbiprofen-treated patients followed 
the same pattern as the OMAS mucositis score. A steep increase in the 
mucositis score was seen after 2 weeks of radiation, with a stabilization of 
the severity during the rest of the radiation period, and a slight decrease 
after cessation of the radiotherapy. All study patients showed a WHO 
mucositis score of at least 2. 
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Figure 1. OMAS mucosit is scores (+ sem) for the flurbiprofen group (A) and the h istorical control 
group (D) 
Pain 
The increase in oral pain and pain on swallowing followed closely the 
OMAS mucositis score. A steep increase in pain was seen between week 2 
and 3, the period of development of the severe forms of mucositis. No 
correlation was found between mucositis, oral pain and pain on swallowing. 
Oral pain and pain on swallowing were higher in the flurbiprofen group 
than in the historical control group. This difference was significant only 
after the second radiation week (P=0.03). 
Feeding and Body weight 
All patients had a global assessment of eating function 2". 2 after 2 weeks of 
radiotherapy. A mean weight loss of 3.2 kg was observed between the start 
of radiotherapy (mean body weight 77.9 kg) and after 6 weeks of radiotherapy 
(mean body weight 74.7 kg). At the study end visit the mean body weight 
loss was 4.6 kg (mean body weight 73.3 kg) from the start of radiotherapy. 
No significant differences were found between the flurbiprofen and 
historical control groups in feeding and weight loss. 
Viability and maturation of epithelial mucosa[ cells 
The percentage of viable epithelial cells at baseline was 52.7% ± 9 .1 %. During 
the first week the percentage of viable epithelial cells decreased, after which 
viability was variable in character. No significant differences were found 
1 00 
Table 2. OMAS scores, ora l pa in ,  pa in on swallowing, weight, viabil ity and maturation of ep thelial cells in the flurb1profen and control groups 
Week (cumulative radiation dose, Gy) 0 (O) 1 ( 1 0) 2 (20) 3 (30) 4 (40) 5 (50) 6 (60) 
M ean SD M ea n  SD M ea n  S D  M ea n  SD M ean SD Mean SD M ean SD 
OMAS 
Flurb1profen 0 0 0.03 0.06 0.4 0.4 1 .6 0 . 1  1 .5 1 . 1 1 .7 1 . 1  1 .7 1 .2 
Control 0 0 0.07 0 . 1 3  1 .0 0.6 1 .4 0.9 1 .4 0.9 1 .6 1 .2 1 .9 1 . 1 
Oral Pain 
Flurb1profen 0.2 0.3 0.4 0.5 2.4 2.2 3.3 2 .2 3 .8 2 .6 4.5 2 .7 4.6 3 .4 
Control 0.2 0.6 0 . 1  0 .3  0.6 0.8* 1 .4 2 .2 1 .4 2 .7 2 .0 3 .2 2 .2 3 .3 
Pain on swallowing 
Flurb1profen 0.7 1 .7 0.5 0.6 2.5 2.3 3 . 1  2 . 5  3 . 6  2.8 4.2 3.0 3.9 3.2 
Control 0 . 1  0.3 0 . 1  0.3 0.8 1 . 1 * 1 .6 2 .2 1 .7 3 .0 2.0 3.3 1 .6 3 .2 
Weight loss 
Flurb1profen 0 0 0.6 1 .4 0.8 1 .6 1 .5 1 .g 2 .3  2 .5  3 .2  3 .4  
Control 0 0 0 . 1  0.2 1 . 1 1 .0 2.4 1 .6 2 .9  2 . 1  4.0 2.5 
m 
Viability of epithelial cells % m 
Flurbiprofen 52.7 9 . 1  46.g 1 6.5 55.0 9.0 58.1 1 2 .2 50.9 1 3 .5 58.8 20.0 52.8 1 5 .3 n 
Control 46.2 1 7 .8 4g_7 1 4.0 58.6 1 3 .2 62.9 1 9.2 56.2 20.0 54. 1 1 3 .0 50.6 1 3 .9  � 
Mature Epithelial cells % 
.,, r 
c 
Flurb1profen 39.8 35.2 45.3 27.2 55.2 29.6 70.4 1 6 .2 7 1 . 1  32.8 69.2 33.7 7 1 .6 26.8 ,, "' 
Control 43.9 25.8 41 .6 1 7 .5 65.7 22.6 74.2 1 0 .0 6 1 .6  1 7 .7 75.3 1 1 . 1  74.4 1 0.8 � ,, 
0 
Intermediate epithelial cells % m z 
Flurb1profen 33 . 1  1 4.7 3 1 .6 1 8.0 29.8 1 6.2 1 8.9 7.5 1 4 . 1  1 2 . 1  1 5 .9 9.0 1 9.3 1 5 .5 0 
Control 52.7 22.2 49. 1 1 8.5 32.8 22.4 25 . 1  1 0 .0 35 .9  1 6. 1  # 24.0 1 0.9  24.2 1 0.9 .. 
0 
Immature epithelial cells % 
,, 
> 
Flurb1profen 20.3 1 6.6 1 5 .9 1 7 .5 1 5 .3 1 9.0 7.2 8.4 0.7 1 .6 1 .6 2.4 2.8 3.6 � Control 3 .5  7 .8  5 .8  7 .8 1 .5 3.6 0.7 1 .8 2 .6 5.7 0.8 1 .2 1 .4 1 .6 c 
n 
0 
* Significant difference between the flurbiprofen and control groups by an independent sample t test I � # Significant difference between the flurbiprofen and control groups by the Mann Whitney U test 
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between the baseline and the other radiation weeks. Neither was a signifi­
cant difference found between the flurbiprofen and the historical control 
group. 
The mean percentage of mature cells increased during radiotherapy, 
but this increase was only significant at the end of third radiation week 
compared to the baseline value (P=0.03) . The mean percentage of 
intermediate cells decreased and was significant for the third, fourth and 
fifth radiation week compared to the baseline outcome (P=0.02, 0.03, 0.04 
respectively). The mean percentage of immature cells also decreased and 
was significant after the third radiation week until the end of the radiation 
period compared to the baseline value (P<0.04). The only significant 
difference between the flurbiprofen and historical control groups was found 
for the intermediate cells during the fourth week of radiation. 
The results for the flurbiprofen and control groups are summarized in 
table 2. 
D ISCUSS ION 
The primary endpoint of this study was prevention of pseudomembranous 
mucositis. The study showed that the flurbiprofen 15 mg tooth patch only 
delayed and did not prevent development of pseudomembranous mucositis. 
The process of development of mucositis is thought to be a five-phase 
process at the cellular level. The reducing influence of a NSAID could be 
expected during the initial phase of inflammation and vascular reactions 
due to the radiation. Flurbiprofen is an efficient inhibitor of COX-2 which 
is induced during inflammatory processes. It has been shown in an animal 
model that after radiation, COX-2 is expressed at high levels on days 10 
and 16, especially in submucosal fibroblasts and endothelium. The kinetics 
of COX-2 parallel mucositis severity. It was concluded that COX-2 is not a 
primary driver of radiation injury, but instead plays an amplifying role.27 
These outcomes might explain the delayed initial development of irradiation 
mucositis during the first 2 weeks in patients treated with flurbiprofen 15 
mg tooth patches compared to a historical control group.23 However, in the 
current study application of flurbiprofen tooth patches was discontinued 
on pseudomembrane/ulceration formation. Because the level of expression 
of COX-2 increases during ulceration, it can be suggested that a longer 
application period of flurbiprofen should be evaluated. 
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Flurbiprofen is a drug with antiproliferative properties. It could therefore 
potentially be used to delay the development of mucositis by its ability to 
attenuate the high rate of basal epithelial cell proliferation even prior to the 
initiation of antineoplastic therapy. This could be the explanation for the 
delay in the development of pseudomembranes in the flurbiprofen group. 
The assessment of viability and maturation of epithelial cells cannot explain 
the delay at a cellular level because no differences were found in viability 
or maturation of epithelial cells between the flurbiprofen and control groups. 
The onset of pseudomembranous/ ulcerative mucositis in this study was 
significantly later in the flurbiprofen group than in the historical control 
group where no preventive measures were tested. However, the clinical 
relevance of this finding is disputable because in none of the flurbiprofen 
treated patients development of pseudomembranes was prevented. Further­
more, no effect was found on the duration of mucositis. This is in contrast 
to the findings in the hamster model in which a reduction in severity and 
duration was found. In the human situation, radiation is on a daily basis, 
five times per week, whereas in the animal situation the effects of a single 
radiation were studied. The proliferation of epithelial cells failed during 
radiotherapy, resulting in a loss of the basal layer after 3 weeks. Apparently 
starting the flurbiprofen tooth patch 1 week before the start of radiotherapy 
did not influence the susceptibility of the epithelial cells to radiation damage, 
as might have been expected from the hamster study. 
The effect of the flurbiprofen tooth patch was found to be minimal, 
probably because of the small sample size, the single tested dosage and the 
application period. In this study no serious side effects related to the drug 
were seen. The outcome of this study together with previously reported 
findings indicate that a higher dosage or longer application period should 
be investigated in a future study. 
The flurbiprofen group experienced more pain than the control group. 
The baseline scores for oral pain and pain on swallowing in the flurbiprofen 
group were already higher. At the end of the second radiation week the 
mucositis was significantly lower in the flurbiprofen group but pain was 
significantly higher. No correlation was found between mucositis, oral pain 
and pain on swallowing. However, in contrast, in the validation study of 
the OMAS score, mucositis, oral pain and pain on swallowing were strongly 
correlated.24 No rational explanation for this phenomenon can be suggested. 
This study showed no effect of the flurbiprofen tooth patch on severity 
and duration of oral mucositis due to radiation. Only a delayed development 
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of pseudomembranous/ulcerative mucositis was seen in the flurbiprofen 
group compared to a historical control group. 
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SUM MAR Y  
Background Intravenous administration of amifostine reduces chemotherapy 
induced toxicity. Preclinical experiments showed a reduction in radiation 
induced mucositis after local application of the active metabolite of 
amifostine (WR-1065). This study evaluated the effect of local application 
of WR-1065 on chemotherapy induced oral mucositis. 
Patients and Methods Non-small cell lung cancer patients treated with 
gemcitabine and epirubicin every 3 weeks for a maximum of five cycles 
were included. WR-1065 was administered during the second and third 
cycle as an oral rinse. Oral mucositis evaluation included WHO toxicity 
grading, a validated oral mucositis assessment scale (OMAS), and a 
questionnaire. 
Results Twenty-four patients were evaluated for at least one control and 
one rinse cycle. Mucositis scores, pain and feeding difficulties increased 
from day 1 to day 15, and were not significantly different between control 
and rinse cycles. Local application of WR-1065 leads to detectable quantities 
of WR-1065 in epithelial mucosa cells. A negative correlation between WR-
1065 concentration and OMAS score was found. 
Conclusion No clinical detectable influence of WR-1065 on oral mucositis 
was found. 
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I NTRODU CT ION 
Oral mucositis i s  an inflammatory-like change of  the oral mucosa due to 
cytotoxic chemotherapy or radiotherapy. The type of antineoplastic 
treatment and patient related factors influence the incidence and severity 
of oral mucositis. The onset is usually between 5 and 8 days after 
chemotherapy and the duration is highly variable. Especially in patients 
receiving high-dose chemotherapy followed by bone marrow or peripheral 
stem cell transplantation, mucositis can be dose limiting.1 The pathogenesis 
of oral mucositis is not fully understood, but is thought to involve direct 
and indirect mechanisms. Direct toxic effect of cytostatic agents on rapidly 
dividing cells of oral epithelium can result in mucosal atrophy, erythema 
and ulceration. Indirect stomatotoxic effects are caused by release of 
inflammatory mediators, loss of protective salivary constituents, and 
therapy induced neutropenia. Bacteria, fungi and viruses can superimpose 
secondary infections of the damaged mucosa. Mucositis is proposed to 
develop in four consecutive phases: 1) the inflammatory /vascular phase 
(release of free radicals and cytokines); 2) the epithelial phase (reduced 
epithelial renewal) with atrophy and ulceration; 3) the ulcerative/bacterial 
phase (colonization mixed flora, causing release of endotoxines) with further 
tissue damage by stimulation of cytokines; 4) the healing phase.2 
Mucositis causes major discomfort in patients. Pain and restriction of 
normal feeding and drug intake are the most important discomforts. In 
severe stages of mucositis secondary infection of mucosal ulcers can provide 
a port of entry for microorganisms into the circulation, which can lead to 
life-threatening septicaemia, especially in myelosuppressed patients. It is 
worthwhile to investigate strategies to prevent oral mucositis since the actual 
regimens for mucositis prevention are mainly palliative. Local and systemic 
analgesics are applied for pain relief, while antimicrobial agents are applied 
for bacterial or fungal infections or for prevention. 
Cytoprotective agents, such as amifostine (Ethyol®, WR-2721),  can 
reduce the toxicity induced by radiotherapy or chemotherapy. Amifostine 
is a prodrug, which is active as a protective agent when dephosphorylated 
by alkaline phosphatase to its active metabolite WR-1065. WR-1065 is 
preferentially taken up into normal rather than neoplastic cells because of 
the higher alkaline phosphatase activity, better vascularization and higher 
pH of normal tissue. Once inside the cell, WR-1065 protects against 
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chemotherapy and radiation induced damage by scavenging free radicals, 
donating hydrogen ions to free radicals, depleting oxygen, and direct binding 
and inactivating cytotoxic drugs. 3•4 Intravenous administration of amifostine 
provides protection against a broad range of cytotoxic agents. Reduction in 
hematological or non-hematological toxicity is described for cisplatin, 
carboplatin, doxorubicin, paclitaxel, and 5-fluorouracil.5·8 Prevention of 
mucositis is mainly described in head and neck cancer patients treated with 
radiotherapy.9•1 1 
Preclinical experiments showed a reduction in radiation induced 
mucositis after local application of amifostine. Topical application of 50 mg 
amifostine to the buccal mucosa in mice reduced the severity of radiation 
induced oral mucositis, without any toxicity.12 However, no prevention 
against radiation induced proctitis and colitis was found after rectal 
administration of amifostine doses between 100 and 450 mg/ enema.13 
Reasons for failure to protect the rectosigmoid mucosa may be related to 
the method of administration (the rectum was not empty), and the relatively 
long period (45 minutes) between application of amifostine and the onset 
of radiation. 
A pilot study in patients with stage IIIb or IV non-small cell lung cancer 
(NSCLC) evaluated the feasibility of 125 mg WR-1065 as a mouthwash. 
Before administration, 200 mg WR-2721 was ex vivo converted to WR-1065. 
No systemic side-effects were observed and WR-1065 was well tolerated. 
In this study, WR-1065 was detectable in washed, isolated, vital mouth 
mucosa cells at a concentration of 3.7-19.9 ng/105 cells.14 Previous in vitro 
experiments showed that a cellular concentration of 13 ng WR-1065 in 105 
mouth mucosa cells induced radioprotection. 1 5•16 Taken together, these 
findings suggest that 200 mg WR-2721 (10 ml 0.09 M) or 125 mg WR-1065 
(10 ml 0.09 M) can be safely administered, and the reached cytoprotective 
concentration achieved might be effective in the treatment of oral mucositis. 
The aim of this phase II trial was to evaluate the effect of local application 
of WR-1065, the active compound of amifostine, on oral mucositis in NSCLC 
patients treated with epirubicin and gemcitabine. The effect of WR-1065 on 
mucositis was the primary end point of this study. The secondary end point 
was to determine WR-1065 in oral epithelial mucosa cells. 
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PATI E NTS AND M ETHO D S  
Patient selection 
Patients (�:18 years) with a histologically or cytologically proven diagnosis 
of unresectable stage III or IV NSCLC were eligible for this study. Exclusion 
criteria were: child bearing potential without effective means of contraception; 
pregnancy or lactation; presence of other malignancies; presence of ulcerative 
lesions in the oral cavity or any grade of mucositis in the last 4 days; Sjogren's 
syndrome; infection requiring systemic antibiotics within the previous 14 
days; significant renal dysfunction (serum creatinine levels > 1 .5 times the 
normal acceptable range (62-106 µmol/L) or creatinine clearance less than 
50 ml/minute); hematological disorders (leukocytes < 3.0xl09 /L, neutrophils 
< l .5xl09 /L, Hb < 5.0 mmol/L); use of topical oral disinfectants within the 
previous two weeks; or use of other investigational drugs within the previous 
30 days. The medical ethics review committee approved the protocol 
and all eligible patients gave written informed consent before study entry. 
Treatment 
Gemcitabine (1125 mg/m2) was administered in 250 mL of 0.9% NaCl by a 
30-minute infusion on days 1 and 8 of each 21-day cycle. Epirubicin (100 
mg I m2, in 50 mL of 0.9% NaCl) was given as an intravenous bolus injection 
within 5 minutes on day 1 (after gemcitabine administration). Treatment 
consisted of a maximum of five cycles and was stopped earlier in case of 
tumor progression, intolerable toxicity or patient's request. Ondansetron 8 mg 
and dexamethason 8 mg were used as antiemetics twice a day on days l, 2, 
and 8. During the second and third cycle, WR-1065 (10 ml, 20 mg/mL) was 
administered as an oral rinse. Before administration, amifostine (WR-2721)  
was converted to WR-1065 ex vivo (WR-2721 at  37 °C for 1 hour, pH 3.5), 
because alkaline phosphatase concentrations in the mouth are low. The oral 
rinse was used 15 minutes before and 5 minutes after epirubicin infusion. 
Patients were instructed to rinse and gargle for 1 minute and subsequently 
to spit out. 
Treatment evaluation 
During the study period, evaluation was conducted on days 1, 8 and 15 of 
each cycle by a dental hygienist or a physician. Oral mucositis was evaluated 
using World Health Organization (WHO) toxicity grading and the Oral 
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Mucositis Assessment Scale (OMAS). 17 OMAS evaluates nine regions of the 
oral cavity for erythema and the presence and size of pseudomembranes or 
ulcerations. The value of OMAS at any given assessment is obtained by 
summing the erythema and ulceration/ pseudomembrane subscores at each 
site and then averaging these scores across all nine sites. The OMAS score 
ranges from 0-5. 
On days 1, 8, and 15 of each cycle patients filled in a questionnaire. This 
questionnaire consisted of 100 mm visual analogue scales for oral pain 
(ranging form 'no pain, 0 mm' to 'very severe pain, 100 mm') and 
swallowing difficulty (ranging from 'no impact on swallowing, 0 mm' to 
'extreme impact on swallowing, 100 mm') and one multiple-choice question 
about eating function (with four levels of functioning: 'normal', 'soft foods 
only', 'liquids only', or 'no oral intake possible'). 
For determination of the cell viability of oral mucosa cells, an oral washing 
was performed before administration of WR-1065 and cytostatics, on days 
1, 8 and 15 of each cycle.18 19 To obtain an oral washing, patients gargled 
and rinsed their mouth for 30 seconds with 10 mL sterile 0.9% NaCl solution 
and than spat it out into a tube. This expectorate was centrifuged within 
10 min of collection (190 g, 10 min, 4°C) and the supernatant was removed. 
The cell suspension was washed with 10 mL of 0.9% NaCl and centrifuged 
again to eliminate salivary fibers. Cell pellets were resuspended in 1 mL 
RPMl (Gibco, Paisley, UK) containing 5% fetal calf serum. Subsequently, 50 µL 
suspension and 50 µL trypan blue dye (0.4% in 0.9% NaCl) were mixed and 
cell counts were performed to calculate the percentage of viable cells. 
For determination of WR-1065, an oral washing was obtained before 
and 15 minutes after treatment with WR-1065 during the second and third 
cycle. Subsequently, the expectorate was subdivided into two portions. For 
determination of cell viability 1 mL was used. The remaining 9 mL was 
centrifuged and washed according to the above mentioned procedure. 
Thereafter, the cell pellet was stored at -80°C. WR-1065 concentrations were 
determined by high performance liquid chromatography as described by 
Korst.20 
Statistical analysis 
Based on the results of a phase II study with epirubicin and gemcitabine 
every 3 weeks, WHO grade 2-3 mucositis is expected to occur in the first 
and/or fourth cycle (control cycles) in 35% of patients.21 The incidence in 
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the second and I or  third cycle (rinse cycles) i s  expected to be  10%. Based on 
the McNemar test on discordance, 20 patients are needed to detect a 25% 
difference with a power of 85% and a two-sided significance level of 5%. 
With a drop out of about 15%, 25 patients have to be included. 
Data are analyzed using a linear mixed effects model. Respondent and 
cycle number are considered to be nested factors, days are modeled linear 
within cycles. When a response variable had a skewed distribution, the 
data was log-transformed. Summary measures were made and compared 
for cycles with and without mouthwash. To exclude the impact of the order 
of the control and rinse cycle in relation to the response variables, a cross­
over design was used for analysis. Therefore, twelve patients with a control 
cycle followed by a rinse cycle, and twelve patients with a rinse cycle 
followed by a control cycle were selected. Spearman's correlation coefficient 
was calculated for correlation of WR-1065 concentration and mucositis. 
RESULTS 
Patient characteristics and treatment 
From December 2000 till April 2002, 29 patients were included. Due to 
discontinuation of chemotherapy, five patients dropped out earlier. The 
remaining 24 patients had at least two evaluable chemotherapy cycles, one 
with WR-1065 rinse and one without. The patients evaluated in this study 
comprised 20 men and 4 women, with a mean age of 61 years (range 46-73). 
Because not all patients had four evaluable cycles, the first chemotherapy 
cycle was used for all patients as a control cycle. The cycle with the fewest 
missing data was used as WR-1065 rinse cycle; 19 times cycle two, 4 times 
cycle three and 1 time cycle five. 
Mucositis 
During the first cycle, 21 % of the patients experienced mucositis WHO grade 
2. The mean mucositis score increased from day 1 to day 15 in both the 
control and rinse cycle (Table 1) .  During the total treatment period, none of 
the patients experienced WHO mucositis score grade 3 and 4. No signifi­
cant differences in WHO and OMAS mucositis score were found between 
control and rinse cycles. 
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Table 1 .  OMAS and WHO mucos1t1s scores, pa in, difficu lties on swallowing and feeding in con ro l and 
rinse cycles (n =24) 
Day 1 
OMAS (mean) Control 0 
Rinse 0.03 
WHO (median) Control 0 
Rinse 0 
Pain (mean, mm) Control 0 . 1  
Rinse 4. 6 
Difficulties on swallowing (mean, mm) Control 1 . 4 
Rinse 4.8 
Feeding (median) Control 
Rinse 
Pain and feeding 
Day 8 





1 0 .2 
1 0 .3  
8 .g  
Day 1 5  
0. 1 9  
0 .26 
24. 6  
23 . 1  
1 7 . 5 
1 6 . 2  
A significant difference for pain was found between the consecutive days 
within the same cycle, with increasing pain in time (P< 0.01).  No significant 
difference for pain was found between the control and rinse cycle (Table 1). 
For difficulties in swallowing and eating function, no significant differences 
were found between the control and rinse cycle (Table 1) .  
The results of the crossover design are shown in Table 2A and B. These 
data suggest a possible influence of the sequence and cycle number of the 
control and rinse cycle. However, analysis of the data summarized in table 
2A and B with use of linear mixed effects model shows no significant 
differences between the control and rinse cycle for all response variables 
(OMAS and WHO mucositis score, pain, swallowing and feeding) . 
Viability of mucosa[ epithelial cells 
The mean percentage viable epithelial cells at the start of the control cycles 
(56 ± 18%) was comparable with this percentage at the start of the rinse 
cycles (56 ± 14%). No significant differences were found between the 
consecutive days within the same cycle. Nor was a significant difference 
found in the viability of mucosal epithelial cells between the control and 
rinse cycle (Table 3). 
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Table 2A. Results of the crossover design (n = 1 2). in  order control-rinse for the variables OMAS and 
WHO mucositis scores, pain ,  difficulties on swallowing and feeding in  control and rinse cycles 
Day 1 Day 8 Day 1 5  
OMAS (mean) Control 0 0. 1 8  0 . 1 3  
Rinse 0.03 0 .28 0 .26 
WHO (median) Control 0 1 1 
Rinse 0 0 . 5  1 . 5 
Pain (mean, mm) Control 0 . 1  1 0 . 5  1 8 .4 
Rinse 5 1 6. 3  28.4 
D1ff1cult1es on swal lowing (mean, mm) Control 0 . 1  1 6 . 3  1 6 .7  
Rinse 8 . 1  1 2 .4 20 . 1  
Feeding (median) Control 1 
Rinse 1 . 5 
Table 2B. Results of the crossover design (n 1 2), in order rinse-control for the variables OMAS and 
WHO mucosit1s scores, pain ,  d1ff1cult1es on swallowing and feeding in  control and rinse cycles 
OMAS (mean) Rinse 
Control 
WHO (median) Rinse 
Control 
Pain (mean, mm) Rinse 
Control 
D1ff1cult1es on swallowing (mean, mm) Rinse 
Control 
Feeding (median) Rinse 
Control 
Table 3. Percentage viable epithelial cells 
Day 1 
before rinsing after rinsing 
Control (SD) 
Rinse (SD) 
56 (1 8.0) 







2 . 1  
1 .4 
2 . 2  
Day B 
0.24 
0 . 2 1  
0 
0 . 5  
5 . 2  
6 . 7  
4 . 8  
5 . 1  
Day 8 
59 (1 8.8) 
62 (1 2.7) 
Day 1 5  




1 4 .9 
24.4 
1 0 .4 
2 2 . 7  
Day 1 5  
56 (1 0) 
58  (1 1 .2) 
1 1 5 
Determination of presence of WR-1065 
It was possible to determine the presence of WR-1065 in washed, isolated, 
vital mouth mucosa cells in 22 out of 24 patients. The cell pellet was lost in 
one patient; another patient had an interfering analytical peak, which made 
determination of WR-1065 impossible. The median cellular concentration 
of WR-1065 was 11.9 ng/105 viable cells (range 0.09-3821 .7 ng/105). Eleven 
patients had a mean cellular concentration < 13 ng/105 viable cells. A sig­
nificant negative correlation was found between the concentration of 
WR-1065 and the OMAS mucositis score (r = -0.54, P=0.012). 
D I SCUSS ION 
This study shows no clinical effect of  local application with WR-1065 on 
oral mucositis in patients with unresectable stage III or IV NSCLC. 
Nevertheless a significant negative correlation was found between the WR-
1065 concentration in mouth mucosa cells and the OMAS mucositis score, 
meaning that a higher cellular concentration of WR-1065 leads to less 
mucositis. 
The cellular concentration of WR-1065 found in mouth mucosa cells 
after the first mouthwash with 125 mg WR-1065 has a large range (0.09 to 
3821.7 ng/105). In vitro studies showed that after a five-minute incubation 
period with 4 mmol/l  WR-1065, a concentration of 13 ng/ 105 cells was 
detectable and effective.16 By adding 4 mmol/l amifostine in combination 
with alkaline phosphatase to V79-171 cells, 40% of the cells were protected 
from damage caused by radiotherapy (8 Gy).1� In the current study, a cellular 
concentration of WR-1065 < 13 ng/105 (range 0.09-7.1) was found in 11 
patients. This concentration was lower than the concentration found by 
Calabro-Jones and colleagues, which was necessary for a protecting effect. 
Another reason for finding no clinical effect on mucositis and the low 
cellular concentrations might be the uptake of WR-1065. Following 
intravenous administration, amifostine is rapidly cleared from the plasma.22 
The rapid clearance of amifostine is largely due to the fast conversion of 
amifostine to its active metabolite, WR-1065. An animal study showed that 
maximum tissue concentrations of WR-1065 occurred within 5 to 15 minutes 
after amifostine injection.23 Based on these results, amifostine should be 
applied a short period (15 to 30 minutes) before chemotherapy. Therefore, 
WR-1065 was given 15 minutes before epirubicine infusion in this study. 
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The uptake of WR-1065 is dependent of the temperature, the pH and contact 
time.16 The inter-individual differences in cellular concentrations of WR-
1065 might be caused by differences in oral temperature and pH. Although 
patients were instructed not to eat or drink during the epirubicine infusion, 
a physiological difference in the pH of saliva could result in different WR-
1065 concentrations. 
The low incidence of the experienced mucositis might be another reason 
for finding no clinical effect. Only 21 % of the patients experienced WHO 
grade 2 mucositis during the first cycle, though at least 35% of grade 2 or 
more was expected.21 During the total treatment period, none of the patients 
experienced a WHO mucositis grade 3 and 4. While in the study of Wachters 
and colleagues 12% of the patients experienced WHO mucositis grade 3 
and 2% grade 4.24 The low cellular concentration of WR-1065, together with 
the relatively low severity of mucositis, may be the reason for not finding a 
significant clinical effect on the presence of mucositis. 
The results of this study indicate that, for prevention of oral mucositis, 
a higher cellular concentration of WR-1065 is necessary. Therefore, future 
studies should aim on a higher cellular concentration of WR-1065. This 
could probably be realized by a higher rinsing frequency, extended rinsing 
time and/ or increasing the concentration of WR-1065. Another aspect is 
the evaluation of the pH value of saliva in patients. It might be interesting 
to better characterize the influence of the pH value on the uptake of WR-
1065 into mouth mucosa cells. 
In conclusion, local application of WR-1065 is feasible and leads to 
detectable quantities of WR-1065 in washed, isolated, vital mouth mucosa 
cells. An effective cellular concentration of WR-1065 was found in only 50% 
of the patients. A negative correlation was found between the concentration 
WR-1065 and the OMAS mucositis score. No clinical detectable difference 
in mucositis between the control and rinse cycle was found. The low cellular 
concentration of WR-1065 and the low incidence and severity of mucositis 
might be the reason for finding no clinical effect of WR-1065. 
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SUM MARY 
Oral mucositis induced by radiotherapy or chemotherapy is a frequently 
occurring toxicity in patients with cancer. It is a painful side-effect and 
restricts oral functions, such as speech, swallowing and chewing. Oral 
mucositis is associated with an increase in the number of systemic infections, 
days in hospital and overall costs. All these aspects can limit the cancer 
therapy and can have a negative impact on cancer patients health-related 
quality of life. 
The aim of this thesis is to investigate new options for evaluation and 
intervention of cancer therapy induced oral mucositis. 
Chapter 2 describes the outcomes of meta-analyses which evaluate the 
effectiveness of interventions for the prevention of oral mucositis in cancer 
patients. A literature search was performed for randomized controlled 
clinical studies between 1966-2004 aiming at prevention of mucositis, in 
cancer patients, undergoing head and neck radiation, chemotherapy, or 
chemoradiation. In order for a study to be eligible for the meta-analyses the 
control group had to consist of a placebo, no intervention or another 
intervention group. Mucositis was scored either by the WHO, or the NCI­
CTC score, or the absence or presence of ulcerations, or the presence or 
absence of grade 3 and 4 mucositis. The meta-analyses included 45 studies 
fulfilling the inclusion criteria, in which 8 different interventions were 
evaluated i.e: - the antiseptic agents chlorhexidine and iseganan; - the anti­
microbial agents PTA (polymyxin E, tobramycine and amphotericin B); 
- the hematopoietic growth factors: granulocyte-macrophage colony­
stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G­
CSF); - oral cooling with ice cubs; - the mouth coating agent sucralfate; - the 
amino acid glutamine; and the cytoprotective agent amifostine. Four 
interventions showed a significant preventive effect on the development 
or severity of oral mucositis; PTA, GM-CSF/G-CSF, oral cooling with ice 
cubs and amifostine. To date, no single intervention completely prevents 
oral mucositis, so combined preventive therapy strategies seems to be 
required to ensure more successful outcomes. 
Chapter 3 describes the study that analyzed the effect of training on 
concordance of evaluators in scoring oral mucositis in a multicenter trial. 
In the assessment of new agents for prevention of mucositis the inter­
evaluator variability needs to be minimized. This would likely best be 
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accomplished by training of  evaluators. To evaluate the effect of  training, 
training meetings were organized, as start up of a phase III multicenter 
trial. Evaluators were informed about intention of the study, the mechanisms 
of development and clinical appearance of mucositis, and were trained in 
scoring mucositis according the Oral Mucositis Assessment Score (OMAS). 
The effect of the training was tested by a pre- and post-training test. The 
test consisted of 15 slides with clinical pictures of mucositis. The evaluator 
had to score mucositis of the depicted region for ulceration and erythema. 
Of each evaluator the scores of the pre- and post-training were compared 
to the reference standard. During 8 months, six meetings were organized 
where in total 65 evaluators were trained (mean 11 per training, range 8-15). 
Comparing the mean performance of the evaluators, the mean evaluator's 
percentage correctly scored slides according the OMAS increases significantly 
for both ulceration (47 to 69%) and erythema (63 to 77%). Comparing the 
results of the evaluators of scoring the absence or presence of ulceration 
and/ or erythema, the correctly scored slides increased significantly between 
pre- and post-test training for both ulceration from 83% to 92% and erythema 
from 79% to 85%. Training evaluators in scoring oral mucositis has a sig­
nificant improvement on the outcome of mucositis evaluation. Therefore 
training must be incorporated in the organization of clinical studies in 
multicenter trials using oral mucositis as a primary endpoint. 
In chapter 4 an in vitro assay is described for quantitative assessment 
of radiotherapy induced oral mucositis. Assessment of mucositis in clinical 
trials is mostly based on observational scores on mucosal changes, subjective 
complaints and impaired function. This study attempted to investigate an 
objective mucositis assessment at a cellular level and to compare the results 
with the WHO scoring method. Ten patients, treated for head and neck 
cancer, participated in this study. All patients were treated with conventional 
fractionated curative postoperative radiotherapy. Prior to, and weekly 
during, the irradiation course, oral washings were obtained to determine 
viability of epithelial cells by trypan blue dye exclusion. Maturation of 
epithelial cells was assessed from smears in buccal mucosa of these patients 
(Papanicolaou staining). The cell viability data were compared with the 
WHO score for mucositis. Epithelial cell viability increased during the first 
three weeks of radiation. This was seen earlier than the subjective mucosa! 
changes with the WHO score. This suggests that, during the early treatment 
phase, the former method is more sensitive in detecting mucosal changes. 
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In this period also the cell maturity shifted from immature and intermediate 
to mature. After three weeks, the percentage of viable epithelial cells 
decreases, while the WHO score does not diminish. The cell viability method 
can therefore only be used for scoring the course and development of 
mucositis during the first three weeks of radiation. The results of this study 
support the idea that the cell viability assay can be considered as an objective 
method for following the development of irradiation mucositis, and seems 
to be more sensitive during the first three weeks of irradiation than the 
clinical WHO scoring method. 
In chapter 5 the relationship is investigated between oral mucositis and 
plasma cytokine interleukin-8 (IL-8) levels in neutropenic cancer patients 
with fever without a local bacterial infection or a clinical sepsis . In 
neutropenic cancer patients, oral mucositis is a potential portal of entry for 
the indigenous oral flora leading to bacteremia or sepsis. Fever is one of the 
first clinical signs of bacterial infection in these patients. The standard 
therapy for patients with fever and chemotherapy induced neutropenia is 
hospitalization and intravenous administration of broad-spectrum antibiotics. 
A risk assessment model has been developed, using objective clinical param­
eters and the plasma IL-8, to select patients with febrile neutropenia at low 
risk for bacterial infection. Plasma IL-8 is considered to be a systemic 
inflammatory response parameter to foci of infection. Oral mucositis is found 
to be a mucosa! injury in which various cytokines, e.g. IL-8 may play a role. 
Patients (n=57) who were hospitalized with chemotherapy induced 
neutropenic fever were scored for oral mucositis on the second day of 
hospitalization according to the validated oral mucositis assessment scale 
(OMAS) and WHO toxicity grading. Patients (n=20) with a clinical sepsis 
or local bacterial infection were excluded from this evaluation. The 
remaining 37 patients were divided in a group with and without oral 
mucositis. The difference in plasma IL-8 level between patients with and 
without mucositis was not significant. In addition no difference was 
observed in the degree and duration of granulocytopenia. These results 
indicate that oral mucositis is not related to the systemic plasma IL-8 level 
in febrile neutropenic cancer patients without a clinical sepsis or local 
bacterial infection. 
Chapter 6 describes the results of a double-blind placebo controlled 
study, evaluating the effects of selective oral flora elimination on 
radiotherapy induced oral mucositis. Changed oral flora, colonizing the 
oral mucosa, may aggravate the mucosa reaction induced by radiation. The 
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carriage and colonization o f  aerobic Gram-negative bacilli are thought to 
play a role in the pathogenesis of irradiation mucositis. In this study 65 
patients were entered, with a malignant tumor in the head and neck regions, 
who were treated with primary curative or postoperative radiotherapy. The 
patients received either the active lozenges of 1 g containing polymyxin E 
2 mg, tobramycin 1 .8 mg and amphotericin B 10 mg (PTA) (33 patients) or 
the placebo lozenges (32 patients), four times daily during the full course 
of radiotherapy. Mucositis, changes in the oral flora, quality of feeding and 
changes of total body weight were assessed. Mucositis score did not differ 
between the groups during the first 5 weeks of radiotherapy. Nasogastric 
tube feeding was needed by six patients (19%) of the placebo group and 
two patients (6%) of the PTA group. Mean weight loss after 5 weeks of 
radiation was less in the PTA group (1.3 kg, SD 3.0) than in the placebo 
group (2.8 kg, SD 2.9). Colonization index of Candida species and Gram­
negative bacilli was reduced in the PTA group and not in the placebo group 
(P<0.05). No effect on other microorganisms was detected. It was concluded 
that selective oral flora elimination in head and neck irradiation patients 
does not prevent the development of severe mucositis. 
Chapter 7 reports the results of a pilot study evaluating the effect of 
flurbiprofen in a tooth patch on the development, severity and duration of 
pseudomembranous oral mucositis in patients treated with curative head 
and neck radiotherapy. Administration of flurbiprofen, a drug with anti­
inflammatory and antiproliferative properties might delay the development 
of mucositis and/ or alleviate its severity. The study group comprised 12 
patients with a malignant tumor in the head and neck region who were 
treated with primary curative or postoperative radiotherapy. Patients 
applied once a day before sleep a flurbiprofen tooth patch to a natural tooth 
or upper denture starting 1 week before the onset of radiotherapy and during 
the full course of radiotherapy. Oral mucositis, pain, feeding, body weight 
and viability and maturation of epithelial cells were assessed. The results 
were compared with the findings in a historical control group. No differences 
were found for severity and duration of pseudomembranous mucositis 
between the two groups. The onset of pseudomembranous/ulcerative 
mucositis occurred later in the flurbiprofen group than in the historical 
control group (P<0.05). This study shows that, beside the latter onset, the 
flurbiprofen 15 mg tooth patch cannot prevent the development of 
pseudomembranous mucositis and has no influence on the duration of oral 
mucositis. 
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In chapter 8 the results of a phase II study evaluating the effect of local 
application of the active metabolite of amifostine (WR-1 065) on 
chemotherapy induced oral mucositis are reported. Cytoprotective agents, 
such as amifostine (Ethyol�, WR-2721), can reduce the toxicity induced by 
radiotherapy or chemotherapy. Amifostine is a prodrug, which is active as 
a protective agent when dephosphorylated by alkaline phosphatase to its 
active metabolite WR-1065. Once inside the cell, WR-1065 protects against 
chemotherapy and radiation induced damage by scavenging free radicals, 
donating hydrogen ions to free radicals, depleting oxygen, and direct binding 
and inactivating cytotoxic drugs. Preclinical experiments showed a reduction 
in radiation induced mucositis after local application of the active metabolite 
of amifostine (WR-1065). Non-small cell lung cancer patients treated with 
gemcitabine and epirubicin every 3 weeks for a maximum of five cycles 
were included. WR-1065 was administered during the second and third 
cycle as an oral rinse. Oral mucositis evaluation included WHO toxicity 
grading, the validated oral mucositis assessment scale (OMAS), and a 
questionnaire. Twenty-four patients were evaluated for at least one control 
and one rinse cycle. Mucositis scores, pain and feeding difficulties increased 
from day 1 to day 15, and were not significantly different between control 
and rinse cycles. Local application of WR-1065 leads to detectable quantities 
of WR-1065 in epithelial mucosa cells. A negative correlation between WR-
1065 concentration and OMAS score was found. No clinical detectable 
influence of local application of WR-1065 on oral mucositis was observed. 
CONS IDERATIONS AND FUTURE  PERSPECTIVES 
To date, despite the current understanding of the complex development of 
oral mucositis in cancer patients, no intervention is available for a complete 
prevention of oral mucositis. Interventions that target one specific process as 
part of the mucositis pathobiology process are shown to be largely ineffective.1 
Future studies in prevention of oral mucositis should aim multiple biological 
targets of the mucositis process either by an intervention with multiple 
mechanism effects or combination of interventions. The effect of local 
application of amifostine, a free radical scavenger and pro-inflammatory 
cytokine reducer, did not shown to be clinically effective in oral mucositis 
prevention (chapter 8). This could be due to the low available concentration 
of amifostine in epithelial mucosa cells. Future studies should aim for a 
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higher cellular concentration of  amifostine, possibly realized by a higher 
rinsing frequency, extended rinsing time and/ or increasing concentration 
of amifostine in the application fluid. 
Because of the partial preventive effect on oral mucositis by selective 
flora elimination and the beneficial effect on the development of mucositis 
by growth factors, further insight in combination of these interventions is 
of high interest for new strategies in mucositis prevention. 
In chapter 7 a delay was found in the development of ulcerative oral 
mucositis with application of an anti-inflammatory drug aiming cyclooxy­
genase-2 (COX-2) suppression. However, this intervention was discontinued 
with the onset of ulcerations. The effects of a longer application period of 
these anti-inflammatory drugs should be considered because the level of 
expression of COX-2 increases within endothelial cells and fibroblasts during 
ulcerations. 2 
In many available mucositis intervention studies the primary endpoint 
is prevention of oral mucositis. However, prevention of the ulcerative phase 
of oral mucositis seems to be more important. Oral ulcerations represent 
the most painful and unpleasant stage of mucositis for patients, and for the 
neutropenic patients there is an increased risk for bacteremia and sepsis. 
Therefore, intervention studies should evaluate the development and 
duration of ulcerations as primary endpoint. 
Possibilities to predict risks for development of mucositis or systemic 
effects of mucositis in cancer patients would represent a great advantage. 
Therapy related factors such as chemotherapeutic agent choice, radiation 
dose and schedule, together with patient related variables such as nutritional 
status, age and gender are known to influence mucositis.3 It is not possible 
yet to identify individual risk for development of mucositis. The developed 
risk assessment model for bacterial infections and complications using the 
plasma interleukin-8 (IL-8) and objective clinical parameters allows selection 
of a low-risk group who could withhold antibiotics and early hospital dis­
charge.4 In chapter 5 is shown that oral mucositis does not influence the 
plasma IL-8 level in febrile neutropenic cancer patients without a clinical 
sepsis or local bacterial infection and therefore should not be considered as 
a local infection in this patient population. However, the overall severity of 
mucositis was low in the studied patient population. Further studies should 
be initiated to show whether these results also hold in febrile neutropenic 
cancer patients with severe mucositis. 
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Most clinical intervention studies on oral mucositis prevention mandate 
larger sample sizes than are available at single study sites. For the needed 
multicenter trials, one of the major concerns is the establishment of adequate 
inter-evaluator reliability with regards to mucositis evaluation. To increase 
the inter-evaluator reliability in multicenter trials start up training meetings 
are necessary to standardize evaluators to the same method of scoring and 
baseline knowledge.5 Chapter 3 describes the short term results of the impact 
of training on the evaluators in scoring oral mucositis. The study showed 
that training of evaluators in scoring oral mucositis has a positive significant 
influence on the outcome of mucositis evaluation. Further studies are 
necessary not only to confirm these results but also to evaluate the effect of 
training in time and the post training monitoring of the quality of scoring 
during intervention studies. 
Progress in the treatment of cancer by innovations in radiotherapy 
concepts or new cancer drugs may be accompanied by earlier and more 
severe side-effects. Supportive care in cancer, aiming for prevention and 
management of adverse effects of cancer and its treatment across the entire 
continuum of a patients illness, will play a more prominent role in the 
treatment of cancer patients. It is identified as fifth dimension in cancer 
therapy in addition to surgery, radiation therapy, chemotherapy, hormonal 
therapy and immunotherapy.6 From the WHO report on strategies to 
improve and strengthen cancer control programs it is concluded that patients 
who have cancer, besides an optimal cancer treatment within a multi­
disciplinary team approach, requires supportive care throughout the 
treatment to ensure an adequate quality of life.7 Team approach can provide 
a comprehensive care for the cancer patient. Specialists (medical, surgical, 
radiation, oncologist) together with several dedicated paramedical specialists 
needs to be a member of the multidisciplinary team. The dental hygienist 
has a pre-eminent background for providing oral supportive care. This 
profession should develop training and research programs for dedicated 
dental hygienists not only because implementation of preventive strategies 
for oral mucositis in cancer patients is complicated but also to be able to 
support new developments. 
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SAM E NVATTI N G  
Mucositis is een ontstekingachtige verandering van het slijmvlies van mond 
en keel. Het is een veel voorkomende bijwerking van radiotherapie als 
behandeling van kwaadaardige tumoren in het hoofdhals gebied. Ook bij 
behandeling met chemotherapie van deze tumoren in het hoofdhals gebied 
of van kwaadaardige afwijkingen elders in het lichaam kan deze aandoening 
van het mondslijmvlies optreden. Mucositis is zeer pijnlijk en belemmert de 
normale functies van mond en keel, zoals spreken, drinken, kauwen, slikken 
en voedselopname. Mucositis is weliswaar van tijdelijke aard, maar veroor­
zaakt, in periode van aanwezigheid, zeer veel last bij deze, vaak toch al  
ernstig zieke patienten en heeft daardoor een sterk negatief effect op de 
kwaliteit van leven. Mucositis wordt bovendien beschouwd als bron van 
systemische infecties bij patienten, die behandeld worden met cytostatica. 
Deze complicaties leiden tot verlenging van de ziekenhuisopname en werken 
kosten verhogend. Bovendien kunnen ze zo ernstig zijn dat de behandeling 
van de patient met een kwaadaardige aandoening in gedrang komt, doordat 
men gedwongen wordt de dosis van de cytostatica te verlagen of de behande­
ling geheel te stoppen. Uit bovenstaande blijkt dat er een grote behoefte 
bestaat aan de mogelijkheid tot preventie van mucositis. 
In dit proefschrift wordt een onderzoek beschreven naar nieuwe moge­
lijkheden voor de beoordeling en de preventie van mucositis van het 
mondslijrnvlies. 
Hoofdstuk 2. Orn inzicht te verkrijgen in de effectiviteit van interventies 
op de preventie van rnucositis van het rnondslijrnvlies werd een literatuur 
onderzoek volgens rnoderne rnethoden uitgevoerd, waarbij gebruik werd 
gemaakt van meta-analyses. Bij het literatuuronderzoek werd gezocht naar 
gerandorniseerde gecontroleerde klinische studies, die gepubliceerd zijn 
tussen 1966-2004 en waarin als doel werd aangegeven preventie van mucositis 
van het mondslijmvlies. Patienten uit deze studies werden behandeld met 
radiotherapie op het hoofdhals gebied, of chernotherapie, of chemoradiatie. 
Belangrijke voorwaarde was dat de mate van rnucositis was bepaald met 
de WHO of de NCI-CTC scoringsmethode, met vermelding van de af- c.q. 
aanwezigheid van ulceraties of de af- c.q. aanwezigheid van graad 3 en 4 
mucositis. Vijfenveertig studies voldeden aan bovengenoemde inclusie 
criteria. Van deze studies was het rnogelijk voor 8 verschillende locale of 
systernisch werkende preventieve rniddelen (interventies) meta-analyses 
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uit te voeren. Van deze 8, bleken er 4 een significant gunstig effect te hebben 
bij de preventie van mucositis of bij de vermindering van de ernst van 
mucositis van het mondslijmvlies. Deze middelen zijn: PTA (polymyxine 
E, tobramycine, amfotericine B), de hematopoetische groeifactoren granulocyt 
macrofaag koloniestimulerende factor (GM-CSF) en de granulocyt kolonie­
stimulerende factor (G-CSF), koelen met ijsblokjes en amifostine. Voor zover 
kan worden nagegaan is er tot op heden in de literatuur geen methode 
beschreven, waarmee mucositis volledig kan worden voorkomen. 
Hoofdstuk 3. Een belangrijk probleem bij de opzet van een klinisch 
onderzoek van geneesmiddelen is het verkrijgen van voldoende proefperso­
nen. Daarom moet vaak gekozen worden voor een multicenter onderzoek. 
Een probleem daarbij vormt de uniformiteit van de beoordeling van 
mucositis door de verschillende beoordelaars. Het is te verwachten dat een 
goede vooropleiding van deze beoordelaars de eenheid in beoordeling zal 
verbeteren. In welke mate dit mogelijk is wordt in dit hoofdstuk aangegeven. 
Om het effect van de opleiding, waaraan beoordelaars van diverse centra 
deelnamen, te evalueren werden er voorafgaand aan het eigenlijke onderzoek 
opleidingsbijeenkomsten gehouden, als start van een fase III studie. Tijdens 
deze opleidingsbijeenkomsten werden toekomstige beoordelaars gemformeerd 
over de opzet van de studie, de ontwikkelingsmechanismen en klinische 
verschijningsvormen van mucositis. Bovendien werden de deelnemers 
getraind in het scoren van mucositis volgens de OMAS scoringsmethode. 
Het effect van de opleiding werd geevalueerd door de deelnemers een test 
af te nemen voor en na de training. Het opleiden van beoordelaars in het 
scoren van mucositis van het mondslijmvlies leidde tot een significante 
verbetering van de uitkomsten van de mucositis evaluatie. De conclusie is 
dan ook dat opleiding van de beoordelaars gemtegreerd moet worden in 
de organisatie van studies, waarbij de klinische beoordeling wordt uitge­
voerd door verschillende beoordelaars. Dit geldt des te meer als het al of 
niet aanwezig zijn van mucositis symptomen wordt gebruikt voor het 
beoordelen van resultaten van maatregelen met als doel het voorkomen 
van mucositis. 
Hoofdstuk 4. Voor de vroegtijdige diagnostiek en preventie van 
mucositis is het nodig objectieve maatstaven te vinden voor vroege stadia 
van mucositis met nog weinig klinische symptomen. Getracht wordt hierin 
door middel van een laboratorium onderzoek verbetering aan te brengen. 
In dit hoofdstuk worden twee cytologische methoden beschreven, waarmee 
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geprobeerd wordt de  ernst van mucositis van het mondslijmvlies, veroor­
zaakt door radiotherapie op het hoofdhals gebied, objectief te kwantificeren. 
De eerste methode berust op het bepalen van het percentage vitale 
epitheelcellen van het mondslijmvlies, in een mondspoelsel, met behulp 
van een celkleuring met trypaanblauw, te beginnen voorafgaand aan de 
bestraling en daarna wekelijks tijdens de periode radiotherapie. Bij de 
tweede methode wordt de mate van rijping van de epitheelcellen van het 
wangslijmvlies beoordeeld met behulp van een uitstrijkje gevolgd door een 
kleuring volgens Papanicolaou. Het onderzoek werd uitgevoerd bij 10  
patienten, die postoperatief werden bestraald in het hoofdhals gebied, 
volgens het principe van de conventionele, gefractioneerde, in opzet curatieve 
radiotherapie. De gegevens over de mate van vitaliteit van de epitheelcellen 
van de mond mucosa werden vergeleken met de uitkomsten van de WHO 
mucositis score. Het percentage losgeraakte vitale epitheelcellen van het 
wangslijmvlies toonde een duidelijke stijging tijdens de eerste drie weken 
van de radiotherapie. Deze verandering trad in een vroeger stadium op 
dan de klinische waarneembare veranderingen van het mondslijmvlies, 
zoals deze werden gescoord op basis van de WHO mucositis score. Deze 
bevindingen wekken de indruk dat, gedurende de eerste fase van de radio­
therapie, de cytologische methode gevoeliger is om initiele veranderingen 
van het mondslijmvlies aan te tonen dan de klinische methode. In dezelfde 
periode verschoof bovendien de mate van rijping van de cellen van het wang­
slijmvlies van onrijpere vormen naar rijpere vormen. Drie weken na aan­
vang van de bestraling verminderde het percentage losse vitale cellen weer, 
terwijl de bevindingen op basis van de WHO mucositis score niet vermin­
derden. De bepaling van het percentage vitale epitheelcellen is hierdoor 
alleen zinvol voor het scoren en het beoordelen van de ontwikkeling van 
mucositis tijdens de eerste drie weken van de radiotherapie. De resultaten 
van dit onderzoek ondersteunen de hypothese, dat deze cytologische me­
thode voldoende objectief is om de beginnende ontwikkeling van een 
bestralingsmucositis te kunnen volgen. Vooral gedurende de eerste 3 weken 
van de radiotherapie is deze methode gevoeliger dan de WHO mucositis 
scoringsmethode. 
Hoofdstuk 5. Bij kanker patienten met neutropenie tengevolge van 
cytostatica toediening kan mucositis van het mondslijmvlies mogelijk een 
porte d' en tree vormen voor lichaamseigen bacterien, waardoor een algemene 
bacteriele infectie of sepsis kan ontstaan. Het optreden van koorts bij deze 
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patienten, met een sterk verminderde weerstand, wordt beschouwd als het 
eerste teken van een ernstige algemene bacteriele infectie. Het standaard 
beleid in deze situatie is om de patient op te nemen in het ziekenhuis en te 
behandelen door intraveneuze toediening van een breedspectrum antibio­
ticum. Om overbehandeling te voorkomen bestaat er in de kliniek, behoefte 
om uit deze patientenpopulatie, een groep patienten te selecteren met een 
laag risico voor een algemene infectie en daardoor het toedienen van anti­
biotica en het aantal klinische opnames te beperken. De waarde van de 
interleukine-8 (IL-8) spiegel in het bloed gecombineerd met objectieve 
gegevens uit lichamelijk onderzoek zou bij deze selectie een rol kunnen 
spelen. Mucositis bestaat uit een beschadiging van het mondslijmvlies 
die gepaard gaat met een ontsteking, waarbij verschillende cytokines, zoals 
IL-8, een rol zouden kunnen spelen. De hoogte van de IL-8 spiegel in het 
bloed zou hierdoor kunnen worden bemvloedt. Deze mogelijke invloed van 
mucositis werd onderzocht bij kankerpatienten met koorts en neutropenie, 
echter zonder algemene bacteriele infectie en klinische symptomen van sep­
sis. Bij patienten (n=57), die chemotherapie hadden ondergaan en opgenomen 
werden vanwege neutropenie en koorts, werd op de tweede dag van de 
ziekenhuisopname de mucositis gescoord volgens de OMAS score en met 
behulp van de WHO scorings-methode. Patienten (n=20) met duidelijke 
klinische symptomen van sepsis of een algemene bacteriele infectie werden 
uitgesloten van deze evaluatie vanwege de zeer waarschijnlijke invloed van 
deze situaties op de IL-8 spiegel. De resterende 37 patienten werden verdeeld 
in een groep met, en een groep zonder mucositis. Er was geen verschil in 
de hoogte van de IL-8 spiegel tussen patienten met en die zonder mucositis 
en er bestond geen relatie met de ernst en duur van de granulocytopenie. 
Deze resultaten laten zien dat mucositis van het mondslijmvlies als zodanig 
geen invloed heeft op de hoogte van de plasma spiegel van IL-8 bij 
neutropene kankerpatienten met koorts bij wie geen duidelijke sepsis of 
een algemene bacteriele infectie is aan te tonen. 
Hoofdstuk 6. In de literatuur worden verschillende factoren beschreven 
die een rol zouden kunnen spelen bij het zich ontwikkelen van mucositis. 
Hiertoe worden gerekend: een stoornis in de regeneratie van de mucosa 
door beschadiging van de basale sneldelende laag van epitheelcellen, het 
optreden van een ontstekingsproces in het epitheel, en de invloed van bacte­
rien op het mucosa oppervlak. Wanneer deze infectie zou kunnen worden 
voorkomen c.q. behandeld zou het lijden van de patient aanzienlijk vermin-
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derd kunnen worden. Daarom werd een onderzoek gedaan naar de invloed 
van langdurige toediening van een combinatie preparaat van polymyxine E, 
tobramycine en amfotericine B (PTA). In dit hoofdstuk worden de resultaten 
beschreven van een dubbelblind, placebo gecontroleerd onderzoek, naar 
het effect van selectieve eliminatie van de mondflora met PTA zuigtabletten 
op een door radiotherapie gemduceerde mucositis. Dit onderzoek betrof in 
het totaal 65 patienten met een kwaadaardige tumor in het hoofdhals gebied, 
die behandeld werden door middel van een bestraling die primair als curatie 
was bedoeld of patienten die een postoperatieve bestraling kregen ter pre­
ventie van eventuele recidieven. Deze totale groep werd onderverdeeld in 
twee gelijkwaardige subgroepen van respectievelijk 33 en 32 patienten. De 
patienten van de eerste subgroep kregen, gedurende de gehele periode van 
radiotherapie vier keer daags een zuigtablet van 1 gram die 2 mg polymyxine 
E, 1,8 mg tobramycine en 10 mg amfotericine B (PTA) (33 patienten) bevatte. 
De patienten van de tweede subgroep kregen een identieke tablet zonder 
werkzame bestanddelen (placebo) (32 patienten). Van beide groepen werden 
de volgende punten geevalueerd: het zich ontwikkelen van mucositis, ver­
anderingen in de samenstelling van de mondflora, voedingsproblemen en 
veranderingen in het lichaamsgewicht. Er werd gedurende de eerste 5 we­
ken van radiotherapie tussen beide groepen geen verschil in mucositis score 
waargenomen. In de placebogroep was, in verband met de ernst van de 
mucositis, sondevoeding nodig geweest bij zes patienten (19%) en in de 
PTA groep bij twee patienten (6%). Het gemiddelde gewichtsverlies na 5 
weken bestraling was in de PTA groep geringer (1,3 kg, SD 3,0) dan in de 
placebogroep (2,8 kg, SD 2,9). De kolonisatie indices van Candida en Gram­
negatieve bacterien was lager in de PTA groep dan in de placebogroep 
(P<0.05). Voor de andere micro-organismen werd geen verschil gevonden. 
Op grond van deze uitkomsten kan worden geconcludeerd dat het zich 
ontwikkelen van een ernstige mucositis bij patienten met een maligne tumor 
in het hoofdhals gebied, die bestraling krijgen, niet kan worden voorkomen 
door een selectieve reductie van de mondbacterien. De symptomen van de 
optredende mucositis lijken echter milder. 
Hoofdstuk 7. Flurbiprofen heeft ontstekingsremmende en antiproli­
feratieve eigenschappen en zou daardoor de ernst van mucositis van het 
mondslijmvlies kunnen verminderen. Bij het zoeken naar medicamenteuze 
behandeling c.q. preventie van mucositis zou deze stof misschien uitkomst 
kunnen bieden. Daarom werd een pilot studie gedaan naar de werkzaam-
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heid van flurbiprofen, waarbij het effect wordt geevalueerd van flurbiprofen, 
in een nieuw ontwikkelde tandkleeftablet, op de ontwikkeling, ernst en 
duur van de door radiotherapie gemduceerde pseudomembraneuze mucositis. 
De testgroep bestond uit 12 patienten met een kwaadaardige tumor in het 
hoofdhals gebied die behandeld werden met primaire curatieve of post­
operatieve radiotherapie. Om een indruk te krijgen van de lokale werking 
plakten patienten gedurende de gehele bestralingsperiode, een nieuw ont­
wikkelde tandkleeftablet met 15 mg flurbiprofen een keer per <lag, voor het 
slapen, op een natuurlijk gebitselement of op de bovenprothese. Mucositis 
van het mondslijmvlies, pijn, voeding, lichaamsgewicht en vitaliteit en 
maturatie van epitheel cellen van het wangslijmvlies werden geevalueerd. 
De resultaten werden vergeleken met een historische controlegroep. Er 
werden geen verschillen gevonden tussen beide groepen voor wat betreft 
de ernst en duur van pseudomembraneuze mucositis. Wel ontstond de 
mucositis later in de flurbiprofen groep dan in de historische controlegroep 
(P<0.05) . Deze studie toont aan <lat de flurbiprofen tandkleeftablet, in deze 
dosering en met deze toedieningswijze althans, het optreden van mucositis 
niet kan voorkomen en geen invloed heeft op de duur ervan. 
Hoofdstuk 8. Amifostine is een organisch thiosulfaat, <lat in het dier­
model cytotoxische schade, die wordt gemduceerd door radiotherapie en 
of door chemotherapie, kan voorkomen. Er werd daarom een fase II studie 
uitgevoerd met lokale applicatie van de actieve metaboliet van amifostine 
(WR-1065), met als doel een door chemotherapie gemduceerde mucositis 
te voorkomen, bij patienten, die behandeld werden voor een niet-kleincellig 
longcarcinoom. Deze patienten werden 3 wekelijks behandeld met de 
cytostatica gemcitabine en epirubicine met een maximum van vijf kuren. 
WR-1065 werd tijdens de tweede en derde kuur als mondspoelmiddel 
toegediend. De mucositis van het mondslijmvlies werd geevalueerd volgens 
de WHO toxiciteitschaal, de OMAS en een vragenlijst. Vierentwintig 
patienten werden voor ten minste 1 controle kuur en 1 kuur, waarbij 
gespoeld werd met WR-1065, geevalueerd. De mucositis scores, pijn en 
voedingsproblemen verergerden van <lag 1 tot dag 15. Er was geen significant 
verschil te zien tussen de controle kuur en de kuur, waarbij met WR-1065 
werd gespoeld. Lokale toediening van WR-1065 leidde wel tot detecteerbare 
hoeveelheden van WR-1065 in cellen van het mondslijmvlies. Er werd een 
negatieve correlatie gevonden tussen de WR-1065 concentratie en de OMAS 
score. Er werd geen klinisch waarneembare gunstige invloed van WR-1065 
1 34 
5 A M E N V A T T N G E N To e � O M S T I G E  O N T W I K K E L I N G E '-
op het optreden van mucositis van het mondslijmvlies waargenomen, 
althans met deze onderzoeksmethode. 
OVERWE G I N G E N  E N  TOE KOM STI G E  ONTWIKKELI N G E N  
Ondanks d e  huidige inzichten i n  d e  ontstaanswijze van mucositis van het 
mondslijmvlies, is er tot nu toe nog geen effectieve methode beschikbaar, 
waarmee het optreden van mucositis kan worden voorkomen. De medica­
menten, gericht op een specifiek onderdeel van het ontwikkelingsproces 
van mucositis zijn tot nu toe grotendeels ineffectief gebleken.1 Toekomstig 
onderzoek naar de mogelijkheden van preventie van mucositis van het 
mondslijmvlies zou gericht kunnen zijn op een selectie van een of meer 
effectieve methoden o.a. op basis van variaties in concentraties en toedienings­
wijzen. Het zou ook gericht kunnen zijn op methoden, die gelijktijdig werk­
zaam zijn op verschillende onderdelen van het ontwikkelingsproces van 
mucositis. 
Lokale applicatie van amifostine, <lat vrije radicalen zou wegvangen en 
pre-ontstekingscytokines zou reduceren, liet in ons onderzoek klinisch geen 
significant gunstig effect zien ten aanzien van de preventie van mucositis 
(hoofdstuk 8). Dit kan echter een gevolg zijn van een te lage beschikbare 
concentratie van amifostine in de epitheelcellen van het mondslijmvlies. 
Toekomstig onderzoek zou dan ook gericht kunnen zijn op het effect van 
hogere concentraties van amifostine in de epitheelcellen. Dit zou mogelijk 
gerealiseerd kunnen worden door de mond vaker te spoelen, de tijdsduur 
van het spoelen te verlengen en/ of de concentratie van amifostine in het 
spoelmiddel te verhogen. 
Zoals reeds eerder gesteld valt er vermoedelijk ook winst te behalen uit 
een geschikte combinatie van geneesmiddelen. Een voorbeeld hiervan zou 
het volgende kunnen zijn. Gelet op het gunstige, reducerende effect van 
een selectieve flora elirninatie, met name van aerobe Gram negatieve bacterien 
en schimmels op de symptomen van mucositis en de remmende werking 
van groeifactoren op de ontwikkeling van mucositis zou verder inzicht in 
het effect van een combinatie van beide medicaties van groot belang kunnen 
zijn voor het ontwikkelen van nieuwe strategieen ter preventie van 
mucositis. 
In hoofdstuk 7 wordt een vertragend effect op de ontwikkeling van 
ulceratieve mucositis beschreven van het toedienen van een ontsteking-
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remmend medicament (flurbiprofen), met als doel het verlagen van de 
expressie van cyclooxygenase-2 (COX-2). Tijdens dit onderzoek werd de 
toediening gestopt, wanneer, ondanks de medicatie, toch ulceraties zicht­
baar werden. Een langere toedieningsperiode zou overwogen kunnen warden, 
omdat de concentratie van COX-2 in endotheel cellen en fibroblasten toe­
neemt bij de aanwezigheid van ulceraties.2 Ook hier kan warden gedacht 
aan een combinatie, n.l. met een selectieve flora eliminatie. 
In veel onderzoeken met betrekking tot mucositis is het primaire eind­
doel de volledige preventie van mucositis. Doch wanneer dit voor alsnog 
niet haalbaar lijkt, zou het onderzoek thans primair het meest effectief gericht 
kunnen warden op methoden, waarmee de kans groot lijkt dat de ontwik­
keling van mucositis afgeremd wordt en de duur van de ulceratieve vorm 
beperkt blijft. De aanwezigheid van ulceraties van het mondslijmvlies zijn, 
namelijk voor de patienten, de meest pijnlijke en belastende fase van 
mucositis. Voor de patienten met een neutropenie is er bovendien in dit 
stadium een verhoogd risico op het optreden van een algemene bacteriele 
infectie en sepsis. 
Het zou ook een grote stap voorwaarts zijn als de kansen op de ontwikke­
ling van mucositis of van de systemische gevolgen van mucositis te voor­
spellen zouden zijn. Het is gebleken dat aan de therapie gerelateerde factoren, 
zoals de keuze van de cytostatica en de toedieningswijze, de bestralings­
dosis en het bestralingsschema, samen met aan de patient gerelateerde factoren, 
zoals voedingsstatus, leeftijd en geslacht, de ontwikkeling van mucositis 
kunnen bemvloeden.3 Het is helaas nog niet mogelijk om de risicofactoren 
die de ontwikkeling van mucositis nadelig be'invloeden bij elk individu 
afzonderlijk te bepalen. Het ontwikkelde risicomodel, waarvan de plasma 
interleukine-8 (IL-8) spiegel wordt gecombineerd met objectieve gegevens 
van het lichamelijk onderzoek van de patient, biedt een mogelijkheid om 
een groep van patienten met een maligniteit met koorts en neutropenie te 
selecteren, bij wie slechts een gering risico bestaat op het ontwikkelen van 
een algemene bacteriele infectie.4 In hoofdstuk 5 wordt aangetoond dat de 
aanwezigheid van mucositis van het mondslijmvlies als zodanig geen 
invloed heeft op de plasma IL-8 spiegel bij patienten met een maligniteit, 
gecombineerd met neutropenie en koorts, bij wie geen klinische sepsis of 
een algemene bacteriele infectie bestaat. Mucositis dient daarom in deze 
patienten populatie niet te warden beschouwd als risicovolle locale ontsteking 
op basis van infectie. Toekomstige studies zouden uitgevoerd moeten warden 
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om te beoordelen of deze resultaten ook gelden bij kankerpatienten met 
neutropenie, met koorts en met ernstige mucositis. 
Voor vele klinische onderzoeken op het gebied van mucositis preventie 
geldt <lat er grotere groepen patienten nodig zijn dan gewoonlijk op een 
onderzoekslocatie aanwezig zijn. Dit maakt combinatie van identieke 
patienten groepen van verschillende locaties noodzakelijk. Deze zogenaamde 
multicenter studies vereisen het tot stand brengen van een adequate inter­
beoordelaars betrouwbaarheid, gericht op de mucositis evaluatie. Om deze 
betrouwbaarheid te optimaliseren in multicenter studies is het noodzakelijk 
om, voorafgaand aan de start het onderzoek, opleidingsbijeenkomsten te 
organiseren. Het onderzoek, beschreven in hoofdstuk 3, laat zien <lat het 
trainen van beoordelaars in het scoren van mucositis de uitkomsten van de 
mucositis evaluatie significant beter gelijkwaardig worden. Verder onderzoek 
is noodzakelijk, niet alleen voor bevestiging van de gevonden resultaten, 
maar ook om de invloed van de factor tijd op de kwaliteit van de trainings­
resultaten te evalueren. De kwaliteit dient na de training bewaakt te worden, 
opdat de scoringsresultaten gedurende de interventiestudie gelijkwaardig 
zullen blijven tussen de verschillende onderzoekscentra. 
De vooruitgang in de behandeling van maligne aandoeningen, bijvoor­
beeld door innovaties op het gebied van bestralingstherapieen of krachtiger 
geneesmiddelen tegen bepaalde maligne afwijkingen kunnen vergezeld 
gaan van een hogere toxiciteit, meer weefselbeschadiging en in een vroeger 
stadium optreden of ontstaan van ernstige bijwerkingen. Additionele zorg, 
gericht op de preventie en behandeling van deze bijwerkingen, zal als 
onderdeel van de totale behandeling, zeer waarschijnlijk steeds belangrijker 
worden. Deze additionele zorg is erkend als de vijfde dimensie in de kanker­
behandeling, naast de chirurgie, radiotherapie, chemotherapie, hormoon- en 
immuno-therapie.6 In het WHO rapport van 2004, over strategieen ter 
verbetering en ondersteuning van kankertherapieen, wordt geconcludeerd, 
dat, naast een optimale kankertherapie, binnen een multidisciplinaire team­
benadering, ook optimale additionele zorg moet worden geboden, om een 
goede kwaliteit van leven van de patient te waarborgen. 7 Alleen een dergelijke 
teambenadering, met een goede onderlinge communicatie, maakt een alles­
omvattende zorg voor de kankerpatient mogelijk. Dit houdt in, <lat naast 
specialisten, die bij de directe behandeling van de patient betrokken zijn 
(artsen, chirurgen, radiotherapeuten, oncologen) ook vertegenwoordigers 
van verschillende ondersteunende beroepen deel moeten uit maken van 
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het multidisciplinaire team. De mondhygienist is hiervan een voorbeeld. 
Na een speciale gedifferentieerde opleiding kan de mondhygienist uitstekend 
additionele mondzorg geven aan oncologische patienten en deelnemen aan 
onderzoek op dit gebied en zo in de nabije toekomst een bijdrage leveren 
aan de behandeling en/ of preventie van mucositis. 
In de werkgroep hoofdhals oncologie van het UMCG is deze proble­
matiek reeds vroegtijdig onderkend. Binnen de afdeling Kaakchirurgie is 
men reeds in 1985 begonnen met onderzoek naar methoden, die het lijden 
van deze patienten, die behandeld warden voor kwaadaardige tumoren in 
het hoofdhals gebied te verminderen. 8 
Ditzelfde geldt oak voor het optreden van mucositis bij patienten, die 
met cytostatica warden behandeld voor een maligne aandoening elders in 
het lichaam. De zorg voor preventie en behandeling van mucositis berust 
in de grate oncologische centra grotendeels bij speciaal daartoe opgeleide 
mondhygienisten. Het is vooral binnen deze beroepsgroep, waar grate behoefte 
bestaat aan gevalideerde kennis op dit gebied. Kennis, die vooral te 
verwerven is, door het zelf doen van wetenschappelijk onderzoek, vooral 
oak omdat men zelf het beste op de hoogte is met de klinische problematiek 
van deze patienten. 
De medische c.q. tandheelkundige professie zal voor mondhygienisten 
die betrokken zullen warden bij de additionele zorg voor kankerpatienten 
speciale opleidings- en onderzoeksprogramma's moeten ontwikkelen, niet 
alleen omdat de implementatie van preventieve strategieen voor mucositis 
van het mondslijmvlies ingewikkeld is, maar oak om daarnaast nieuwe 
ontwikkelingen op dit gebied beter te kunnen evalueren en ondersteunen. 
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D a n kwoord 
Toen ik in 1988 op de afdeling Kaakchirurgie als mondhygienist kwam 
werken, had ik niet kunnen bedenken dat ik ooit nog eens een proefschrift 
zou schrijven. Na 9 jaar patientenzorg zocht ik in mijn werk een nieuwe 
uitdaging, waarvan het ondersteunen van onderzoek een van de mogelijk­
heden was. Na het participeren in een multicenter onderzoek, als een van de 
beoordelaars van mucositis en als datamanager, kwam daama de mogelijkheid 
om zelf, parttime, onderzoek te doen. Het ging om projectmatig klinisch 
onderzoek, waarbij het contact met de patienten, wat belangrijk voor mij is, 
bleef bestaan. Zo kwam het, dat na een drietal projecten er ineens gesproken 
werd over promoveren. Is dat mogelijk als mondhygienist? Ja dus, maar <lit 
proefschrift zou er niet gekomen zijn zonder de hulp van velen. 
Door het uitvoeren van onderzoek binnen de verschillende afdelingen 
van een academisch ziekenhuis en waar je daamaast, als mondhygienist, 
het werkveld hebt, is er een lange lijst van personen die op enige wijze 
hebben bijgedragen tot de voltooiing van mijn proefschrift. Graag wil ik 
dan ook iedereen bedanken die mij heeft gei"nspireerd, ondersteund, geadvi­
seerd en gestimuleerd bij het onderzoek. Enkelen wil ik bij name noemen. 
Grote bewondering heb ik voor alle kankerpatienten die een behandeling 
moesten ondergaan met radiotherapie of chemotherapie, maar die desondanks 
aan de diverse onderdelen van mijn onderzoek hebben meegewerkt. Ik wil 
dan ook graag alle patienten bedanken die, ongeacht de vaak kapotte monden, 
toch weer wilden spoelen, slijmvliescellen wilden afstaan, medicamenten 
wilden gebruiken en klinische inspectie van de mond toelieten. Zonder 
hun bijdragen was <lit onderzoek niet mogelijk geweest. 
Prof. dr. J.L.N. Roodenburg, hooggeleerde promotor, beste Jan. Jij was 
een van de leden van de sollicitatiecommissie die mij in 1987 aannam op de 
afdeling Mondziekten, Kaakchirurgie & Bijzondere Tandheelkunde. Ik heb 
me altijd afgevraagd of het dragen van het legergroene pak dat ik toen 
droeg, invloed heeft gehad op de uitkomst. De persoonlijke gesprekken, 
jouw steun en wijze van coachen heb ik altijd erg gewaardeerd. Je betrokkenheid 
bij "onze" patienten verdient veel respect. Daamaast stel ik het op prijs dat je 
"de mondhygienist", als paramedische beroepsbeoefenaar, altijd als gelijk­
waardige (gespreks)partner hebt beschouwd bij de behandeling van de 
oncologische patient. Bedankt voor jouw begeleiding bij het onderzoek en 
voor mijn persoonlijke ontwikkeling in de uitvoering van mijn vak als 
mondhygienist. 
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Prof. dr. E.G.E. de Vries, hooggeleerde promotor, beste Liesbeth. Je 
heldere visie op het onderzoek en het vermogen om dingen weer op een rij 
te krijgen, is geweldig. Meerdere promovendi hebben dat in het verleden 
genoemd, maar jouw snelle beoordeling van de manuscripten is duizeling­
wekkend. Op het moment dat ik dacht, even "rust" te hebben, omdat het 
manuscript naar de medeauteurs was, kwam ik bij jou bedrogen uit. Bedankt 
voor de snelle correcties, zelfs van de referentielijsten, en je opbouwende 
kritiek. Daarnaast wil ik je bedanken voor het vertrouwen in mij. Het is een 
voorrecht dat jij mijn promotor wilde zijn. 
Dr. F.K.L. Spijkervet, zeergeleerde copromotor, lieve Fred. Door het 
beoordelen en scoren van je onderzoekspatienten kwam ik in aanraking 
met het doen van onderzoek. Je expertise op het gebied van de mucositis, 
was reden voor diverse farmaceutische firma's om onze afdeling te 
benaderen voor het uitvoeren van onderzoeken op het gebied van mucositis. 
Door jouw toedoen heb ik de mogelijkheid gekregen de verschillende 
onderzoeken uit te voeren. Je ondersteuning bij het leren presenteren en 
het schrijven van artikelen is met geen pen te beschrijven. Bedankt voor alle 
inspirerende gesprekken en vele discussies. Onze intensieve samenwerking 
leidde niet alleen tot dit proefschrift, maar ook tot onze liefde voor elkaar. 
Ik had, 18 jaar geleden, nooit kunnen denken dat jij nu en copromotor en 
echtgenoot zou zijn. Bedankt voor alle fijne momenten en dat we nog lang 
van elkaar mogen genieten. 
Prof. dr. L.G.M. de Bont, hooggeleerde professor, beste Lambert. Je 
managementkwaliteiten en vooruitziende blik op zaken, met een scherp 
oog voor de dingen die ertoe doen, wekken veel respect en waardering. 
Zonder jouw inspirerende inbreng was de wetenschappelijke ontwikkeling 
die onze afdeling doormaakt niet daar, waar die nu is. Ik wil je bedanken 
voor de mogelijkheid die ik kreeg om binnen de afdeling Kaakchirurgie 
onderzoek te doen. Daarnaast bood je mij de gelegenheid naar diverse 
nationale en internationale congressen te gaan om de resultaten van mijn 
onderzoek te presenteren. 
De heer R.M. Rolvink, beste Richard. Jij bent degene, die ervoor heeft 
gezorgd dat ik de afdeling niet verliet, toen ik minder wilde gaan werken. 
Daarnaast gaf je mij, later, mede de mogelijkheid en de ruimte om mij verder 
te ontwikkelen in het onderzoeksveld. Wie had toen kunnen denken dat 
deze twee cruciale punten zo'n enorme invloed op mijn verdere leven 
zouden hebben. Ik wil je bedanken voor het feit dat je me niet hebt laten 
1 42 
D � '> < W O O R D 
gaan, alsook voor alle ondervonden steun en de vele persoonlijke gesprekken 
die we hadden. Ik heb veel van je geleerd. 
Prof. dr. J.A. Langendijk en Prof. dr. I. van der Waal, hooggeleerde leden 
van de beoordelingscommissie. Ik wil u bedanken, als gewaardeerde leden 
van de beoordelingscommissie, voor de snelle beoordeling van het manuscript. 
Prof dr. J.B. Epstein. It is a great privilege that a person with such a well 
recognized reputation in the supportive oral care field is willing to come 
all the way from Chicago to be opponent for the defence of my thesis. Thanks 
for being member of my thesis review committee and the quick judgement. 
Our personal contact at the different supportive care meetings and your 
humoristic views have been an indispensable inspiration for me. 
Prof. dr. G. Boering, hooggeleerde professor, lieve Geert. Jij was, als hoofd 
van de afdeling, voorzitter van de sollicitatiecommissie die mij aannam in 
1987. Daar ben ik je nag altijd erkentelijk voor. Het werken op een afdeling 
Mondziekten, Kaakchirurgie & Bijzondere Tandheelkunde van een academisch 
ziekenhuis is een uitdaging gebleken en een goede plek om je vakinhoudelijk 
en als persoon te verrijken en te ontwikkelen. Ik heb je altijd gewaardeerd 
voor je betrokkenheid bij de diverse disciplines van de afdeling. Oak na je 
emeritaat zijn we elkaar niet uit het oog verloren en je bent me bij het 
onderzoek van waardevolle adviezen blijven voorzien. 
Alle medeauteurs wil ik bedanken voor hun energieke inzet en de 
prettige samenwerking om de manuscripten tot een publiceerbare versie te 
maken. 
Dr. P.U. Dijkstra, beste Pieter. Jouw relativerende kijk op het doen van 
onderzoek en het beoordelen van wel of niet significante verschillen is voor 
mij een enorme steun geweest. Bedankt voor alle waardevolle en opbeurende 
gesprekken over de statistische uitkomsten. Je motto:"Denk erom, je moet 
oak blijven genieten" is een waarheid als een koe en dat kan ik nu beamen. 
Ors. P.R. Burlage, beste Fred. Bedankt voor alle prettige jaren van 
samenwerking bij de behandeling van de hoofdhals oncologische patienten. 
Jij hebt het mede mogelijk gemaakt dat diverse onderzoeken op de afdeling 
Radiotherapie konden warden uitgevoerd. Jouw onderzoek naar de functie 
van de speekselklieren na hoofdhals bestraling laat zien hoezeer jij als 
radiotherapeut betrokken bent bij de "oral supportive care" van deze 
patienten. 
Drs. F.M. Wachters en Dr. C.S.M. Oude Nijhuis, beste Floris en Claudi. 
Ik wil jullie bedanken voor de goede samenwerking en dat jullie de metingen 
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deden als ik niet aanwezig was, zodat het onderzoek gecontinueerd kon 
worden. 
Dr. E.S.J.M. de Bont, beste Eveline. Jij bent de drijfveer achter de IL-8 
studie. Bedankt voor de prettige discussies over de opzet van de studie en 
het uiteindelijke manuscript. Het is ons toch gelukt, het is geaccepteerd. 
Dr. G.A.P. Hospers, beste Geke. Bedankt voor je vertrouwen <lat je de 
amifostine studie door mij liet uitvoeren, voor de gesprekken en voor het 
uitschrijven van de formulieren voor de medicatie. 
Dr. H.M. Boezen, drs. J.G.M. Burgerhof en drs. J.P. Schouten, beste 
Marike, Hans en Jan. Bedankt voor jullie statistische analyses. Jullie inbreng 
was iedere keer van onschatbare waarde. 
Medewerkers van de afdeling Kaakchirurgie, de sectie Bijzondere 
Tandheelkunde, de afdeling Radiotherapie en de afdeling Kinderoncologie. 
Bedankt voor jullie interesse in mijn onderzoek, de prettige werksfeer en 
de plezierige samenwerking. 
Mijn collega-mondhygienisten, de dames J.M. Ekelhoff, H. van der Lei­
Groenewegen, G.M. Meijer en C.H.J.M. Zegger, beste Judith, Hester, Marieke 
en Carla. Jullie zorgden voor een stabiele factor in de mondhygienische 
behandeling van onze patienten. Mede hierdoor kreeg ik de afgelopen jaren 
de gelegenheid mijn proefschrift af te schrijven. Ik ben jullie daar zeer 
erkentelijk voor. De collegialiteit, goede samenwerking, vriendschap en 
vakinhoudelijke expertise doen me beseffen <lat we een goed team vormen 
waar ik nog jaren mee hoop te kunnen samenwerken. 
Medewerkers van het Lab, voormalig HO. Bedankt voor de gezelligheid. 
Speciale dank voor Dr. H. Timmer en Dr. J. Meijer, beste Hetty en Coby, 
voor jullie bereidwilligheid mij op het gebied van de laboratoriumproeven 
bij te staan. 
Medewerkers van het Interne Dagcentrum. Bedankt voor jullie mede­
werking bij de amifostine studie en het steeds weer op tijd piepen als er een 
patient moest spoelen. 
Medeonderzoekers en oud-onderzoekers van de derde verdieping. 
Bedankt voor de vele gezellige koffieuurtjes, de taartjes, de adviezen en de 
onderzoeksondersteuning. 
De heer H. de Jonge, beste Harry. Bedankt voor de ondersteuning op 
financieel en computergebied. Jij zult vaak gedacht hebben "daar heb je d'r 
weer", als de computer het weer eens liet afweten. Het was je nooit teveel. 
De dames van het secretariaat Kaakchirurgie en Medische Oncologie, 
K. Wolthuis, N.E. Jaeger, L. Kempers en G.H. Beuker, beste Karin, Nienke, 
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Lisa en Gretha. Bedankt voor jullie secretariele ondersteuning, gezelligheid 
en belangstelling. 
Drs. B. van Minnen, beste Baucke. Vier jaar lang was jij mijn kamergenoot, 
medeonderzoeker, het luisterende oor en de helpende hand. Bedankt voor 
de vele kopjes koffie die je voor me haalde, de gezelligheid, de afleiding, 
de humor en de vele gesprekken niet alleen over onderzoek, maar ook over 
de alledaagse dingen. Fijn dat je mijn paranimf wilt zijn. 
Mevrouw H. van der Lei-Groenewegen, lieve Hester. In 1993 kwam jij 
het team van de mondhygienisten versterken. Tijdens ons congresbezoek, 
in 1995 naar Japan, ontstond er tussen ons een hechte vriendschap. We 
hebben in de afgelopen 10 jaar veel samen meegemaakt. Bedankt voor al 
die keren dat je me hebt bijgestaan. Je bent er altijd voor me en daarom 
waardeer ik het zeer dat je vandaag aan mijn zijde staat. De kwaliteit van 
vriendschap is niet afhankelijk van de kwantiteit, maar gelukkig komt er 
nu weer meer tijd om samen leuke dingen te gaan doen. 
Lieve Karin, Lars en Erik, bedankt dat jullie mij altijd het gevoel geven 
dat ik erbij hoor. 
Lieve ouders, ook al deed ik atheneum B, ik wilde bij nader inzien geen 
academische studie volgen. Toen ik aangaf, nadat ik gezakt was, meteen 
naar de opleiding mondhygiene te gaan, was dat voor jullie geen punt van 
discussie. Jullie steunden mij in mijn keuze en daar ben ik jullie nog steeds 
dankbaar voor. Daarnaast wil ik jullie bedanken voor de plezierige jeugd 
die ik heb gehad en het gevoel dat bij ons thuis zoveel mogelijk was. Fijn, 
dat jullie er altijd voor me waren en zijn. 
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